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CHAPTER I  
General Introduction 
1 BACKGROUND 
1.1. Challenges in Vaccine Development 
Vaccines have been remarkably effective in promoting global health through the reduction 
of mortality and morbidity caused by infectious diseases. 1, 2 Especially considering 
conditions for which effective therapies do not exist, prophylactic vaccines represent a 
decisive tool to advance public health. 3 For instance, the eradication of smallpox, and the 
drastic reduction of incidences of polio, diphtheria, tetanus, pertussis, and measles represent 
direct successes of immunization programs worldwide. 1, 2 Despite this, and the increasing 
knowledge on immunization, the development of new vaccines is much slower than the 
growing necessity for new therapeutic and prophylactic alternatives. 4 Widespread life-
threatening pathogens which could potentially be prevented through vaccination are for 
example, the human immunodeficiency virus (HIV), leishmanias, chlamydia, Helicobacter 
pylori, schistosomas, hepatitis C virus (HCV), respiratory syncytial virus (RSV), 
cytomegalovirus, Staphylococcus aureus, Pseudomonas aeruginosa, Plasmodium falciparum 
(malaria), dengue viruses (DENV-1, 2, 3 and 4), and Mycobacterium tuberculosis. 1, 4 However, 
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efficacious vaccines against these infections are not yet available. Significant obstacles reside 
in both scientific and financial areas. 4  
A factor that considerably contributes to the difficult and lengthy development of vaccines is 
the complexity of pathogens. 5 For instance, the genetic diversity of pathogens is a 
substantial barrier in this process. Vaccines against multi-strain pathogens and pathogens 
exhibiting high mutation rates demand the incorporation of a broader range of antigens. In 
these cases, multivalent vaccines are established in order to better cover the antigen 
variability. 6 However, some cases require additional strategies to compensate the 
modifications of the pathogens. As an example, multivalent vaccines against seasonal 
influenza are annually reformulated to enhance the antigen coverage. 1 Yet, this approach is 
not adequate to overcome extremely high antigen variability. HIV and HCV for instance, 
rapidly undergo mutations even during the infection process. 1 This generates changes in the 
target antigenic epitopes and consequently diminishes the functionality of antibodies. 5 
Therefore, the concomitant induction of cellular responses is of utmost importance against 
this kind of pathogens. 1 In contrast, strong antibody responses are the main biomarkers of 
protection for several licensed vaccines (e.g. smallpox, pertussis, tetanus, diphtheria, rubella, 
measles, and yellow fever). 7, 8 This shows that the correlates of immunity vary according to 
the characteristics of the pathogen. Although difficult, their identification constitutes an 
important and strategic stage of rational vaccine design. 3, 8 
In a simplistic way, vaccines are formulated to mimic natural infections in a tolerable way 
and ultimately induce immunity. This relies on the premise that the host naturally becomes 
immune to a re-infection after overcoming the disease. Unfortunately, this is not true for 
many pathogens (e.g. malaria and RSV). 1 In such circumstances, the vaccine must be able to 
activate immunological pathways that go beyond the scenario encountered in a natural 
infection to eventually induce protection. Similar challenges are also present in the 
development of vaccines against pathogens that provoke chronic infections (e.g. HIV, HCV 
and S. aureus). 1 Therefore, it is fundamental to thoroughly understand the pathophysiology 
and the mechanisms of protection against the pathogen concerned not only in humans, but 
also in the specific animal model used in the research. In this context, the absence of good 
animal models that closely resemble the human organism considerably intensifies the 
challenges in vaccine development. For instance, despite considerable differences between 
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the immunological responses of rodents and humans, mouse models have been a frequent 
tool in the development of vaccines. 9 Even nonhuman primate models show significant 
discrepancies to the human immune system with respect to immunogenetics, microbiome 
and specificity of viral vectors. 4 Inadequate preclinical data is frequently generated and 
hampers the identification of predictive markers of protection, leads to failure in clinical 
trials, retards the development process, and increases research costs. 1-3 For example, several 
vaccine candidates against S. aureus were tested in clinical trials, but today an effective 
vaccine against this pathogen is still not available. In animal studies, independent reports 
indicated opsonophagocytic activity as the main predictive marker of protection against S. 
aureus. Unfortunately, this biomarker did not seem to be a correlate of protection in 
humans. 10 
Traditionally, vaccines have been developed for pediatric patients, who are especially 
susceptible to threats of infectious diseases. With this strategy, protection can be provided to 
individuals as early as possible. However, there is an urgent need to expand the benefits of 
vaccination to other groups of the population, e.g. elderly and immune-compromised 
individuals that are highly vulnerable to infections. 11 Needless to say, due to the particular 
immunological situation and risk of pathogen exposure, vaccine development strategies 
have to be adjusted. Suitable vaccine candidates must be highly tolerable (ideally, by all 
groups of the population) and at the same time, potent enough to overcome the low 
responsiveness of the immune system. 12 Pregnant women constitute another delicate 
population group that would substantially benefit from additional vaccines. Maternal 
immunization provides protection to both, mother and infant. For this reason, this is a 
valuable strategy for health promotion. 13 Despite the success of maternal vaccination 
against tetanus, pertussis and influenza, safety concerns are still the main barriers to 
advance in this field. 13  
Overall, the key impasse in vaccine formulation is the necessity to combine safety and 
tolerability with potent and persistent immune responses. 14 The so-called traditional 
approaches of vaccine formulation use live attenuated [e.g. Bacillus Calmette Guérin (BCG) 
against tuberculosis, and MMR against measles, mumps and rubella] or whole inactivated 
microorganisms (e.g. hepatitis A vaccine Epaxal®). 15 Here, concerns regarding the 
reactogenicity of these vaccines and the safety of the patients exposed to them are the prime 
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limitations. 16 In this context, subunit vaccine technology brought a notorious improvement. 
These vaccines are based on highly purified and well-defined antigenic motifs (e.g. peptides, 
proteins or polysaccharides) of the target pathogen. 14, 15 In this way, specific immune 
responses can be induced, excluding the risk of pathogen replication and drastically 
reducing the occurrence of unwanted host reactions. Therefore, this technique allows for 
higher tolerability in comparison to whole-pathogen preparations. 14, 15 However, subunit 
vaccines are frequently inefficient, because they do not promote the same level of 
immunogenicity demonstrated by the traditional ones. 17, 18 To circumvent this, adjuvants are 
co-administered to improve the magnitude and type of the immune response. 17, 18  
1.2. Vaccine Adjuvants 
Adjuvants are defined as additives able to enhance specific immune responses against a 
determined pathogen. 19 In addition to the decisive role of adjuvants in the efficacy of low-
immunogenic antigens, they allow significant vaccine dose sparing, which is of utmost 
importance in the context of global supply. 19 Adjuvants may be either immunopotentiating 
compounds (section 1.2.3.), particulate delivery systems (section 1.2.4.), or a combination of 
both. 20 The incorporation of antigens into particles provides the possibility of mimicking 
size, geometry, and kinetics of viruses and bacteria. 21 Moreover, the particle design encloses 
a range of possibilities to tune the interaction between the antigen and immune cells, and 
even eliminate the necessity of multiple dose regimens. 21 Therefore, the combination of 
these approaches (particles and immunopotentiators) has been frequently investigated to 
take advantage of synergistic effects, revealing promising perspectives. 22-24 Accordingly, 
adjuvants represent a broad and heterogeneous group. In the context of subunit vaccines, 
the incorporation of adjuvants into the formulation is performed considering the immune 
responses desired, without neglecting safety. 19 Here, diverse aspects must be taken into 
account. For instance, the route of administration, and the interactions between adjuvant 
and antigen can modify the biological performance of the formulation. This not only affects 
the immunological output and effectiveness of the vaccine, but also changes its toxicity 
profile. 14, 19 In the next sections, some of the most important adjuvant systems are described. 
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1.2.1. Aluminium Salts 
Aluminum adjuvants (aluminum hydroxide, aluminum phosphate, and potassium alum), 
collectively referred to as "alum", are the most common adjuvants and were for many years 
the only approved adjuvants in the USA. 25 Aluminum hydroxide is the form of alum most 
commonly employed as adjuvant. 26 Alum is certainly the most employed adjuvant in 
human vaccines and its safety profile is very well characterized. 18 Despite this, its 
mechanism of action is less well understood than that of other adjuvants. Alum is formed by 
charged crystalline aggregates that normally enable the adsorption of antigens. 19 Upon 
injection, an inflammatory focus is formed, triggering series of events that increase antigen 
uptake by dendritic cells (DCs), stimulate cell-recruitment and activate immune cells via 
inflammasome. 19, 27 The main limitation of aluminum adjuvants is the overall Th2-biased 
immune response. This makes these adjuvants inappropriate for vaccine formulations 
against cancer or intracellular pathogens, because in these cases, the induction of Th1 or 
cytotoxic T lymphocyte (cell-mediated responses) plays a central role. 14, 27  
1.2.2. Emulsions 
Similarly to the aluminum adjuvants, emulsions also have an extensive record of 
applications in the field of vaccines. The study of emulsions as vaccine adjuvants started 
with the Freund’s Complete Adjuvant (FCA). FCA is a water-in-oil (w/o) emulsion and 
contains mineral oil, mannide monooleate and killed Mycobacteria tuberculosis. This emulsion 
was found to have a high immunostimulatory profile, but revealed strong adverse effects 
making it unsuitable for clinical applications. 28 The Freund’s Incomplete Adjuvant (FIA) 
was prepared without the mycobacterial component. Despite its lower toxicity compared to 
FCA, FIA still presented high reactogenicity and its clinical use was limited. 29, 30 Intense 
research in this field led to the development of alternative w/o emulsions such as, 
Montanide ISATM51 and Montanide ISATM720. The first is composed of a mineral oil with 
50% water and the latter is formed by squalene oil plus 30% water. Both preparations are 
stabilized with surfactants from the mannide monooleate family (esters of oleic acid and 
mannitol). 29, 31 Their mechanism of action is based on the formation of a depot at the 
injection site and slow antigen release, culminating with enhanced antibody levels and 
cytotoxic T lymphocyte (CTL) responses. 29, 31 These adjuvants have been evaluated in 
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clinical trials in immunotherapeutics against HIV, malaria, cancer, and autoimmune 
diseases. 29, 31 In spite of the successes obtained with w/o emulsions, the development of oil-
in-water (o/w) formulations has been preferred due to the better tolerability and lower 
viscosity, which allows for better injectability and more accurate dosage. 30 Another factor 
that improved tolerability was the substitution of non-degradable mineral oils by 
metabolizable oils. 29, 30 The application of these concepts resulted in the development of 
MF59 and AS03, both present in several licensed human vaccines. 30 
MF59 and AS03 are squalene-based o/w emulsions licensed in several countries for 
pandemic influenza vaccines. 29 MF59 is composed of nonimmunogenic molecules, namely 
squalene, Tween 80, and Span 85. 29, 32 Therefore, its activity originates from the resulting 
emulsion. Differently, AS03 contains squalene, Tween 80 and the immunopotentiator α-
tocopherol. 29 Two of the most interesting contributions of MF59 and AS03 to influenza 
vaccines are the induction of cross-reactivity against multiple strains of the virus and the 
considerable reduction of the amount of antigen needed (dose sparing). 32, 33 Their 
mechanism of action differs from that of alum in a way that these emulsions do not create a 
depot-effect and the association between antigen and oil droplets is not important for the 
adjuvancity. 30 When compared to alum, MF59 and AS03 generally induce higher antibody 
and mixed Th1/Th2 responses. 19, 32 A limitation in the use of emulsions in vaccines is the 
challenging characterization of antigen molecules in these systems. Therefore, the 
establishment of suitable separation protocols is required to enable reliable analytics for the 
monitoring of quality and stability. 32 
1.2.3. Immunopotentiators 
The adjuvant class of immunopotentiators is represented by ligands able to directly activate 
receptors of the innate immune system, such as toll-like receptors (TLRs), nucleotide-
binding oligomerization domain proteins (NODs), NOD-like receptors (NLRs), C-type 
lectins receptors (CLRs), and RIG-I-like receptors (RLRs). 15  
Monophosphoril lipid A (MPL®) is a prominent example of this category. It is a TLR4 
agonist derived from lipopolysaccharide (LPS), which is found in the cell wall of Gram-
negative bacteria and is able to induce Th1-biased immune responses. 15, 19 It was the first 
TLR ligand included in a licensed human vaccine (hepatitis B vaccine, FendrixTM). MPL® is a 
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natural product and today many TLR4 agonists are being developed synthetically. 34 
Unmethylated CpG motifs constitute another example of TLR ligand applied as adjuvant. 
These sequences are present in bacterial DNA, but in the vertebrate genome they are 
suppressed and methylated. 35, 36 Thus, through TLR9 recognition, immune cells are 
activated and defense mechanisms are induced towards Th1 cell responses. 17, 18 Vaccine 
candidates against hepatitis B, containing unmethylated CpGs as adjuvant system, reached 
phase III clinical trials with promising results. 19, 36 Likewise, several other pathogen-
associated molecular patters (PAMPs) are identified through TLRs and constitute the basis 
of a variety of adjuvant molecules [e.g. bacterial flagellin (detection through TLR5 induces 
Th1/Th2 responses), and dsRNA analogues (detection through TLR3 induces Th1 
responses)]. 15, 19 Besides TLR ligands, trehalose-6,6-dibehenate (TDB), which is a synthetic 
analog of the mycobacterial cord factor trehalose-6,6-dimycolate (TDM), has received much 
attention due to its capacity of inducing strong cellular responses. 19, 37 The adjuvancity of 
this glycolipid results from the activation of CLR mincle (macrophage-inducible C-type 
lectin receptor), which is also known to bind certain fungal species and S. pneumoniae. 37, 38 
Synthetic analogues of muramyl dipeptide (MDP), which is originally encountered in the 
bacterial cell wall, are NOD2 ligands and were also reported to show promising adjuvant 
activity. 39, 40 For instance, in a study with dogs, a vaccine candidate containing MDP 
induced Th1-biased responses and protection against leishmaniasis. 41 The saponin-derived 
QS21 also represents an important immunostimulatory molecule. This potent adjuvant is a 
purified fraction of Quil-A® and shows lower toxicity in comparison to other saponins. 35 Its 
mechanism of action is yet to be elucidated. However, it was suggested that Quil-A® acts 
through a NLR protein 3-dependent mechanism based on the secretion of the pro-
inflammatory interleukin (IL)-1β following inflammasome activation. 42 Nevertheless, 
several combination systems containing QS21 have been tested in clinical phase III studies. 19 
Alternatively to the use of these molecules to stimulate the immune system, the direct 
application of cytokines [e.g. IL-1, IL-2, IL-12, interferon (IFN)-γ] as adjuvants has also been 
studied. 35 However, due to considerable instability issues, efforts are still necessary to 
establish this strategy. 35  
These examples represent only a small portion of the adjuvant molecules available and 
highlight the wide range of possibilities regarding mechanisms of action and consequent 
immunological outputs. 
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1.2.4. Particulate Vaccine Delivery Systems 
Antigen delivery using nanoparticles has several interesting advantages in vaccination. 
Firstly, the encapsulation into particles enables antigen protection and so avoids its rapid 
enzymatic degradation. 43 Secondly, it is speculated that particulate carriers simulate the 
antigen presentation naturally performed by the pathogen. Thus, the resulting immune 
response against the vaccine would be similar, but associated with lower risks. 21, 43 Other 
promising attributes are targeted delivery, prolonged antigen release, and the combination 
of more than one immunogenic agent in the same delivery system to create a multivalent 
vaccine. 43 The limitations regarding the use of nanoparticles as vaccine delivery systems are 
frequently related to potential unknown toxic effects and intracellular accumulation. 43 In 
addition to this, there are also several obstacles concerning the potential scale-up of their 
production. 43  
Among several particulate delivery systems, the most relevant ones for vaccination are 
virus-like particles (VLPs), immunostimulating complexes (ISCOMs), polymeric 
nanoparticles, inorganic nanoparticles and lipid-based formulations (liposomes, virosomes, 
transferosomes, ethosomes, cubosomes). 44, 45  
1.2.4.1. Virus-like Particles 
VLPs are formed by viral capsid proteins that self-assemble into stable particles in a size 
range of 20-150 nm. Depending on the viral source, the particles display different geometries 
and shapes, such as spherical, icosahedral, or rod-like. 21, 43, 46 These systems are attractive 
adjuvants, because they combine high density of epitopes with nanocarrier properties, 
which results in improved immunostimulation. 21, 43 VLPs mimic virus morphology and cell 
tropism, and have great safety profile, because they lack genomic material and cannot 
replicate or promote infections. 47 These advantages are reflected in the increasing number of 
approved VLP vaccines, such as Engerix® (GlaxoSmithKline) and Recombivax® (Merck & 
Co.) against hepatitis B virus (HBV), Cervarix® (GlaxoSmithKline) and Gardasil® (Merck & 
Co.) against human papillomavirus (HPV), Inflexal V® (Crucell) against influenza, and 
Epaxal® (Crucell) against hepatitis A virus (HAV). 43, 46 It is important to mention that VLP-
based formulations, including commercially available ones, commonly include additional 
adjuvants to achieve the desired quality and magnitude of immune responses. 48 A crucial 
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limitation of this carrier system is the small antigen load that can be incorporated within the 
particles. This makes the presentation of large antigens like HIV envelope or influenza 
haemagglutinin proteins difficult. 49 In addition, in comparison to other particulate systems, 
the production and purification of VLPs is more challenging, especially at an industrial 
scale. 46  
1.2.4.2. Immunestimulating Complexes (ISCOMs) 
ISCOMs are micellar colloidal systems of approximately 40 nm, formed by well-defined 
ratios of cholesterol, phospholipid (phosphatidylethanolamine or phosphatidylcholine) and 
saponine (Quil-A® extracted from Quillaia saponaria). 50 The components are mixed in the 
presence of a surfactant and the removal of the latter through dialysis or centrifugation 
results in a pentagonal dodecahedron arrangement of micelles (cage-like structure) 
containing saponins and lipids. 48 Similar to VLPs, ISCOMs are self-assemblies featuring 
peculiar geometry and surface structure, 50 and also have limited antigen loading capacity. 23 
However, it has already been shown that the simple mixture of ISCOMs with the antigens, 
without incorporation (ISCOMs matrices), elicits potent immune responses, which are 
comparable with the encapsulated system. 23 In pre-clinical studies with small animal 
models and non-human primates, ISCOMs induced remarkable levels of cytotoxic T 
lymphocyte (CLT) responses. However, these results were not reproducible in clinical 
trials. 48 Many veterinary vaccines include ISCOMs, e.g. ISCOM-EVI vaccine against equine 
influenza. 51 In spite of this, concerns about severe toxic effects (local reactions, granulomas, 
and hemolysis) of this saponin-based adjuvant have hindered its establishment for human 
use. 43, 52  
1.2.4.3. Polymeric Particles 
Adjuvant effects can also be achieved by incorporating the antigen into polymeric 
particles. 53 Depending on their composition, these systems present a diverse range of 
characteristics regarding size, surface charge, hydrophobicity, targeting, toxicity, and 
antigen release. These properties may determine their performance in a biological 
environment and enable immune response optimization. Several materials have been 
evaluated for the production of biodegradable vaccine carriers such as poly(lactic-co-glycolic 
acid) [PLGA], poly(lactic acid) [PLA], and poly(γ-glutamic acid) [γ-PGA]. 43, 54 The interest in 
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PLA/PLGA particles for antigen delivery started in the late 70s due to the well-known 
safety of these materials and the possibility to control antigen release. However, it was 
reported that the pH reduction inside the particles, arising from the polymer degradation, 
promotes damage in a large fraction of the antigen. 28 This is an important limiting factor 
considering that the antigen delivered must be in its antigenically active form to induce 
proper immune reactions. 28 Natural polymers have also been investigated for the 
preparation of biodegradable vaccine delivery systems. For instance, the polysaccharides 
pullulan, alginate, inulin (AdvaxTM), and chitosan have been extensively studied. 52 
1.2.4.4. Inorganic Particles 
Inorganic particles are also being developed for vaccine delivery purposes. Here, gold, 
carbon and silica are the most studied materials. 43 For instance, novel porous carbon 
nanoparticles, loaded with bovine serum albumin (BSA), were able to induce humoral, 
cellular and mucosal responses in vivo after oral immunization. Similarly, in an animal 
experiment, mesoporous silica nanoparticles, loaded with ovalbumin (OVA), were able to 
provoke cellular and humoral responses in levels comparable to the Quil-A®-adjuvanted 
control. 55 Successful antigen delivery and immunostimulation were also demonstrated for 
gold nanoparticles. 56, 57 In addition, changes in size and shape of these carriers were shown 
to be suitable tools to tailor the immunological output. 58  
Overall, these materials allow for rigid structures and controlled and well-reproducible 
preparation. However, they are mostly non-degradable and can accumulate within the cells. 
Therefore, especially in continuous or prolonged periods of exposure, this can become a 
toxicity issue. 43, 52  
1.2.4.5. Liposomes 
Liposomes are one of the most studied lipid-based drug carriers and are currently applied in 
several licensed formulations (Doxil®, AmBisome®, Myocet®). Liposomes are vesicles 
composed of one or more concentric lipid bilayers enclosing an aqueous inner 
compartment. 59, 60 They can be prepared using different methods (e.g. ethanol injection, film 
hydration, reverse phase evaporation, and microfluidic) and lipid compositions, resulting in 
formulations with different physicochemical properties (particle size, size distribution, 
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lamellarity, polarity, zeta potential, stability, encapsulation volume etc.). These 
characteristics highly impact their in vivo performance. 59-61  
The growing number of studies applying liposomes in vaccines is improving the 
understanding of their biological performance and helping to clarify what determines their 
activity. 48 By exploiting possible customization, liposomes can be tailored to achieve the 
protective responses needed against a specific pathogen. For instance, it is known that 
cationic and anionic vesicles are more effective in inducing immune responses than neutral 
vesicles. 61 This is mainly attributed to the ability of charged particles to interact with the cell 
membrane, and to release the antigen. 61, 62 In addition, the comparison between the immune 
responses elicited by non-PEGylated and PEGylated cationic liposomes [i.e. liposomes 
without and with polyethylene glycol (PEG) coating, respectively] revealed a change from 
Th1 responses to mainly Th2 responses, respectively. 63 This might have been a consequence 
of the changes in the biodistribution of the liposomes in vivo. PEGylation avoids aggregation 
and inhibits the formation of a depot in the site of injection, which improves the drainage to 
lymph nodes and results in a different immunological output. 63 It was also found that rigid 
liposomes, formed by lipids with high transition temperatures (Tm), are in general more 
effective as adjuvant systems. 62, 64 
A complementary strategy used to improve the levels of immunogenicity of liposome-based 
vaccines is the incorporation of immunopotentiators in the formulations. For example, the 
adjuvant AS01 formed by the combination of liposomes, MPL® and QS21 is included in a 
vaccine candidate against malaria, which reached phase 3 in clinical studies. 19 Another 
important example is the cationic adjuvant formulation (CAF) 01 constituted by liposomes 
formed by dimethyldioctadecylammonium (DDA) and TDB. CAF01 typically elicits 
Th1/Th17 biased responses and is in clinical trials phase 1 in a vaccine against 
tuberculosis. 19, 65 Similarly, the adjuvant CAF04 is based on the combination of DDA and a 
synthetic analogue of monomycoloyl glycerol (MMG-1), which is known to stimulate 
dendritic cells. 66, 67 CAF04 induces strong Th1/Th17 responses and has shown promising 
adjuvancity in vaccine candidates against tuberculosis 68 and chlamydia. 69   
Due to the ability to transport a wide range of molecules, the incorporation of additives in 
liposomal formulations is often relatively simple. Hydrophilic compounds can be 
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encapsulated into the aqueous core and hydrophobic compounds can be intercalated into 
the lipid bilayer. 23, 70, 71 In theory, this enables the incorporation of antigens and adjuvants of 
all classes into liposomal formulations. However, the lipid bilayer capacity can become a 
limiting factor for the inclusion of hydrophobic molecules. 72 The lipid bilayer may not 
provide enough hydrophobic environment for the incorporation of a feasible antigen 
payload. Another important limitation of liposomes is their poor stability and short shelf-
life. 73 The need of stable particulate systems with higher solubilization capacity for 
hydrophobic and hydrophilic components increased the research interest in non-lamellar 
lyotropic liquid crystalline phases including the cubic and hexagonal phases. 
1.3. Lyotropic Liquid Crystalline Phases 
Liquid crystals (LCs) are thermodynamic phases found between the crystalline solid and 
simple liquid states. They are also called "mesophases", which originates from the Greek 
meso meaning "in between". Physical properties of LCs combine characteristics of crystals 
(e.g. orientation and order) and liquids (capacity to flow). 74 LCs formed by organic materials 
can be divided into two main groups: thermotropic and lyotropic. Thermotropic LCs 
undergo phase transitions upon changes in the temperature, whereas lyotropic LCs are 
formed in the presence of a suitable solvent and phase transitions occur as a result of both, 
temperature and concentration changes. 75 Lyotropic liquid crystalline phases are 
spontaneously formed in the presence of water by the self-assembly of amphiphilic lipid 
molecules. Amphiphilic lipids comprise a hydrophilic headgroup and a hydrophobic 
hydrocarbon chain region. 76 Examples of this class of lipids are monoglycerides (e.g. 
monoolein), phospholipids [e.g. 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)], 
urea-based lipids (e.g. oleylurea), and glycolipids (e.g. 1-o-phytanyl-beta-D-xyloside) as 
shown in Figure 1. 76, 77  
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Figure 1: Molecular structures of different amphiphilic lipid molecules: (a) monoolein; (b) DOPE; 
(c) oleylurea; (d) 1-o-phytanyl-beta-D-xyloside. 
The driving force for the lipid self-assembly is the hydrophobic effect, which triggers a re-
organization of the amphiphilic molecules to minimize oil-water interactions between the 
hydrophobic chains and the aqueous environment. 78 The bulk phases formed can be highly 
viscous and difficult to handle. In addition, the contact with epithelial tissues may promote 
irritation. For these reasons, their application in the pharmaceutical and medical fields is 
limited. 77 However, there is a growing application potential for the particulate dispersions 
of these bulk phases. 79 Using an emulsifier or a steric stabilizer, stable nanoparticles with 
the same internal organization as found in the parent bulk phase can be generated. 77, 79 This 
nanostructured particle class has been collectively called “isasomes”, which means: 
internally self-assembled particles or “somes”. 80 
1.3.1. Structural Assembly 
The structure of lyotropic liquid crystalline assemblies depends on the molecular shape of 
the amphiphiles involved. Here, the evaluation of the critical packing parameter (CPP), also 
known as dimensionless shape parameter, can be used as a tool to better understand and 
sometimes to support predictions regarding the phase topology of the formulation. 79 The 
CPP can be estimated according to the equation below: 
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where v is the molecular volume of the hydrophobic chain,    is the headgroup area and    
is the critical chain length. 81 As displayed in Figure 2, inverse structures (also known as 
Type II) are built by wedge-shaped molecules (CPP>1), cylindrical-shaped lipids 
(0.5<CPP<1) form lamellar phase, and normal structures (called Type I) are generated by 
cone-shaped lipids (CPP<1). 81 The CPP is not constant and will vary according to the 
environment of the molecule. For instance, variations in temperature, pressure, pH and ionic 
strength can affect the headgroup hydration, inter-headgroup interactions, and the volume 
occupied by the hydrophobic chains. 72 These modifications will in turn culminate with 
structural rearrangements of the amphiphilic molecules. 72 In complex formulations, with 
more than one lipid component and further additives, the structure is a result of the 
interactions between all formulation components and the manner in which they exist in the 
given conditions.  
 
Figure 2: Self-assembly structures and corresponding CPPs. 79 
The dispersion of a lamellar bulk phase (Lα), in excess of aqueous medium, yields liposomes 
(Figure 2). These are well studied vesicles composed of one or more concentric lipid bilayers 
enclosing an inner aqueous compartment. 59 As highlighted in section 1.2.4.5, liposomes 
have been successfully employed in the clinic as drug delivery systems. 79, 82 With an 
increasing CPP and negative curvature, the inverse cubic phase (QII) is formed (Figure 2). 
This topology includes three different internal arrangements or space groups: gyroid (G or 
C H A P T E R   I    General Introduction 
DEVELOPMENT OF NOVEL VACCINE CARRIERS                                                                                                                            15 
 
Ia3d), double diamond (D or Pn3m), and primitive (P or Im3m). 76 Despite the particular 
geometries, the three arrangements are all constructed by a single continuous highly twisted 
bilayer, which forms a complex 3-D cubic network separating the space into two 
independent and non-intersecting water channels. 22, 44, 76, 83 In general, the dispersion of 
inverse cubic phases yields internally structured particles called cubosomes, which are not 
necessarily cube-like. They can be spherical and even relatively flat. 84 The inverse hexagonal 
phase (HII) has an even higher CPP and a stronger negative interfacial curvature (Figure 2). 
In particulate form, the HII phase is called hexosome. Hexosomes are internally structured 
particles, whose repeating unit consists of rod-like arrangements of micelles hexagonally 
packed with closed water channels. 76, 85  
1.3.2. Structure Characterization 
A major part of the development of nanoparticles internally structured with non-lamellar 
lyotropic liquid crystalline phases is screening and optimization of the formulation to ensure 
the generation of the desired structure. In this process, small-angle X-ray scattering (SAXS) 
is an essential characterization tool. It is the most accepted method for identifying the 
structure of particles in dispersion. 86 Time-resolved SAXS (TR-SAXS) further expanded the 
application of this technique and allowed the kinetic monitoring of phase transitions as well 
as the identification of intermediary phases. However, TR-SAXS requires the use of 
synchrotron sources of X-rays. 87 Laboratory-based SAXS instruments have a relative low 
photon flux and the measurements take from minutes to hours. In addition, to obtain 
suitable scattering signal from dispersions, highly concentrated samples are needed. 88 In the 
present work concentrations of roughly 10 wt% (total lipid) were used for measurements in 
laboratory-based SAXS. If performed correctly, this method is non-destructive and the 
samples can be recollected for further use. 89 In comparison, data acquisition with 
synchrotron sources is much more efficient and can be performed in milliseconds in 
relatively low concentrated samples. 87  
SAXS analyses are based on the fundamentals of light diffraction. Radiation is deviated from 
its trajectory when it enters a non-uniform medium and the analysis of this scattered 
radiation can be used to obtain information about the scattering material. 89 Normally, the 
scattered light is diffuse and does not provide much information on the scattering object. To 
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obtain structural information on the scattering element, the detected scattered radiation 
must have specular (mirror-like) properties. This means that the radiation coming from a 
single incoming direction is scattered in a single outgoing orientation. 89, 90 In this way, the 
pattern of the scattered radiation is angle-dependent and can be associated with the 
periodicity of well-ordered scattering objects. 86 Wavelengths (λ) larger than the scattering 
element produce Rayleigh scattering, which is angle-independent and cannot provide full 
understanding of the element structure. 90 To obtain specular scattered light of lyotropic 
liquid crystalline dispersions, the wavelength of the incident radiation must be in 
conformity with the nanostructure dimensions. 90 In addition to this, the radiation used 
should not damage or modify the object and must be able to penetrate into the material. For 
these reasons, X-ray (λ in the range of 10 to 0.01 nm) is commonly used in the structural 
analysis of cubosomes and hexosomes. 86  
As shown in Figure 3, during a SAXS measurement, the sample is irradiated with a well-
collimated (minimum spreading, zero-angle position) X-ray beam with a defined 
wavelength (typically λ = 0.154 - 0.08 nm) under vacuum (lower background scattering). 89 
Electron density variations in the sample promote scattering of part of the X-rays from the 
primary beam. The unscattered radiation is blocked by a "beam stop" to protect the detector 
from the high intensities of the direct beam and improve the observation of weak signals. 89 
The scattered waves reach the detector generating bright or dark spots for constructive (in-
phase) or destructive (out of phase) interferences, respectively. 89 The radiation intensity is 
recorded in a specific range of angles, generating a 2D scattering pattern of intensities 
distributed on a plane. This 2D representation can be radially integrated in order to create a 
1D plot of intensity measured in function of the scattering angle 2θ. 17, 19 Alternatively, the 
1D representation can be shown in function of the momentum transfer (q), which can be 
calculated according to the equation below: 90 
  
         
 
 
The patterns of rings (2D plot) or peaks (1D plot) obtained is characteristic of the internal 
structure of the sample. These patterns are formed by the strong signals originated from 
constructive interferences of the scattered radiation. In this context, the Bragg's law 
describes the conditions for the occurrence of constructive interferences. 91 Figure 3B shows 
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two schematic parallel lattice planes of a hypothetical crystalline system. The incident 
radiation number "1" hits the first plane and the incident radiation number "2" hits the 
second lattice plane. The waves "1" and "2" come from the same source with the same 
wavelength (λ) and with peaks and valleys aligned (in-phase). A constructive interference 
happens if the scattered radiation remains in-phase. 90, 91 However, due to the interaction 
with the sample, "2" has a longer path length than "1". Therefore, the condition for keeping 
alignment is that the path length difference is an integer multiple (n) of the wavelength 
(λ). 89-91  The path length difference between "1" and "2" is the sum of AB and BC (shown in 
red), which is equal to 2AB. 2AB can be geometrically calculated as demonstrated (increased 
detail Figure 3B), resulting in 2dsinθ, where d is the distance between the parallel lattice 
planes and θ is the scattering angle. In this way, the Bragg's law (nλ = 2dsinθ) 92 describes the 
condition for the occurrence of constructive interferences, which result in peaks of high 
intensity called "Bragg peaks". 90 
 
Figure 3: Principles of SAXS measurement (A) and the Bragg's law (B). 89, 91 
The identification of structural features of a material is based on the analysis of the relative 
q-positions of the Bragg peaks (q-position of peak x /q-position of peak 1), which can also be 
identified with Miller indices. Table 1 displays the typical Bragg Peaks (with the 
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correspondent Miller indices) observed for the different types of mesophase commonly 
assembled by lipids. 93, 94  
Table 1: Bragg peaks and corresponding Miller indices of lyotropic liquid crystal phases. 93, 94  
 Bragg Peaks 
Mesophase 1                       
QII Pn3m --- 110 111 200 211 --- 220 221 M
ille
r in
d
ice
s 
QII Im3m --- 110 --- 200 211 --- 220 --- 
QII Ia3d --- --- --- --- 211 --- 220 --- 
Lα 110 --- --- 220 --- --- --- 300 
HII 10 --- 11 20 --- 21 --- 30 
Different from the patterns shown in Table 1, the typical scattering profile of micellar phases 
(L2) is composed by only one broad peak. 88   
In comparison to solid crystals, the Bragg peaks measured from lyotropic LCs formed by 
lipids occur at much lower q-positions. 79 This indicates lower scattering angles (θ) and 
consequently larger dimensions. As indicated by the Bragg's Law (Figure 3B), the scattering 
angle is inversely proportional to the interplanar distances (d). 
The coexistence of multiple phases in the same sample may produce SAXS data, which is 
difficult to interprete. This happens because the contribution of different structures to the 
scattering pattern cannot be separated. To understand the structural properties of such 
systems, other complementary characterization methods are necessary, such as cryogenic 
transmission electron microscopy (cryo-TEM). 95 
In cryo-TEM, the sample is vitrified in liquid ethane prior to analysis, being imaged in the 
frozen-hydrated state. In this way, the structures are better preserved and maintain a higher 
fidelity with their native state in dispersion. 96 The visualization of dried samples may yield 
discrepant micrographs and lead to misinterpretations. Therefore, vitrification is highly 
important when studying lyotropic LC systems, whose morphology depends on the 
hydration level. 72  
Due to its resolution of 2 to 3 nm, cryo-TEM allows for a detailed morphological analysis of 
single particles. The combination of tilting experiments (modification of observation axis) 
and Fast Fourier Transformation (FFT) enables not just the differentiation between QII and 
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HII phases, but also precise identification of the particular space group of QII structures. 
This makes cryo-TEM especially advantageous for the analysis of complex systems. 72, 95, 97 
The application of SAXS and cryo-TEM as complementary techniques for the 
characterization of lyotropic liquid crystalline dispersions allows for a reliable and 
substantial understanding of the structural properties of the particles. 79 However, both 
methods are expensive and not easily accessible. In this context, optical polarization 
microscopy showed to be a reliable method for a preliminary mesophase characterization 
and formulation screening. 98 This technique is affordable, rapid, and typically available in 
most laboratories. 72 Furthermore, microscopes equipped with a temperature controlled 
stage enlarged the scope of the analyses, enabling the additional investigation of phase 
behavior upon temperature variations. 72 It is important to consider that this method does 
not enable conclusive identification of the mesophase, but provides critical information on 
the material. In addition, it is only feasible for the evaluation of bulks. Assuming that the 
dispersed nanostructured particles retain the internal organization of the original bulk 
mesophase, 99, 100 polarization microscopy is an important tool for the screening of 
formulations for nanoparticle dispersions. 
The analysis is mainly based on the determination of the optical isotropy or anisotropy of 
the mesophase. Crossed polarizing filters do not allow the transmission of light. However, if 
a sample placed between these polars is anisotropic, the light is rotated and some light 
transmission is observed. 98 Regarding lyotropic liquid mesophases, lamellar (Lα) and 
inverse hexagonal (HII) phases show birefringence (both are anisotropic). Differently, 
inverse cubic (QII) and micellar (L2) phases are isotropic. Lα can be distinguished from HII 
based on their "optical texture". 98, 101 Characteristic textures of Lα phases are for instance, 
long and thin cords, mosaic-like structures, or circular formations containing the "Maltese-
cross". The typical texture of HII phases is the so-called "fan texture". 98, 101 Knowledge of 
"optical textures" can be useful to support this preliminary identification of a mesophase. 
However, this is a very challenging task, which can lead to fragile conclusions. In addition, it 
is crucial to consider that unusual textures can occur. QII and L2 phases do not show 
birefringence under polarized light, but can be differentiated from each other based on their 
apparent viscosity. QII phases are highly viscous, for this reason the samples normally have 
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structured interfaces. L2 phases in contrast, have low viscosity and therefore display smooth 
interfaces. 72  
Overall, optical polarization microscopy is a very useful technique to obtain insights about 
the sample and monitor the initial formulation developing process. In order to precisely 
identify the structure of the material, it is absolutely necessary to confirm the results with 
more powerful techniques (e.g. SAXS and cryo-TEM).   
1.3.3. Inverse non-lamellar Phases: Current Status 
Cubosomes and hexosomes are the most prominent examples of particles internally 
structured with inversed non-lamellar phases. They show advantageous physical-chemical 
properties, which make them promising drug carriers. For instance, these formulations have 
good stability in excess water, their intricate structure, network of water channels, high 
amount of lipid per particle, and large internal interface area allow for high loading 
efficiencies of a wide range of compounds (e.g. hydrophobic, hydrophilic and amphiphilic 
molecules). Therefore, these systems have great potential to overcome encapsulation 
constraints encountered in other nanoparticles. 76, 100, 102 In the context of vaccine 
development, an important limitation of other kind of particles is the small antigen load that 
can be incorporated within the particles (VLPs, ISCOMs, liposomes). Moreover, it has been 
reported that non-lamellar structures show fusogenic properties. 103, 104 Considering this, it is 
hypothesized that cubosomes and hexosomes also have this property, which could enable 
cargo delivery directly to the cytosol. This characteristic could be of great advantage for 
vaccination. The delivery of antigen to the cytosol of antigen presenting cells (APCs) may 
further enhance the stimulation of cytotoxic T lymphocyte (CTL) immune responses. 105 In 
addition, it has been demonstrated that the induction of transitions between the different 
structures can be used as an efficient tool to modify and control the release profile of 
entrapped active molecules. 85, 106, 107  
In spite of the growing interest in non-lamellar lyotropic liquid crystalline phases and their 
great potential for application in the pharmaceutical context, this research field is still very 
much in its infancy. 79 The main challenges arise from the intrinsic multidisciplinarity of this 
subject, low availability of the principal characterization tools and from the lack of 
predictability regarding the structure and its behavior in complex formulations and 
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environments. A key issue with much of the literature on non-lamellar phases, is that it 
comprises mainly physico-chemical analyses. There is a lack of comprehensive studies and 
concrete evidences, and an excess of conjectures regarding the performance of these systems 
in the biological environment. This is especially critical with respect to hexosomes. To date 
there are no studies demonstrating the application of hexosomes as vaccine carriers and only 
surprisingly few reporting their general evaluation in a biological context. This status 
hinders interlaboratory comparisons and analysis regarding reproducibility. Nevertheless, it 
was demonstrated for instance, that hexosomes loaded with progesterone improve 
oromucosal delivery and storage stability. 108 In addition, hexosomes were reported to 
greatly enhance the topical delivery of cyclosporine A. 109 In another study, hexosomes were 
successfully radiolabeled and their theranostic potential was investigated in mice through 
single photon emission computed tomography combined with computed tomography 
(SPECT/CT). 110 Besides this, hexosomes loaded with docetaxel showed 20-fold higher 
cytotoxicity against HeLa cells than the free antineoplasic drug. 111 Overall, these 
nanoparticles have been less well studied than cubosomes and not much is known about 
their feasibility as delivery systems. In contrast, studies reporting the application of 
cubosomes as vaccine delivery systems have already been reported showing promising 
results. It was demonstrated in an animal model that cubosomes were more efficient in 
inducing antigen-specific cellular responses than liposomes. 112 In addition, in a study on 
needle-free transcutaneous immunization using lipid carriers, cubosomes showed superior 
skin penetration and retention in comparison to liposomes and transferosomes. 44 
Furthermore, cubosomes also revealed promising perspectives when applied as an ocular 
delivery system for flurbiprofen, showing suitable tolerability and enhanced transcorneal 
penetration. 113  
Overall, there is little known about the performance of particles internally structured with 
inversed non-lamellar phases in vivo. Consequently, the potential application of these 
formulations remains speculative. The present study aims to fill this gap in knowledge and 
provides a comprehensive investigation on hexosomes from formulation development, 
interaction with the cell membrane and internalization mechanism, to their application as 
adjuvant and vaccine delivery system in vivo.  
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1.4. Cellular Internalization of Nanocarriers 
1.4.1. Overview of the Main Endocytic Pathways  
It is well known today that nanoparticle-based formulations have the potential to improve 
the biological performance of drugs with poor solubility, non-specific cytotoxicity, low 
bioavailability, and/or inappropriate pharmacokinetics and pharmacodynamics. 114 
However, the favorable performance of a nanoparticle-based formulation depends largely 
on their interactions with the cells, especially when the drug target is localized 
intracellularly. 115 The therapeutic outcome is determined by efficient cellular uptake, 
appropriate post-internalization traffic and intracellular fate. Considering that the 
mechanism of cellular internalization generally determines the uptake rate and the 
subsequent series of intracellular events, it is of utmost importance to evaluate and optimize 
this aspect. 115 It is well known that the physicochemical properties of the nanocarriers (e.g. 
size, shape, surface features) play a central role in this matter. However, reliable tools and 
patterns, that help to predict via which pathway drug delivery vehicles may enter cells, have 
yet to be established. 116  
The main internalization pathways can be divided into phagocytosis and pinocytosis (Figure 
4). Phagocytosis is performed primarily by specialized cells, called phagocytes (e.g. 
macrophages, monocytes, neutrophils, and dendritic cells). It is involved in several 
physiological processes, for example, in tissue remodeling, clearance of dying cells, and host 
defense against pathogens and non-self elements. 116 In a simplified way, this internalization 
pathway occurs in three steps. First, the nanocarriers are opsonized through the interaction 
with immunoglobulins (IgG, IgM), complement components (C3, C4, C5), and serum 
proteins (laminin, fibronectin, type I collagen, C-reactive protein). 116 Then, the opsonized 
particles adhere onto the phagocyte through specific interactions between the opsonins and 
receptors of the cell surface (e.g. Fc receptors, complement receptors, mannose receptors). 116 
This initiates a signaling cascade that induces actin rearrangement and pseudopodia 
projection around the particle, culminating with its engulfment. After ingestion, the vesicle 
formed acidifies, ultimately forming a phagolysosome with enzymatic content (esterases, 
cathepsins) to induce degradation of the internalized material. 116  
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Figure 4: Principal endocytic mechanisms of nanocarrier internalization and some of their main 
regulatory proteins. CLIC (clathrin-independent carriers). 117 
Due to the importance of particle opsonization for the phagocytosis, particle surface 
characteristics 118-120 play a decisive role in this internalization pathway. It is known that the 
adsorption of proteins is fostered by surface hydrophobicity and charge. 118, 119 Thus, surface 
coating with the hydrophilic PEG, poloxamer, or poloxamine polymers impedes protein 
binding and decreases interaction with phagocytes, yielding long-circulating stealth® 
particles. 121, 122 A recent report further highlights the effect of particle shape, whereby 
elongated PLGA nanoparticles were less efficiently taken up by macrophages than their 
spherical counterparts. 123 The same study demonstrated a synergistic effect of PEGylation 
and particle elongation to inhibit phagocytosis. 123  Besides these factors, larger particles 
generally show a higher uptake via phagocytosis. 116, 124 
Pinocytosis is a non-phagocytic process and refers to the internalization of the bulk 
extracellular fluid (“cell-drinking”). 115 It can be subdivided in macropinocytosis, clathrin-
mediated endocytosis (CME), caveolae-mediated endocytosis (CvME), and clathrin- and 
caveolae-independent pathways, which are less well characterized (Figure 4). 
Macropinocytosis occurs in diverse cell types, including macrophages. Similarly to 
phagocytosis, it is actin-dependent and involves the formation of long membrane 
protrusions. However, while during phagocytosis these protrusions are projected around 
the opsonized particle and close the vesicles (“zipper-up”), during macropinocytosis a 
pseudopodium surrounds the particle, collapses, and fuses with the membrane (Figure 4). 125 
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Another contrast is that macropinocytosis seems to be unspecific and it does not involve any 
kind of receptor-ligand interaction. 115 
CME takes place in all mammalian cells and it plays an important role in the internalization 
of essential nutrients [e.g. cholesterol low density lipoprotein (LDL), iron-laden transferring 
(Tf-Fe)] and in the intercellular communication. CME can be triggered through specific 
receptor-ligand interactions, but it can also occur in a receptor-independent manner. 125, 126 
Clathrin is a three-legged protein (triskelion), which assembles in basket-like structures with 
polyhedral lattice and supports membrane budding. Thus, clathrin-coated pits are formed 
on the plasma membrane and at late invagination stages the guanosine triphosphatase 
(GTPase) dynamin aids their fission, releasing clathrin-coated vesicles (Figure 4). 126, 127 
CvME occurs through flask-shaped structures called calveolae (Latin for “little caves”) 
(Figure 4) 128, which are formed by caveolin and cavin family proteins. Caveolin-1 (Cav1) is 
the main structural component. 125 Caveolae are present in diverse extents among the 
different mammalian cell types. For instance, while they are extremely abundant in 
endothelial cells, smooth muscle cells, adipocytes, and fibroblasts, their presence is 
insignificant in kidney cells. 129 Considering that the physiological functions of caveolae are 
not fully understood, this heterogeneous distribution could suggest their implication in 
specialized cellular processes. 129 For example, in endothelial cells, it is suggested that CvME 
is involved in the transcytosis of serum proteins from the bloodstream into tissues. 125, 126 
Regarding the role of CvME in the uptake of drug delivery vehicles, it is proposed that the 
particles interact with the cell surface moving along to caveolae, where they get trapped and 
subsequently internalized. 126 Similarly to clathrin-coated pits, scission of caveolae from 
plasma membrane is thought to be driven by dynamin. 125, 126  
In general, nanoparticles internalized through the mechanisms above described are 
transported primarily to endosomes. 114 Early endosomes, also referred to as sorting 
endosomes, have a pH~6. Further acidification by ATP-dependent proton pumps, results in 
late endosomes (pH~5). Posterior fusion with lysosomes exposes the cargo to a digestive 
hydrolytic environment. 114 Interestingly, for many years, it was believed that the contents 
internalized by the CvME pathway were transported to independent organelles of neutral 
pH and rich in caveolin, called caveosome. 130 For this reason, CvME was considered a 
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suitable internalization route to deliver sensitive molecules (e.g. peptides, proteins, nucleic 
acids) and circumvent lysosomal degradation. 116 However, subsequent work classified 
caveosomes as aberrant formations of late endosomes and multivesicular bodies resulting 
from the overexpression of Cav1. 131 Thus, it is still unclear whether CvME indeed 
constitutes an alternative pathway to avoid degradative fate of the internalized cargo. 132   
Besides these classical endocytic routes, several clathrin- and caveolae-independent 
pathways have already been identified. For instance, cell adhesion molecule (CAM)-
mediated endocytosis, flotillin-1-dependent endocytosis, ADP ribosylation factor 6 (Arf6)-
dependent endocytosis, interleukin-2 receptor β (IL2Rβ)-mediated endocytosis, and the 
clathrin independent carriers (CLICs)/GPI-anchored protein enriched early endosomal 
compartment (GEEC) pathway were described. 115 The CLICs pathways (Figure 4) have been 
reported to be involved in the internalization of bacterial exotoxins, 
glycosylphosphatidylinositol (GPI)-linked proteins, and fluid. 133 In addition, CLICs have 
been suggested to play a fundamental role in membrane repair and remodeling, 
homeostasis, and cell migration. 134 Interestingly, Howes et al. found that CLICs constitutes 
the major pathway for fluid internalization in fibroblasts, accounting for up to 70% of total 
fluid internalization. 134 This pathway occurs through pleiomorphic tubovesicular structures 
of several micrometers, originated directly from the cell membrane, and without rigid coat 
(Figure 4). 134-136 Cdc42 activity is essential to form these structures, 134 and the protein 
GTPase regulator associated with focal adhesion kinase-1 (GRAF-1) governs this 
internalization route. 133 CLICs mature into GEECs and subsequently fuse with early 
endosomes. 134 The relevance of CLIC/GEEC and other clathrin- and caveolae-independent 
pathways in the context of drug delivery has yet to be established. 126  
The identification of clear patterns that link physico-chemical properties of nanocarriers to a 
preferred internalization route is challenging. 116 In contrast to phagocytosis, pinocytic 
mechanisms occur essentially in all kinds of cells. 116 Unfortunately, experiments performed 
with different cell types often show considerable disparity. 116 In addition, more than one 
internalization pathway may take place simultaneously, which increases the complexity of 
data analysis and comparison. 116 For this reason, the impacts of determined particle 
characteristics on the uptake must be carefully interpreted, without extrapolation. For 
example, size-dependence has been demonstrated for polystyrene beads in B16 cell line 
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(murine melanoma). In this study, the authors observed predominantly CME for particles 
smaller than 200 d.nm (diameter in nm) and a shift to CvME for larger particles. 137 In 
another study using HeLa cells, polystyrene particles larger than 45 d.nm were internalized 
through CME and particles smaller than 25 d.nm seemed to undergo a clathrin-independent 
pathway and to by-pass lysosomal degradation. 138 Regarding particle surface charge, 
several studies reported higher uptake for positively charged particles in comparison to 
their negative counterparts. 116 Considering that the cell membrane is negatively charged, 
the positive charge of particles may facilitate interactions and consequently improve 
internalization efficiency. 116 Different from the phagocytosis evasion observed for stealth® 
particles discussed above, it was demonstrated that PEGylation of polymeric particles 
impacted the protein corona and improved uptake efficiency. 139, 140  
It should be highlighted that studying particle uptake is challenging and must be carefully 
performed in order to obtain useful results. Important control aspects are often neglected in 
this type of study, which limits interpretation of the findings. For example, it should be 
considered, that widely used pharmacological inhibitors generally have unspecific effects on 
endocytosis, and impact cell physiology as a whole. 115 For this reason, the depletion of 
specific proteins has become the method of choice to achieve better selectivity. 115 
Furthermore, it is crucial to take into account that the suppression of an internalization route 
might induce the stimulation of other pathways. 115 Another important aspect is, when using 
the expression of fluorescently tagged proteins as structural markers [for example Cav1-
green fluorescent protein (GFP) as a marker for caveolae], the expression should be similar 
to that of the endogenous protein to avoid artifacts caused by overexpression. 129 In addition, 
the experimental conditions of in vitro assays (e.g. cell density, phase of growth, and 
confluence) have to be kept consistent, since they might interfere in the endocytic 
behavior. 115 
1.4.2. Relevance of the Internalization Route for Vaccine Carriers 
The innate response involves the activity of the phagocytic and complement system. 141 This 
first line of defense plays an elemental role in recognizing vaccines and adjuvants, and 
starting protective reactions that will culminate in pathogen destruction and enhancement of 
adaptive responses. 142 The adaptive system is the second line of defense with highly specific 
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responses against the pathogenic agent. 141 It was originally proposed that pathogens or 
vaccines in the extracellular medium are engulfed by antigen-presenting cells (APCs), 
processed, and displayed on major histocompatibility complex (MHC) class II on the cell 
surface. Then, these molecules are recognized by CD4+ T cells, which mature to become T 
helper cells 1 or 2 (Th1 or Th2). In contrast, antigens being produced within infected cells 
(intracellular pathogens) are presented on MHC class I and activate CD8+ T cells, which 
differentiate to cytotoxic T lymphocytes (CTLs). 143 However, posterior investigation 
revealed a process called cross-presentation, in which antigens from the extracellular 
environment are presented trough MHC class I and induce CTL responses. 144 Due to the 
pivotal role of CTL responses against challenging vaccination targets, such as HIV and 
cancer, 73 there is a growing interest in exploring cross-presentation in vaccine 
development. 144 For this purpose, optimal interactions between immune cells and antigen 
delivery systems are necessary. It has already been reported that the mechanism of antigen 
internalization combined with its subsequent intracellular trafficking are decisive to allow 
cross-presentation. For instance, it was demonstrated that when APCs internalize soluble 
ovalbumin (OVA) via mannose receptor-mediated endocytosis, the antigen is processed and 
presented through MHC class I (cross presentation). However, if the mannose receptor is 
suppressed, the antigen presentation occurs through MHC class II. 73 Therefore, the 
importance of the internalization route of vaccine carriers goes beyond issues with antigen 
degradation in the lysosomes. The uptake pathway is directly involved in the series of 
events that determine the immunological output and the vaccine efficacy. 
2 AIM AND OUTLINE OF THE THESIS 
This project was conceived to increase the understanding in vaccine delivery and generate 
new tools to address challenges involved in modern vaccine development. The aim of this 
work was to develop and characterize new self-adjuvanting vaccine carriers to help bridge 
the gap between tolerability and induction of potent and persistent immune responses. The 
strategy was to use lipids, with proven immunostimulatory properties, to produce 
nanoparticles internally structured with lyotropic liquid crystalline phases, and develop 
new adjuvant formulations with improved performance. Thus, this work summarizes the 
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development of novel formulations and their physicochemical characterization, their 
interactions with cell membrane, and their biological performance in vitro and in vivo.   
Thesis outline: 
Chapter I: This chapter gives a comprehensive overview of the scientific literature and 
background knowledge used to support the studies shown in the following chapters. A 
thorough introduction to modern vaccine formulations, lyotropic liquid crystalline phases, 
and cellular internalization mechanisms is provided. 
Chapter II: This chapter shows the rational formulation development of hexosomes based on 
phytantriol and mannide monooleate (Phy/MaMo). It presents different preparation 
methods, structural characterization, loading and controlled customization of the systems 
based on changes in size, surface charge and internal structure. 
Chapter III: This chapter describes the studies elucidating the internalization mechanism of 
hexosomes by cells. Here, different methods were applied to understand the uptake 
pathway for Phy/MaMo hexosomes in comparison to a conventional DOPC/DOPE 
liposomal formulation in HeLa cells. Comprehensive experiments with model cell 
membranes are also shown.  
Chapter IV: This chapter demonstrates the important role of delivery systems in eliciting 
immune responses. Hexosomes and cationic liposomes, both containing the lipid adjuvant 
MMG-1, are compared by probing their immunostimulatory activity in vitro and in an 
animal model.  
Chapter V: This chapter brings together the main outcomes of this work and constructs a 
general conclusion about the knowledge gained. Besides this, a critical outlook is presented 
with comments on the remaining open-questions and possibilities to elucidate them. In 
addition, hypothesis about the potential and perspectives regarding the application of the 
novel nanocarriers are given.       
29 
 
CHAPTER II  
Characterization of Hexosomes as  
Versatile Vaccine Carriers 
A version of this chapter has been published in Molecular Pharmaceutics: 
Rodrigues L., Kyriakos K., Schneider F., Dietz H., Winter G., Papadakis C. M., Hubert M. 
(2016). „Characterization of lipid-based hexosomes as versatile vaccine carriers.” Molecular 
pharmaceutics, 13(11), 3945-3954. 
This work was conducted in collaboration with the Soft Matter Physics Group and Institute for 
Advanced Study of the Technische Universität München. The manuscript was written by Rodrigues 
L. The SAXS measurements were performed by Rodrigues L and Kyriakos K under the supervision of 
Papadakis C M. Cryo-TEM image acquisiton was conducted by Schneider F and supervised by Dietz 
H. All data analyses and additional experimental work were performed by Rodrigues L and 
supervised by Winter G and Hubert M.      
The section 4.5 “Expanding the Customization Tool Box of Hexosomes” of this chapter and the 
figures showing molecular structures are not present in the published article.  
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1 ABSTRACT 
Sub-unit vaccines typically show insufficient immunogenicity. To address this issue, we 
developed a novel self-adjuvanting particulate carrier system based upon the lipids 
phytantriol (Phy) and mannide monooleate (MaMo). Phy is a lipid known to form non-
lamellar phases in fully hydrated systems, whereas MaMo has been found to promote 
immune responses in emulsion form. A bulk phase composition of Phy/MaMo (14 wt%) 
showed hexagonal (HII) phase behavior over a practical temperature range (including room 
and body temperature), and was therefore used for particle development. Hexosomes 
stabilized with different concentrations of either poloxamer 407, Myrj 59 or Pluronic F108 
were successfully prepared. To demonstrate the versatile nature of these systems, the 
particles were further modified with positively and negatively charged lipids to change the 
zeta potential, and loaded with model antigens, whilst maintaining the HII structure. In 
addition, octyl-β-D-glucopyranoside was shown to be a suitable tool to transform 
hexosomes in cubosomes in a controlled manner. Overall, Phy/MaMo based hexosomes are 
structurally robust and amenable to customization, rendering them suitable as antigen 
delivery carriers. 
 
Figure 5: Graphical Abstract – Characterization of Lipid-Based Hexosomes as Versatile Vaccine 
Carriers. 
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2 INTRODUCTION 
Vaccines are of utmost importance for global health and demonstrate one of the greatest 
medical successes. Especially vaccines based on highly purified and well-defined antigenic 
motifs (sub-unit vaccines) improved the safety and tolerability over the traditional whole-
pathogen preparations. 14 Nevertheless, sub-unit vaccines are often inefficient, because they 
are not able to induce the same level of immunogenicity demonstrated by the traditional 
ones. 145 To circumvent these issues, several strategies have been considered. For instance, 
potent immunostimulatory compounds (adjuvants) are co-administered with the antigen 
molecules to improve the strength and type of the immune response. 25 The incorporation of 
antigens into particulate delivery systems can prevent the premature degradation of the 
antigen in-vivo and at the same time allows mimicking the size, geometry, and kinetics of 
viruses and bacteria. 145 Moreover, the particle design offers a range of possibilities for 
tuning interactions between antigen molecules and immune cells as well as overcoming 
multiple dose regimens. 145 Progresses in the field of particulate delivery systems revealed 
promising potential for lipid-based particles such as cubosomes and hexosomes. 22, 146 
Cubosomes are internally structured with an inverse bicontinuous cubic phase. They are 
formed by a highly twisted continuous lipid bilayer creating a complex network with 3-D 
cubic symmetry and two non-intersecting water channels. 76 Hexosomes are rod-shaped 
inverse micelles organized in a hexagonal structure with closed water channels. 76 Due to 
their high interfacial areas and network of water channels, these particles are known as 
multi-compartment carriers and have great potential to overcome encapsulation constraints 
encountered with other particulate systems (liposomes, virus-like particles, and ISCOMs). 22, 
100, 102 Moreover, it has already been reported that non-lamellar structures (like cubic and 
hexagonal) show fusogenic properties,103, 147 which could contribute to the delivery of 
antigens directly to the cytosol of antigen-presenting cells (APCs), stimulating cytotoxic T 
lymphocyte (CTL) immune responses.  
The present work proposes the development of new self-assembled lipid-based particles 
with non-lamellar internal structures and immunostimulatory properties for vaccine 
delivery. For this purpose, the phase behavior of systems containing phytantriol (Phy) and 
mannide monooleate (MaMo) was investigated (Figure 6).  
C H A P T E R   I I    Characterization of Hexosomes as Versatile Vaccines Carriers 
DEVELOPMENT OF NOVEL VACCINE CARRIERS                                                                                                                            32 
 
 
Figure 6: Molecular structures of (a) phytantriol and (b) mannide monooleate. 
Phy is a well-characterized lipid able to form non-lamellar phases in fully hydrated systems. 
148 MaMo is an emulsifier applied in several adjuvant systems (Montanide ISA 51 and 720, 
and Freund´s adjuvant) 149 and it is known to promote Th1 and Th2 responses in emulsion 
form. 150 The current approach aimed to synergistically combine the structural properties of 
Phy with the intrinsic biological activity of MaMo in one unique system to deliver antigens 
for immunization purposes. Different analytical methods, such as small-angle X-ray 
scattering (SAXS), cryogenic transmission electron microscopy (cryo-TEM) and polarization 
microscopy, were applied to characterize these new systems and to systematically develop 
customized nanostructured particles. The hexosomes could be modified with other charged 
lipids and model antigens without compromising the internal hexagonal structure. Taken 
together, the results presented here emphasize the versatility of these systems and 
demonstrate their great application potential for the delivery of biopharmaceuticals. 
3 MATERIALS AND METHODS 
3.1. Materials 
Phytantriol (Phy) from DSM Nutritional Products Europe Ltd was kindly provided by 
Nordmann, Rassmann GmbH (Hamburg, Germany). Mannide monooleate from plant 
(MaMo), dimethyldioctadecyl-ammonium bromide (DDA), poloxamer 407, albumin from 
chicken egg white (OVA), and lysozyme from chicken egg white (LYS) were purchased from 
Sigma-Aldrich (Taufkirchen, Germany). Pluronic F108 and Myrj 59 were a gift from Croda 
(Barcelona, Spain). 1,2-dioleoyloxy-3-trimethylammonium propane chloride (Dotap), and 
1,2-distearoyl-sn-glycero-3-phospho-rac-glycerol sodium salt (DSPG) were purchased from 
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Lipoid GmbH (Ludwigshafen, Germany). CBQCA Protein Quantitation Kit was purchased 
from Life Technologies GmbH (Darmstadt, Germany). Phosphate buffer saline solution 
(PBS) was prepared at pH 7.2-7.6 using potassium chloride (Merck KGaA), potassium 
phosphate monobasic (Merck KGaA), sodium chloride (Merck KGaA), and sodium 
phosphate dibasic anhydrous (Grüssing GmbH). 
3.2. Preparation of Bulk Phases 
Appropriate amounts of Phy and MaMo were melted together at 70°C using the 
Thermomixer comfort (Eppendorf). In order to obtain a homogeneous molten, the samples 
were frequently vortexed. Highly purified water was added to obtain fully hydrated bulks 
(final lipid concentration of 50 wt%). 
3.3. Preparation of Particles 
Phy (86 mg), and MaMo (14 mg) were weighed and homogenized together as described for 
the bulk phases. To disperse particles from the bulk phase poloxamer 407, Pluronic F108 or 
Myrj 59 were applied as stabilizers in concentrations ranging from 5 to 30 wt% of the total 
lipid mass. The stabilizer solution in PBS was added to the Phy/MaMo mixture and 
followed by intense vortexing to give a final lipid concentration of 10 wt%. The samples 
were then agitated for 30 min at 3500 rpm in a dual asymmetric centrifuge (SpeedMixerTM), 
followed by 3 cycles of sonication of 1 min with 4 s pulse, 2 s pause, and 20% amplitude 
(Bandelin Sonopuls HD3200 with sonotrode MS72). To introduce different particle surface 
charges, Phy and MaMo were homogenized with different amounts of charged lipids (DDA, 
Dotap, or DSPG). The samples were then processed as described above. In order to prepare 
protein loaded particles, appropriate amounts of either LYS or OVA were dissolved in the 
stabilizer solution and added to the lipid molten. Subsequently, the samples were agitated 
and sonicated as specified above. All samples were stored at room temperature (rt). 
3.4. Polarization Microscopy 
Polarization microscopy was performed as a preliminary screening method to select the 
bulk phases for SAXS measurements. The analyses were carried out using the Keyence 
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microscope BZ-8100E equipped with a heating stage (Thermo Plate from TokaiHit) and 
polarization filters. A thin layer of sample (fully hydrated bulk) was applied between 2 
cover glasses and observed under polarized light at temperatures from 25°C to 50°C. The 
presence of birefringence is an indication of lamellar (Lα) or inverse hexagonal (HII) phases. 
Inverse bicontinuous cubic (QII) and micellar (L2) phases typically show isotropic behavior. 
151 Liposomes, hexosomes, cubosomes, and micelles can be derived from the dispersion of 
bulk phases with Lα, HII, QII, and L2 structures, respectively. 103     
3.5. Small-Angle X-ray Scattering (SAXS) 
SAXS analyses were accomplished using a Ganesha 300XL instrument equipped with a 
GENIX 3D microfocus Cu X-ray source and a 2D Pilatus 300K detector in a fully evacuated 
sample chamber. The bulk samples were mounted in a Linkam cell between mica windows 
(thickness 5-7 µm). For the characterization of particles, the dispersions were introduced into 
glass capillaries (1 mm light path), which were then hermetically sealed and mounted in a 
heatable/coolable cell. The samples were measured after 10 min of equilibration at the 
selected temperature. The wavelength was λ=1.54 Å and the sample-to-detector distance 
401.4 mm (Linkam cell) and 406.2 mm (capillaries). The acquisition time was 30 and 120 min 
for bulks and particles, respectively. Longer acquisition times were used for the particles in 
order to increase the statistics and compensate the lower scattering signal. A pin diode was 
used to measure the transmission of the sample. The 2D images were azimuthally averaged 
and the background from the mica windows was subtracted, taking the transmission into 
account.   
In order to identify the different liquid crystalline phases, the q-position (                
is the momentum transfer) of each Bragg reflection was determined by fitting a Lorentz 
function. The ratios of the relative peak positions were calculated and compared to patterns 
described in the literature. 152, 153 The repeat distance d was calculated using        , 
where q1 is the position of the first peak. The mean lattice parameter a was determined 
according to the scattering law for the respective mesophase, namely       for Pn3m 
(cubic double diamond) and         for HII (inverse hexagonal). 154 
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3.6. Dynamic Light Scattering (DLS) 
Size and zeta potential analyses were performed using the Malvern Zetasizer Nano ZS 
(Malvern Instruments GmbH). Samples were diluted (1:200) and measured in PMMA 
cuvettes or DTS1060C capillary cells for the determination of size and zeta potential, 
respectively. All measurements were performed in triplicate, at 25°C, and in buffering 
conditions relevant for biological experiments (PBS, pH 7.4).     
3.7. Protein Load Determination 
In order to separate the free protein, the particles were washed four times with PBS using a 
centrifugal concentrator (Vivaspin 20 with PES membrane and MWCO 100k). To disrupt the 
particles and release potentially encapsulated protein molecules, the washed samples were 
incubated for 30 min at rt with Triton-X 0.5%. After centrifugation (21000 g, 10 min), the 
protein content was quantified with the CBQCA Kit according to the manufacturer's 
protocol. Considering possible material loss that may occur during the washing steps, the 
values obtained after protein quantification were corrected by the dry mass of each sample 
(determined gravimetrically). The experiments were conducted in triplicates. Relative 
loading efficiencies were compared using a paired Student’s t-test performed by SigmaPlot 
12.5 (Systat Software Inc., Germany).  
3.8. Tryptophan Accessibility Assay 
The accessibility of tryptophan residues to the collisional quencher acrylamide was 
evaluated. The fluorescence of protein molecules in buffered solution, and when loaded in 
particles, was investigated upon the addition of acrylamide at different concentrations (0.2 
to 2 M). The fluorescence was monitored using the Cary Eclipse Fluorimeter at 25°C with 
excitation 280 nm (slit width 10 nm) and emission 300-400 nm (slit width 5 nm). To compare 
the fluorescence intensities in different environments, the ratios between unquenched (F0) 
and quenched (F) signals were calculated for each sample.    
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3.9. Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Vitrified specimens of selected formulations at approximately 5 wt% (total lipid) were 
prepared in a Vitrobot (FEI, The Netherlands) at 22°C and 90% humidity. A volume of 3 µl 
of the particle dispersion was applied on 400-mesh Quantifoil R2/1 cupper grids 
(Quantifoil, Germany) that were negatively glow discharged with a Plasma Cleaner (EMS, 
USA) at 35 mA for 45 s. After 15 s equilibration, the excess of liquid was removed through 
blotting (3 s, blot force -1) and the grids were automatically vitrified in liquid ethane below -
172°C. The samples were imaged using a Tecnai Spirit microscope (FEI, The Netherlands), 
equipped with an Eagle 4k charge-couple device (CCD) camera and a Cryo-Transfer Holder 
(Gatan, Inc.,USA). The system was operated at an acceleration voltage of 120 kV under low 
dose conditions (SerialEM acquisition software) with 26’000-, 30’000-, and 40’000-fold 
magnification. Image analysis was performed using Fiji.   
4 RESULTS AND DISCUSSION 
The design of novel particulate systems with non-lamellar internal structures and desired 
characteristics can be challenging, especially in complex formulations. Moreover, as it is 
very difficult to predict the impact of each additive on the mesophase structure, 
comprehensive studies are required. In the present work, formulations based on a 
combination of Phy and MaMo were systematically developed and the effects of various 
additives on relevant properties such as size, morphology, stability, charge, and loading 
were evaluated. 
4.1. Characterization of Bulk Phases 
To investigate the behavior of systems formed by Phy and MaMo, fully hydrated bulk 
phases of Phy/MaMo were prepared at different ratios in highly purified water and 
characterized using polarization microscopy and SAXS. Polarization microscopy was used 
to pre-screen a large number of samples and establish a phase diagram outline (Figure 7A), 
which enabled the selection of feasible temperature and concentration ranges for the SAXS 
analyses. The observation of anisotropy under polarized light is an indication of lamellar 
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(Lα), or inverse hexagonal (HII) structures, which, in dispersion, can yield liposomes, or 
hexosomes, respectively. Isotropy, in turn, is an evidence of inverse bicontinuous cubic 
(QII), or micellar (L2) structures, which can be dispersed in cubosomes, or micelles, 
respectively. 103, 151 This analysis is challenging for liquid samples due to their high mobility, 
which hampered the visualization of transitions and birefringence. For this reason, the phase 
diagram outline was restricted to samples containing 0-20 wt% MaMo which were gel-like at 
rt.  
As displayed in Figure 7A, bulks prepared with Phy at 100% appeared isotropic under 
polarized light at almost all temperatures investigated. This, together with the gel-like 
consistency, illustrated the typical aspect of inverse bicontinuous cubic phases (QII). 
Likewise, Dong et al. observed isotropic properties and high viscosity for fully hydrated 
bulks of Phy. 155 However, they reported a transition to anisotropic behavior at temperatures 
above 60°C, while in the present work, the formation of birefringent structures occurred 
already at 50°C (Figure 7A). The phase diagram outline (Figure 7A) revealed that even low 
concentrations of MaMo had a remarkable impact on the structure of pure Phy. At 2-4 wt%, 
MaMo induced a transition from iso- to anisotropic behavior with an intermediate region 
showing characteristics of both phases. This transition can be seen in more detail in Figure 
7B, in which the micrographs obtained for a fully hydrated bulk formed by 3.3 wt% MaMo 
in Phy are displayed. At 25°C, the isotropic and featureless aspect of this bulk was evident. 
In addition, the high viscosity of the sample was noticeable through its irregular interface, 
which suggested an inverse cubic structure (QII). At 33°C, the formation of small 
birefringent areas was observed. This anisotropic aspect is characteristic for both, lamellar 
(Lα), and inverse hexagonal (HII) phases. 151 At higher temperatures (34-50°C), the 
anisotropic properties became gradually more dominant and the addition of more MaMo 
(Figure 7A) shifted the transition from iso- to anisotropic behavior to temperatures below 
25°C.  
These findings demonstrated the remarkable ability of MaMo to modify the phase behavior 
of Phy and indicated the establishment of an anisotropic mesophase at room temperature 
(Figure 7A). At 15-20 wt% MaMo, the bulk samples underwent a transition from anisotropic 
to isotropic at higher temperatures (above 35°C). In comparison with the initial isotropic 
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structure, the second isotropic phase displayed higher fluidity, which may be an indication 
of a micellar (L2) structure. 155, 156 
 
Figure 7: A: Phase diagram outline established through polarization microscopy of fully hydrated 
bulk phases formed by Phy and MaMo at different weight ratios and temperatures. B: Polarization 
micrographs of a fully hydrated bulk formed by 3.3 wt% of MaMo in Phy at different 
temperatures. 
In order to fully understand the impact of MaMo on Phy systems and to precisely identify 
the mesophases along with their internal arrangements in a broader concentration and 
temperature range, SAXS measurements were performed. As shown in Figure 8A, in pure 
Phy systems, a phase transition from inverse bicontinuous cubic double diamond (Pn3m) to 
HII occurred at approximately 50°C. At 60°C, a pure HII topology was identified. 
Interestingly, this structure did not prevail in a large temperature range, and already at 
70°C, the sample displayed an inverse micellar (L2) structure. Similarly, the characterization 
of Phy bulks reported by other groups 155, 157 revealed Pn3m structures at room temperature, 
followed by transitions to HII and subsequently to L2 upon temperature increase. However, 
the literature is not fully consistent with respect to the phase transition temperatures 
determined in the present work. Deviations of up to 10°C were identified. 100 It is known that 
the origin of the substances used plays a decisive role in this matter, i.e. the phase behavior 
strongly depends on the purity of the Phy used. 100, 158 This may explain the deviations from 
reports of other groups.  
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Higher MaMo ratios facilitated the formation of HII structures (Figure 8A). The phase 
transition from Pn3m to HII observed in pure Phy systems at 50°C was reduced to values 
below 25°C. Analogously, the temperature of the phase transition from HII to L2 was 
progressively decreased as the MaMo content increased (from 60-70°C in 100% Phy to 25-
37°C in 28 wt% MaMo in Phy). Samples containing 40-80 wt% MaMo in Phy showed phase 
separation, while concentrations above 80 wt% resulted in stable and homogeneous samples 
with L2 structure.  
The phase modulation demonstrated by MaMo in Phy bulks is comparable to other lipidic 
systems, such as Phy/vitamin E acetate, 155 glyceryl monooleate/diolein, 159 and glyceryl 
monooleate/oleic acid. 160 Analogously, the original inverse cubic structure was successfully 
transformed to HII with the incorporation of each component in a concentration dependent 
fashion. 155, 159, 160  
Among all Phy/MaMo ratios evaluated, Phy bulk phases containing 14 wt% MaMo were 
found to be the most suitable for this study. At this MaMo content, HII mesophases were 
formed and maintained over the largest temperature range, including body and room 
temperature, as indicated by SAXS analysis (Figure 8B). Interestingly, the SAXS results 
revealed that a temperature increase from 25 to 37°C promoted a reduction of the lattice 
parameter from 4.85 ± 0.01 to 4.63 ± 0.01 nm. This temperature dependent behavior was seen 
in all samples and may be explained by the higher conformational disorder and volume 
expansion in the chain region of the lipid molecules at higher temperatures. 103 At 50°C, the 
first and most intense peak became broader, while the intensity of the second and third peak 
was reduced, indicating a HII-L2 phase transition (Figure 8B). At 60°C and 70°C, the typical 
scattering profile for L2 structures, featuring only one broad peak, was observed. The 
presence of HII structures over a large temperature range may be advantageous for the 
customization of the systems and particle stabilization without sacrificing the non-lamellar 
profile. 
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Figure 8: A: Phase diagram obtained by SAXS measurements of fully-hydrated bulk phases 
formed by Phy and MaMo at different weight ratios and temperatures. B: SAXS curves as a 
function of temperature of 14 wt% MaMo in Phy (fully hydrated bulk phase); Pn3m (inverse 
bicontinuous cubic double diamond); HII (inverse hexagonal); L2 (inverse micellar). 
4.2. Particle Preparation 
The preparation of particles requires the addition of a stabilizing agent, which enables the 
dispersion of the bulk phase and prevents particle aggregation and/or flocculation. 100 
However, depending on the concentration used, this emulsifier can increase the toxicity of 
the particles and also disturb their internal structure. 161 Poloxamer 407 (also known as 
Pluronic F127) is the most commonly used stabilizing agent in lyotropic liquid dispersions. 
100 A recent study identified Pluronic F108 (poloxamer 338) to be even more effective as a 
stabilizer than Pluronic F127 for dispersed systems composed of Phy or glyceryl 
monooleate. 162 Similarly, an excellent stabilization capacity of Phy-based cubosomes has 
also been reported for Myrj 59 (Polyoxyethylene-100-stearate). 163 The molecular structures 
of these three stabilizers are displayed in Figure 9. 
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Figure 9: Molecular structures of poloxamer 407 and Pluronic F108 (a), and Myrj 59 (b). 
The feasibility of these three stabilizers to disperse concentrated Phy/MaMo systems and to 
yield hexosomes within the submicron range was evaluated in the present study. The results 
obtained for the size analyses of the particles through dynamic light scattering (DLS) are 
depicted in Figure 10 and indicated that all stabilizers effectively dispersed the Phy/MaMo 
bulks. SAXS analyses of the samples containing 5 and 30 wt% of each stabilizer showed that 
the internal inverse hexagonal structure of the particles was maintained (Figure 11). As 
displayed in Figure 10, at high concentrations (above 20 wt%), all stabilizers promoted a 
drastic reduction in size and polydispersity of the samples. Such remarkable impact of 
stabilizer concentration on the particle size profile has not been observed in similar 
investigations. 155, 162, 163 An explanation may be that the size is not only determined by the 
stabilizer type and concentration, but also by the dispersion method. Dong et al. prepared 
Phy/vitamin E acetate hexosomes stabilized with 10 wt% Pluronic F127 and reported a 
diameter of approximately 250 nm and polydispersity index (PdI) below 0.25. 155 These 
results strongly contrasted with the sizes displayed in Figure 10A, which can be attributed to 
the different ultrasonication protocols used. In the present study, the hexosomes were 
prepared using mild conditions (3 cycles: 1 min of 4 s pulse/2 s pause, 20% amplitude), 
while Dong et al. 155 applied much higher energy input (20 min of 0.5 s pulse/0.5 s pause, 
40% amplitude). We assumed that high-energy dispersion methods are able to increase the 
efficiency of the stabilizing agent, diminishing the concentration dependence displayed in 
Figure 10. This was supported by the preparation of Phy/MaMo hexosomes stabilized with 
5 wt% poloxamer 407 using harsh ultrasonication conditions (2 cycles: 5 min of 4 s pulse/2 s 
pause, 50% amplitude) that yielded particles with an approximate diameter of 200 nm and a 
PdI below 0.15. Despite the enhancement of the size profile, the energy excess is mainly 
dissipated as heat, which makes these conditions unsuitable for potential encapsulation of 
proteinaceous material. 
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Based on the reduction of the particle size seen in Figure 10, it may be assumed that at 5 wt% 
Myrj 59 dispersed the bulk phase more efficiently than the other stabilizers. However, when 
considering the number of stabilizer molecules necessary to stabilize a specific number of 
lipid molecules, 5 wt% of Myrj 59, corresponding to 0.37 mol%, can be practically compared 
to samples stabilized with 15 wt% poloxamer 407 and Pluronic F108, corresponding to 0.41 
and 0.35 mol%, respectively, within this data set. This comparison revealed that Myrj 59 is 
the least potent stabilizing agent and thus contradicts descriptions by Chong et al., in which 
Myrj 59 was considered a more potent stabilizing agent than Pluronic F127. 163 Particles 
dispersed with Pluronic F108 and poloxamer 407 showed comparable size profiles, whereby 
Pluronic F108 promoted a slightly better size reduction, possibly due to its longer 
polyoxypropylene chain (Figure 9). 162  
It is important to consider that stabilizers with longer chains may promote a more intensive 
stealth effect in biological systems, as observed with a standard PEGylation. In this work, 
the hexosomes are intended to be used for vaccine delivery, and the particle uptake by the 
immune cells is a desired effect. For this reason, stabilizing agents with shorter molecules, 
such as poloxamer 407 and Myrj 59, are preferred over Pluronic F108 (Figure 9). 
 
Figure 10: Size characterization by dynamic light scattering of Phy/MaMo (14 wt%) formulations 
containing poloxamer 407 (A), Pluronic F108 (B), and Myrj 59 (C) at different concentrations. The 
stabilizer concentrations are given in weight% and in mol% of the total lipid in the formulation. 
Bars depict mean ± SD of three independent measurements. 
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Figure 11: Structure characterization through SAXS of Phy/MaMo (14 wt%) formulations 
containing poloxamer 407 (A), Pluronic F108 (B), and Myrj 59 (C) at 5 and 30 wt% of total lipid. The 
black curve represents the non-dispersed bulk phase without stabilizer. Measurements were 
performed at 25 °C. The curves were vertically shifted for clarity. 
4.3. Particle Size Optimization 
The formation of non-lamellar structured particles is typically achieved through the 
dispersion of the bulk phase in the presence of stabilizers. 151, 164 In order to prepare 
relatively monodisperse systems with stable particles in the submicron range, the dispersion 
technique is followed by a post-treatment to further improve the size profile. For instance, 
heat treatment (125°C for 20 min), 165 autoclaving (121°C for 15 min at 1 bar) 83 and high 
pressure homogenization 166 have been reported as suitable dispersion post-treatment 
methods to reduce the size distribution of glyceryl monooleate cubosomes stabilized with 
Pluronic F127. Figure 12 shows strategies applied in the present work to optimize the size 
profile of Phy/MaMo particles stabilized with 30 wt% Myrj 59. When incubated overnight at 
40°C, the particles showed a drastic size reduction in comparison to samples kept at room 
temperature (Figure 12A). Maintaining constant storage conditions, size and PdI remained 
constant over 45 days. Interestingly, samples not subjected to this temperature treatment 
underwent a progressive size reduction over time.  
These results suggested that the temperature treatment accelerated an equilibration process 
of the system, yielding a stable and relatively monodisperse particle dispersion that can be 
stored at rt for at least 45 days. This phenomenon was observed only in samples stabilized 
with Myrj 59, and to date, to the best of our knowledge, there are no reports addressing 
similar findings. Studies on cubosomes stabilized with Pluronic F127 showed that intensive 
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heat treatment (125°C for 20 min) yielded larger particles with a more narrow size 
distribution, 165, 167 while lower temperatures for longer time periods (95°C for two hours) 
did not induce the same effects. 165 It may be hypothesized that Pluronic F127 and Myrj 59 
have different stabilization mechanisms and interact differently with the lipidic structure.  
Alternatively, three-fold extrusion of the formulations through a polycarbonate membrane 
of 400 nm pore size yielded stable particles with a similar size profile (Figure 12B). One 
major advantage of the temperature treatment over the extrusion is that it maintains the 
sample integrity, because material loss is not possible. However, depending on the 
encapsulated content, the temperature treatment may induce instability issues and 
premature release. SAXS analysis confirmed the conservation of the HII structures after both 
size optimization strategies (Figure 12) and affirmed that both methods are suitable to 
improve the size profile of these systems.  
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Figure 12: Size optimization strategies shown for Phy/MaMo (14 wt%) hexosomes stabilized with 
30 wt% Myrj 59. A: Size (columns) and PdI (squares) monitored by DLS of samples stored at room 
temperature (rt) (dark grey), and samples incubated overnight at 40°C (light grey). B: Effect of size 
optimization using temperature treatment at 40°C and extrusion through a polycarbonate 
membrane of 400 nm pore size. Data is displayed as mean ± SD of three independent 
measurements. C: SAXS curves from particles without size optimization (black), subjected to 
extrusion through a polycarbonate membrane of 400 nm pore size (red), and subjected to 
temperature treatment overnight at 40°C (blue). 
4.4. Particle Customization 
Considering the relevance of the overall surface charge of delivery systems in the 
interactions with cells, hexosomes carrying a positive or negative overall surface charge 
were developed in the present work. For this purpose, DDA (+), Dotap (+), and DSPG (-) 
(Figure 13) were added at various concentrations (5-30 wt%) to the standard Phy/MaMo (14 
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wt%) formulation. The measured zeta potential of each hexosome formulation correlated 
with the amount of incorporated charged lipid, whereby increased concentrations resulted 
in higher absolute values (positive/negative) (Figure 14).  
 
Figure 13: Molecular structures of DDA (a), Dotap (b), and DSPG (c). 
 
Figure 14: Zeta potential values of Phy/MaMo (14 wt%) hexosomes stabilized with 15 wt% 
poloxamer 407 containing different amounts of charged lipids, as given in the graph in wt% of the 
total lipid amount. All measurements were performed at rt, in buffering conditions relevant for 
biological studies (PBS, pH 7.4). Data shows the average of three independent measurements ± 
SD. 
The nature of the charged lipid and its concentration are critical for the internal structure of 
the particles. 100 SAXS was used to verify whether the hexagonal structure in samples 
containing relatively high concentrations of charged lipids was maintained (Figure 15). The 
addition of DDA had a considerable impact on the HII mesophase at 25°C (Figure 15). The 
C H A P T E R   I I    Characterization of Hexosomes as Versatile Vaccines Carriers 
DEVELOPMENT OF NOVEL VACCINE CARRIERS                                                                                                                            47 
 
first and third peak at 1.217±0.003 and 1.481±0.006 nm-1, respectively, corresponded to the 
    and    reflections and indicated Pn3m structures. This suggested a transition or 
coexistence of Pn3m and HII phases. Within the lipid domain, the positive charge of DDA 
increased the repulsion between the headgroups. It was assumed that this imbalance of 
lateral stresses reduced the negative curvature of the structure, which promoted a transition 
from a hexagonal to a cubic geometry. 168, 169 Interestingly, a temperature increase from 25°C 
to 37°C promoted a recovery of the system, which displayed peaks at 1.381±0.001, 
2.395±0.006, and 2.752±0.009 nm-1 (corresponding to 1,   , and    reflections in Figure 15) 
and represented a predominant HII profile. A plausible explanation may be that higher 
temperature led to greater conformational disorder and splay in the chain region and so 
compensated the lateral stresses between the headgroups. 103 The HII structure formed at 
37°C showed Bragg reflections at lower q values than the original bulks (black curves) 
suggesting an enlargement of the cell unit.  
 
Figure 15: Effect of additional charged lipid on Phy/MaMo (14 wt%) hexosomes stabilized with 15 
wt% Poloxamer 407. SAXS patterns are shown for the following samples at 25°C and 37°C: 
standard Phy/MaMo (14 wt%) bulk phase (black), 30 wt% DDA (green), 25 wt% Dotap (blue), and 
15 wt% DSPG (red). The curves were shifted vertically for clarity. The vertical dashed line 
highlights a shift of the Bragg reflections to lower q values for samples containing charged lipids 
in comparison with the original Phy/MaMo (14 wt%) bulk. 
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Formulations containing Dotap (blue curves), and DSPG (red curves) maintained the HII 
structure at both temperatures and showed an increased lattice parameter from 4.84±0.01 
nm (bulk phase) to 5.62±0.01 and 5.75±0.01 nm for Dotap and DSPG, respectively (at 25°C, 
Table 2). A higher lattice parameter correlates with an enlargement of the water channel 
diameter. 170 This modulation of the internal structure may be used as potential tool for drug 
encapsulation. Similarly to the Phy/MaMo bulk phases (Figure 8B), hexosomes containing 
DSPG and Dotap revealed a reduction of the lattice parameter upon temperature increase 
(Table 2). However, this behavior was less pronounced, which is most likely due to 
repulsion between the charged headgroups (Figure 13) and sterical hindrance. 103 
Table 2: Change in lattice parameter upon temperature increase of charged Phy/MaMo (14 wt%) 
hexosomes stabilized with 10 wt% Poloxamer 407. 
 Lattice Parameter 
Formulation at 25°C (nm) at 37°C (nm) Difference** (%) 
Bulk* 4.84 4.64 4.08 
Hexosomes + 25 wt% Dotap 5.62 5.55 1.28 
Hexosomes + 15 wt% DSPG 5.75 5.66 1.61 
*Bulks do not contain stabilizers and charged lipids. **Lattice parameter reduction from 25°C to 37°C. 
The effect of DDA on the internal structure in comparison to Dotap at similar molar 
concentrations was surprising (Figure 16). Due to its smaller headgroup and saturated 
hydrocarbon chains (Figure 13), DDA was expected to show minimal impact on the 
hexagonal structure. However, it seemed to induce a transition from the hexagonal to the 
cubic phase, whereas Dotap, which consists of a trimethylammonium headgroup and two 
unsaturated hydrocarbon chains (Figure 13), only enlarged the lattice parameter. As 
mentioned earlier, it is believed that due to its molecular structure, DDA generated an 
imbalance between the hydrophobic chains and headgroup. Even though Dotap is a more 
voluminous molecule than DDA, the results indicated that the headgroup and hydrocarbon 
chain regions contributed more equally to the packing parameter 100, 103 and the HII structure 
was preserved. 
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Figure 16: Effect of the headgroup dimension on the internal structure of Phy/MaMo (14 wt%) 
hexosomes stabilized with 10 wt% poloxamer 407. SAXS data are displayed for hexosomes 
containing the same molar concentration (ca. 14 mol%) of DDA (green) and Dotap (blue) at 25 and 
37 °C. Arrows indicate perturbance of the pure HII peak profile. The curves were vertically shifted 
for clarity. 
The effect of the addition of charged lipids on the structure of Phy/MaMo hexosomes was 
also observed with Cryo-TEM (Figure 17). The electron micrographs of the standard 
formulation (without addition of charged lipid), and formulations containing 25 wt% Dotap 
or 15 wt% DSPG revealed particles with clear parallel lines forming curved striations, 
and/or hexagonal shape, which are characteristic for hexosomes. 97 Differently, samples 
containing 30 wt% DDA displayed a more undefined structural profile. The particles 
appeared to have a spherical shape and showed internal structures with undulated distorted 
lines. These observations are in agreement with the SAXS measurements (Figure 17).   
C H A P T E R   I I    Characterization of Hexosomes as Versatile Vaccines Carriers 
DEVELOPMENT OF NOVEL VACCINE CARRIERS                                                                                                                            50 
 
 
Figure 17: Cryo-TEM images of Phy/MaMo (14 wt%) formulations stabilized with 15 wt% 
Poloxamer 407. A: without additional charged lipid; B: addition of 30 wt% DDA; C: addition of 25 
wt% Dotap; D: addition of 15 wt% DSPG. 
4.5. Expanding the Customization Tool Box of Hexosomes 
In order to amplify the variety of potential applications of Phy/MaMo dispersions, and 
prove the versatility of these formulations, octyl-β-D-glucopyranoside (OG) was evaluated 
as a tool to modify the internal structure of the particles in a controlled manner. This 
additive has been successfully used to enlarge the water channels of glyceryl monooleate 
cubosomes. 171 A preliminary evaluation of the effect of OG addition in Phy/MaMo systems 
was performed in the bulk phases using polarization microscopy (Figure 18A). Bulks 
containing 5 wt% OG showed a considerable reduction of the birefringence, which became 
limited to very small areas. The anisotropic regions probably constituted conserved HII 
structure of the original bulk, suggesting the coexistence of two phases in the system. A 
further concentration increase of OG to 10 wt% promoted a fully conversion of the sample to 
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an isotropic bulk. The SAXS measurements of Phy/MaMo (14 wt%) dispersions containing 
OG (Figure 18B and C), confirmed the phase transition observed with polarization 
microscopy and revealed the formation of Pn3m (cubic double diamond) phases, indicated 
by the reflections in the relative positions equivalent to       ,       ,  and   . 93 OG might 
have promoted an increase of the positive curvature of the lipid arrangement, resulting in a 
shift from HII (lattice parameter 4.8 nm) to Pn3m (lattice parameters 6.8 and 7.2 nm for 5 and 
10 wt% OG, respectively). Moreover, the SAXS analysis indicated that samples containing 10 
wt% OG seemed to lose the Pn3m structure (black arrows) only at temperatures above 45°C. 
In contrast, samples with 5 wt% OG already displayed L2 structure at 45°C. In this way, OG 
demonstrated the capacity to modulate the structure of Phy/MaMo systems, inducing the 
phase transition from HII to Pn3m in a concentration dependent manner, which gives room 
for control and further optimization depending on the other formulation additives.  
 
Figure 18: Effect of octyl-β-D-glucopyranoside (OG) on Phy/MaMo (14 wt%) formulations. A: 
Polarization microscopy of Phy/MaMo (14 wt%) fully hydrated bulks containing different 
concentrations of (OG) at 25°C; B and C: SAXS measurements at different temperatures of 
Phy/MaMo (14 wt%) particles stabilized with 5 wt% poloxamer 407 with addition of 5 wt% (B) 
and 10 wt% (C) OG. L2 (micellar); Pn3m (cubic double diamond); HII (inverse hexagonal). Black 
curve represents the bulk phase (without stabilizer, and OG) for comparison. Curves were shifted 
vertically for clarity. 
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4.6. Particle Loading 
The entrapment of two different model antigens, namely lysozyme (LYS) and ovalbumin 
(OVA), into the delivery systems and its impact on the HII structure of Phy/MaMo (14 wt%) 
was investigated. In comparison to OVA, LYS is smaller in size and positively charged at pH 
7.4 (Table 3). Due to these characteristics, a simple encapsulation and interactions with the 
negatively charged Phy/MaMo hexosomes were thought to be facilitated for LYS, which 
could result in higher loading efficiency in comparison with OVA. The macromolecules 
were added to the homogenized lipid molten in a buffered solution together with the 
stabilizer. According to the literature, lipid molecules self-assemble upon contact with 
aqueous medium containing a model antigen, which is then enclosed within the water 
channels. 146, 172 Contrary to the expectations, the relative loading efficiency obtained for 
OVA was significantly higher compared to LYS (rLE% of 25 vs. 7, p ≤ 0.001, Table 3).  
Table 3: Characteristics of the model proteins used in the loading studies. 173, 174 
Protein Dimensions (nm) pI* Charge at pH 7.4 rLE% ± SD** 
Lysozyme (14.2 kDa) 2.8 x 3.2 x 3.0 11 Positive 7 ± 3 
Ovalbumin (42.7 kDa) 7.0 x 3.6 x 3.0 4.5 Negative 25 ± 3 
*pI (Isoelectric point); **rLE% ± SD (Mean relative loading efficiency ± standard deviation). 
SAXS measurements of hexosomes loaded with either OVA or LYS revealed that the HII 
topology and lattice parameter were conserved for both proteins (Figure 19A). However, 
when comparing the dimensions of these proteins (Table 3) and the lattice parameter 
(distance between the centers of two adjacent cylinders) 175 of 4.8 nm, a simple encapsulation 
into the water channels without a noticeable impact on the structure is highly unlikely. An 
alternative loading mechanism suggested by Angelova et al. 176 proposes the association of 
protein molecules to the interfaces of the domains of cubic arrangement within the 
cubosomes, creating "pockets of local disorder". 177 This mechanism may explain the 
considerable rLE%, despite the geometric mismatch between the proteins and water 
channels, but it does not justify the absence of modifications in the Phy/MaMo HII 
structure.  
To obtain insights into the localization of the loaded protein within the hexosomes, a 
tryptophan accessibility assay was performed, whereby the fluorescence of tryptophan 
residues is quenched with acrylamide. Proteins encapsulated within the hexosomes are in a 
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more isolated environment and thus less exposed to the acrylamide than proteins adsorbed 
to the particle surface. 178 In contrast to the buffer solution, less quenching of the 
fluorescence and thus lower quencher efficiencies (F0/F) was observed for both proteins 
when loaded into hexosomal formulation (Figure 20). This suggested that OVA and LYS 
were to some extent integrated into the lipidic structure. However, in direct comparison to 
OVA, LYS showed a stronger reduction of the quenching efficiency when it was loaded into 
hexosomes. This indicated that the incorporation into hexosomes shielded LYS from the 
aqueous environment more efficiently than OVA and thereby, reduced its availability for 
acrylamide quenching.  
The Phy/MaMo (14 wt%) system was further challenged by simultaneously including 30 
wt% DDA and either OVA or LYS as a model antigen (Figure 19B). As discussed earlier, the 
inclusion of DDA led to a combination of cubic and hexagonal phases. Upon protein 
loading, the intensity of the Pn3m reflections, at approximately 1.22 and 1.48 nm-1, were 
reduced (indicated by stars in Figure 19B). Additionally, the reflections observed at q > 2.0 
nm-1 appeared more visible for loaded particles. Overall, the protein addition seemed to 
drive the systems back to pure HII assemblies. This effect was more profound for samples 
containing LYS. This ability of both proteins to modify the internal structure suggested a 
strong association of the protein molecules with the lipid network.  
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Figure 19: A: SAXS curves of hexosomes formed by Phy/MaMo (14 wt%), stabilized with 5 wt% 
poloxamer 407 and loaded with either 1 wt% (of total lipid) of LYS (blue) or OVA (red). B: SAXS 
characterization of hexosomes formed by Phy/MaMo (14 wt%) and 30 wt% DDA, stabilized with 
15 wt% poloxamer 407. Plain hexosomes (red), loaded with 1 wt% OVA (green), loaded with 1 wt% 
LYS (blue). Black curve represents the bulk phase (without stabilizer, DDA, and protein) for 
comparison. Curves were shifted vertically for clarity. Measurements were performed at 25°C. 
A comparable recovery of the HII structure was seen for plain hexosomes containing 30 wt% 
DDA (Figure 15) upon temperature increase. With rising temperature, the fluidity of the 
hydrocarbon chains increased, and compensated the lateral stresses introduced by the 
positive headgroups of DDA. Similarly to the temperature effect, the incorporation of 
protein molecules may have caused a volume expansion in the hydrophobic chain region, 
which contributed to the reestablishment of the hexagonal structure. These findings 
suggested that the proteins mostly interacted with the hydrophobic chains via nonpolar 
interactions. That this effect was more pronounced for LYS is in agreement with findings 
from the tryptophan accessibility assay. Considering that both, the lipid assembly and LYS, 
were positively charged at pH 7.4 (Table 3), it may be hypothesized that the loading 
mechanism is mainly driven by the hydrophobic forces rather than electrostatic interactions.  
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Figure 20: Tryptophan accessibility assay with acrylamide in Phy/MaMo (14 wt%) hexosomes 
stabilized with 25 wt% poloxamer 407, and loaded with 0.1 wt% (of total lipid) ovalbumin (A) or 
lysozyme (B). Unquenched protein (F0); Quenched protein (F). Data is shown as mean ± SD of two 
independent experiments performed in triplicate. 
5 CONCLUSION AND OUTLOOK 
This study demonstrated the rational development of novel vaccine delivery systems based 
on internally structured particles. Phy/MaMo (14 wt%) hexosomes were successfully 
dispersed from their bulk phases using either poloxamer 407, Myrj 59, or Pluronic F108. The 
particle size profiles of the various formulations were a result of the combination of 
dispersion method, as well as the type and concentration of the stabilizer. Different 
approaches, such as inclusion of various additives and dispersion post-treatments, were 
combined in order to obtain systems with desired characteristics. Phy/MaMo (14 wt%) 
revealed broad margins to tune relevant properties without sacrificing the HII internal 
arrangement. For example, the incorporation of charged lipids to modify the overall particle 
charge, as well as the loading of different model proteins could be performed without 
compromising the HII profile of the particles. This remarkable structural robustness is 
unusual in lyotropic liquid crystalline dispersions, which are known for their susceptibility 
to phase transformations without satisfactory predictability. 103 Nonetheless, the addition of 
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OG was identified as a suitable tool to transform Phy/MaMo (14 wt%) hexosomes in 
cubosomes with Pn3m structure in a concentration-dependent and controlled manner. 
Future efforts are needed to fully understand the role of internally structured particles in 
living systems. In this context, relevant investigations will be performed to further optimize 
hexosomes and improve their current status as antigen delivery system.   
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CHAPTER III  
Cellular Internalization of Hexosomes 
 
A version of this chapter is ready for submission: 
Rodrigues L., Schneider F., Zhang X., Papadakis C. M., Dietz H., Larsson E., Winter G., 
Lundmark R., Hubert M. „Hexosomes have unsual cellular internalization mechanism.”  
This work was conducted in collaboration with the Soft Matter Physics Group and Institute for 
Advanced Study of the Technische Universität München, and the department of Medical 
Biochemistry and Biophysics of the Umeå University. The manuscript was written by Rodrigues L. 
The SAXS measurements were performed by Rodrigues L and Zhang X under the supervision of 
Papadakis C M. Cryo-TEM image acquisiton was conducted by Schneider F and supervised by Dietz 
H. Western Blot experiments were performed by Larsson E and Rodrigues L. All data analyses and 
additional experimental work were performed by Rodrigues L and supervised by Winter G, 
Lundmark R and Hubert M.    
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1 ABSTRACT 
The growing importance of biotherapeutics increased the interest in the development of 
innovative delivery systems, able to carry and protect high amounts of the cargo molecules 
and deliver them to their targets intracellularly. In this context, lipid-based particles 
internally structured with non-lamellar phases, such as cubosomes and hexosomes gained 
attention. The research in this field is still in its infancy and little is known about the 
performance of these nanoparticles in biological environments. An important subject of 
speculation is whether non-lamellar structured particles have fusogenic properties. This 
hypothesis arises from the involvement of non-lamellar conformations of lipids in natural 
processes of the cell membrane such as fusion. This work aims to address this, investigating 
the cellular internalization mechanism of hexosomes in comparison to liposomes. For this 
purpose, series of particle uptake experiments in HeLa cells were performed after silencing 
of important regulatory proteins of the major endocytosis pathways, and modifying the 
rigidity and tension of the cell membrane. Additionally, the interactions of the nanoparticles 
with model lipid membranes were studied from a physico-chemical perspective. The results 
showed that liposomes were internalized by multiple endocytic pathways. Surprisingly, 
hexosomes showed an uncommon uptake mechanism independent of standard endocytosis 
and distinct from fusion, or poration of the cell membrane. Hexosomes revealed superior 
interaction capacity with model lipid membranes and showed the ability to induce 
distorsions that most likely enable their rapid cellular internalization. In addition, our 
results suggested that the occurance of these distorsions requires some extent of membrane 
flexibility. Thus, this work reveals hexosomes as potential intracellular delivery systems. 
2 INTRODUCTION 
Carrier systems for drug delivery have been extensively investigated to enhance the 
properties of therapeutics and enable their application in the biomedical context. 179, 180 
Naturally occurring nanostructures have been a source of inspiration to develop new 
particulate delivery systems made of biomolecules. For instance, due to their diverse 
chemical structure, amphiphilic lipids offer a range of desirable properties to provide a 
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powerful toolbox for the design of nanocarriers. 181 In the presence of aqueous media, these 
molecules self-assemble into distinct mesophases as a function of their shape features and 
correspondent critical packing parameter (section 1.3.1). 79, 100 Besides the typical lamellar 
phase found in biomembranes, lipids can adopt negatively curved non-lamellar structures 
such as inverse cubic or hexagonal phases. 181-183 It is proposed that these structures are 
involved in transitory processes of the cell membrane, such as fusion, fission, and pore 
formation. 184 
Liposomes, the best-known lipid-based drug delivery systems, are vesicles based on one or 
more lipid bilayers. They are extensively used experimentally to deliver various 
pharmaceuticals and are commercially available in several licensed preparations, e.g. 
liposomal amphotericin B (AmBisome®), liposomal cytosine arabinoside (DepoCyt®), and 
liposomal doxorubicin (Myocet®). 179 However, due to key limitations such as low 
encapsulation efficiency of hydrophobic and voluminous drugs, short shelf life, and high 
manufacturing costs, 100, 185, 186 particles with a non-lamellar internal structure have recently 
gained increasing attention. As an example, hexosomes are internally structured with an 
inverse hexagonal (HII) phase and are assemblies of rod-shaped inverse micelles, which 
create cylinders filled with water organized in a hexagonal geometry. 88 Due to their intricate 
internal structure of lipids and water channels, these particles have a large lipid-water 
interface 100 and several studies demonstrated adequate entrapment capacities for diverse 
molecules (e.g. amino acids, peptides, proteins, nucleic acids, small molecules). 172, 187-191 In 
addition, liquid formulations of non-lamellar internally structured particles provided good 
storage stability over 160 days at rt (stability after longer storage periods was not 
evaluated). 192  
Cellular internalization of liposomes occurs through different endocytic machineries (e.g. via 
clathrin-coated pits). 181 Over the last two decades, several strategies have been developed to 
target certain uptake process and to enhance delivery to the target organelle. 82 It is widely 
accepted that the therapeutic effect of proteins, peptides or nucleic acids depends on either a 
direct delivery to the cytoplasm, or the ability to escape from the early endosomes to avoid 
enzymatic degradation in the lysosomes. 179, 193 Facilitating an endosomal escape has long 
been the focus of gene delivery research. For instance, pH-sensitive PEGylated cationic 
liposomes are used for siRNA (small interfering ribonucleic acid) delivery. 194 Here, the 
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PEGylation enhances stability of the positive vesicles in serum and upon slight pH decrease 
in endosomes, the PEG chains are cleaved, allowing the cationic vesicles to fuse with the 
endosomal membrane and to release the cargo into the cytoplasm. 194 Another strategy is the 
incorporation of fusogenic agents, such as cell penetrating peptides (CPPs) into the delivery 
systems. 194, 195 Similarly, the use of virusporins, a virus peptide with lytic activity, to induce 
pore formation in the cell/endosomal membrane has also been reported. 196, 197 However, all 
these strategies are frequently associated with toxicity issues, short circulation times, 
instability of the formulation, and low specificity. 179, 181, 198 In this context, particles with a 
non-lamellar internal structure emerged as promising alternatives to liposomes as 
cytoplasmatic delivery systems. Different studies highlight the superior silencing efficiencies 
of siRNA when delivered using non-lamellar structured nanoparticles [bicontinuous cubic 
gyroid (QIIG) and HII] in comparison to liposomes. 198, 199 The authors explained this 
outcome with an enhanced endosomal escape provoked by fusion of the nanocarriers with 
the endosomal membrane. 198, 199 A similar phenomenon is seen in natural processes of cell 
membrane fusion, 184 when increasing negative curvature of two apposed bilayers results in 
the formation of a non-lamellar intermediate conformation (stalk structure) connecting the 
bilayers. 181, 200  
Nanoparticles based on non-lamellar structures, such as hexosomes are believed to be able 
to fuse with cell membranes and are generating considerable interest in terms of their 
potential for direct cytoplasmic delivery of therapeutics. 78, 181 Despite this interest, what we 
know about the interaction of non-lamellar structured nanoparticles with cell membranes is 
largely based on very limited data. Moreover, the way they enter cells remains highly 
speculative. The aim of the present work was therefore to comprehensively study the 
internalization of hexosomes in cells. Previous work of our group described the physico-
chemical characterization of a robust hexosomal formulation based on phytantriol (Phy) and 
mannide monooleate (MaMo). 88 Due to its remarkable structural stability, this formulation 
was selected for the present internalization studies. We monitored the uptake of 
fluorescently labeled hexosomes in HeLa cells by spectrophotometry and quantitative 
fluorescence imaging in comparison to liposomes. To understand how their uptake is 
mediated, we silenced regulatory proteins of major endocytic pathways alone and in various 
combinations. Additionally, the membrane activity was assayed from a physico-chemical 
perspective using lipid monolayers, giant unilamellar vesicles (GUVs) and cryo-TEM.  
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The results revealed that the uptake of liposomes was mediated by multiple pathways as 
suggested earlier. We found that the internalization of hexosomes was independent of any 
endocytic activity and could only be inhibited by increasing the tension and rigidity of the 
membrane. This and the data obtained from the interaction studies with model membranes 
argue against a simple membrane fusion, but suggest that hexosomes have uncommon 
membrane-destabilizing properties. An implication of this is the possibility that hexosomes 
induce a distortion of the lipid bilayer that enables their rapid passage through the 
membrane without the generation of permanent pores. 
3 MATERIALS AND METHODS 
3.1. Materials 
Phytantriol (Phy) from DSM Nutritional Products Europe Ltd was a gift from Nordmann, 
Rassmann GmbH (Hamburg, DE). Mannide monooleate (MaMo), poloxamer 407 (P407), 
thiazolyl blue tetrazolium bromide (MTT reagent), cytochalasin D, paraformaldehyde (PFA), 
goat serum, and saponin from quilaja bark were purchased from Sigma-Aldrich (St. Louis, 
MO, US). 1,2-Dioleoyl-sn-glycero-3-phosphocholine (DOPC) and 1,2-dioleoyl-sn-glycero-3-
phosphoethanolamine (DOPE) were purchased from Avanti Polar Lipids Inc. (Alabaster, 
AL, US). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased from 
Lipoid GmbH (Ludwigshafen, DE). Octadecyl rhodamine b chloride (R18), Marina Blue 1,2-
dihexadecanoyl-sn-glycero-3-phosphoethanolamine (Marina Blue DHPE), high purity 
calcein and 4',6-diamidino-2-phenylindole dihydrochloride (DAPI) were purchased from 
Life Technologies (Eugene, OR, US). All other chemicals and reagents were of analytical 
grade and were purchased from commercial suppliers. 
3.2. Antibodies 
Purchased primary antibodies were: mouse anti-clathrin heavy chain (1:1000), clone 23 (BD 
Transduction Laboratories), rabbit anti -caveolin1 (1:5000), clone ab2910 (Abcam), rabbit 
anti-Cdc42 (1:5000), clone ab109553 (Abcam). Secondary antibodies conjugated to 
horseradish peroxidase (HRP, Sigma Aldrich and Agrisera) were used for western blot 
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detection. Immunoprecipitation of GRAF1 was performed using the same siRNA and 
method as described by Doherty GJ et al. 201  
3.3. Preparation of Liposomes 
DOPC/DOPE (1:1 molar ratio) liposomes labeled with 0.05 mol% R18 were prepared 
according to the film method 202. The appropriate amounts of each lipid (DOPC, DOPE, and 
R18 as stock solutions in chloroform) were added to a mixture of methanol:chloroform (3:7, 
v/v) and gently vortexed. The lipids were then dried under a stream of nitrogen to give a 
thin film. To generate vesicles, the lipid film was rehydrated in an appropriate volume of 
phosphate-buffered saline (PBS, pH 7.4) and incubated for 30 min at room temperature (rt). 
Glass beads were added to facilitate rehydration. Subsequently, the liposome dispersion was 
bath sonicated for 15 min (Transsonic T 310, Elma, Singen, DE). 
3.4. Preparation of Hexosomes 
Phy/MaMo (8:1 molar ratio) hexosomes labeled with 0.05 mol% R18 were prepared as 
previously reported 88. Briefly, appropriate amounts of Phy and MaMo were weighed and 
melted at 70°C using the Thermomixer comfort (Eppendorf, Hamburg, Germany). The 
sample was agitated for 15 min in a dual asymmetric centrifuge (SpeedMixerTM DAC 150.1 
CM41) at 3500 rpm to homogenize the lipid melt. Subsequently, R18 dissolved in DMSO was 
added to the lipid melt followed by dual asymmetric centrifugation (15 min at 3500 rpm). 
Then, 1 ml of poloxamer 407 solution in PBS was added to the sample (0.41 mol% of the total 
lipid content) and the sample was again thoroughly mixed using the dual asymmetric 
centrifugation (30 min at 3500 rpm). The sample was then probe-type ultrasonicated in three 
cycles of 1 min with 4 s pulse and 2 s pause at an amplitude of 20% (Bandelin Sonopuls 
HD3200 with sonotrode MS72).  
3.5. Small-Angle X-ray Scattering (SAXS)  
In order to improve the scattering signal, highly concentrated samples (100 mg/ml) of R18-
labeled DOPC/DOPE liposomes and Phy/MaMo hexosomes were prepared. SAXS 
measurements were performed using a Ganesha 300XL instrument (SAXSLAB ApS, 
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Copenhagen, DK) equipped with a GENIX 3D microfocus Cu X-ray source (XENOX, 
Sassenage, FR) and a 2D Pilatus 300K detector (Dectris, Baden-Daettwil, CH). The sample 
chamber and beam path were under vacuum. The samples were loaded into glass capillaries 
(1 mm light path, SAXSLAB), which were hermetically sealed and mounted in a 
temperature-controlled cell. The samples were measured after 10 min of equilibration at 
25°C, 37°C and 42°C. The wavelength was λ = 1.54 Å, the sample-to-detector distance was 
406.2 mm, and the acquisition time was 60 min. A pin diode was used to measure the 
transmission of the sample. The 2D images were azimuthally averaged, and the background 
from the glass capillaries was subtracted, taking the transmission into account.   
To identify the different liquid crystalline phases, the q-position [             λ is the 
momentum transfer] of each Bragg reflection was determined by fitting a Lorentz function 
(  is the scattering angle). The ratios of the relative peak positions were calculated and 
compared to patterns described in the literature 93, 152.  
3.6. Dynamic Light Scattering (DLS)  
The hydrodynamic diameter (z-average), polydispersity index (PDI) and zeta potential of 
the particles were measured with a Malvern Zetasizer Nano ZS (Malvern Instruments, 
Worcestershire, UK). The dispersions were diluted (1:100) and added into PMMA cuvettes 
(BRAND®) or DTS1060C capillary cells (Malvern Instruments) for the analysis of z-average 
and zeta potential, respectively. The measurements were not affected by the sample 
concentration within the range used in this study. The measurements were performed in 
triplicate at 25°C under buffering conditions relevant for biological experiments (PBS, pH 
7.4). The values of PBS were used for viscosity and refractive indexes. The Zetasizer 
Software version 7.03 (Macromedia Inc.) was used for acquisition and analysis of the data. 
3.7. Cell Cultures, Cell Lines and Transfections 
HeLa cells (ATCC-CRM-CCL-2) were grown in Dulbecco`s Modified Eagle’s medium 
(DMEM, high glucose, L-glutamine, sodium pyruvate, and phenol red) supplemented with 
10% (v/v) fetal bovine serum (FBS, both from Life Technologies) at 37°C in 5% CO2. The Flp-
In TRex HeLa cell line expressing caveolin-1-GFP was generated as previously described 203 
and maintained in DMEM supplemented with 10% (v/v) FBS, 100 μg/ml hygromycin B, 
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and 5 μg/ml blasticidin S HCl (InvivoGen, San Diego, CA, USA) for plasmid selection. Low 
expression of the fluorescently tagged caveolin-1 was induced by incubation with 0.5 ng/ml 
doxycycline hyclate (Sigma-Aldrich) for 18-24h.  
To study the uptake mechanism(s), targeted proteins were silenced with stealth RNAi 
(siRNA) against either caveolin1 (Cav1HSS141467), dynamin II (DNM2HSS102856), GRAF-1 
(ARHGAP26HSS118162), CLTC (CLTCHSS102017, all from Life Technologies), Cdc42 (ON-
TARGETplus siRNA human, J-005057-05, Dharmacon, Lafayette, CO, US) or a combination 
of these. Stealth RNAi siRNA negative control 462001 (Life Technologies) was used as 
control. Transfections for single and double knockdowns were performed with 
Lipofectamine 2000 and Opti-MEM (both from Life Technologies) according to the 
manufacturer’s instructions. HeLa cells were transfected twice over a period of 72 h before 
the uptake experiment. Protein levels were analyzed by SDS-PAGE and immunoblotting.  
3.8. MTT cell proliferation assay  
HeLa cells were seeded in transparent 96-well plates (Sarstedt, Nümbrecht, DE) at 15×103 
cells/well and incubated overnight (37°C, 5% CO2). A range of concentrations from 10 to 150 
nmol/ml (total lipid) of either liposomes or hexosomes (both labeled with R18) were added 
to the cells and incubated for 24 h at 37°C in 5% CO2. The medium was subsequently 
replaced with MTT reagent solution in cell culture medium (0.5 mg/ml). Following 3 h of 
incubation, the supernatant was discarded and DMSO/ethanol (1:1, v/v) was added to 
dissolve the purple formazan precipitate. The absorption was then measured at 570 nm and 
corrected with a background measured at the range 630-690 nm. 
3.9. High-Throughput Quantification of Particle Uptake  
HeLa cells were seeded in black 96-well plates with flat clear bottom (Corning, NY, USA) at 
15×103 cells/well and incubated at 37°C in 5% CO2. On the following day the cells were 
incubated with either liposomes or hexosomes (both labeled with R18) at 30 nmol/ml (total 
lipid) for different periods of time over 6 h. This experiment was performed at 37°C and 4°C, 
to distinguish particle internalization from particle attachment on the cell surface 
(membrane trafficking is blocked at 4°C) 204. After incubation, the cells were washed twice 
with cold PBS containing 10% FBS, fixed with 4% PFA in PBS, and the nuclei stained with 
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DAPI. Fluorescence intensities were measured with a Synergy H4 plate reader (BioTek 
Instruments Inc., VT, USA). The quantification was based on the fluorescence intensity of 
R18 (λex/λem = 548/578 nm) normalized by the fluorescence of DAPI (λex/λem = 358/461 nm), 
which is proportional to the cell density in each well and allows for a signal correction based 
on the cell number. This experimental setup was also used to investigate the effect of the 
single knockdown of either caveolin1, clathrin, dynamin, Cdc42, or GRAF-1 on the cellular 
internalization of liposomes and hexosomes.  
3.10. Immunofluorescence microscopy 
For immunofluorescence analysis, HeLa cells were seeded on glass coverslips (diameter 12 
mm, No. 1.5H, high precision, Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, DE) 
in 24-well plates at 50×103 cells/well and incubated overnight (37°C, 5% CO2). Following 
incubation with either R18-labeled liposomes, or hexosomes at 30 nmol/ml (total lipid) for 1 
h and 6 h, the cells were washed twice with cold PBS containing 10% FBS. Cells were fixed 
with 4% PFA in PBS and then immunostained with primary mouse monoclonal antibody 
anti-CD44 (Abcam plc, Cambridge, UK) and goat anti-mouse IgG secondary antibody 
coupled to Alexa Fluor 647 (ThermoFisher Scientific Inc., Waltham, MA, US) as previously 
described 133. Fixed samples were imaged using the Nikon A1R confocal (laser scanning 
confocal microscope) controlled by Nikon NIS Elements interface with a Nikon Eclipse Ti-E 
inverted microscope, equipped with a Nikon CFI Plan Apochromat 60x oil (N.A 1.40) DIC 
objective. Micrographs were prepared using Fiji 205 and Adobe Photoshop (CS6). 
3.11. Particle Uptake Assay Using Live Cell Microscopy  
The day before the uptake experiment, HeLa cells, induced caveolin-1-GFP Flp-In TRex 
HeLa cells or HeLa cells treated with different siRNA were seeded on glass coverslips 
(diameter 25 mm, high precision, Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, 
DE) in 6-well plates at 3×105 cells/well. Live cell experiments were conducted in phenol red-
free DMEM supplemented with 15 mM HEPES and 1 mM sodium pyruvate using an 
Attofluor cell chamber (ThermoFisher Scientific Inc.) at 37  C in 5% CO2. R18-labeled 
liposomes and hexosomes were added to cells at 30 nmol/ml (total lipid). For quantification 
purposes, z-stacks of at least ten different cells were taken. Images were acquired using the 
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Zeiss Cell Observer Spinning Disk Confocal controlled by ZEN interface with an Axio 
Observer.Z1 inverted microscope with a 63× lens, equipped with a CSU-X1A 5000 Spinning 
Disk Unit and an EMCCD camera iXon Ultra from ANDOR. Micrographs were prepared 
using Fiji 205 and Adobe Photoshop (CS6). To block actin polymerization, induced caveolin-
1-GFP Flp-In TRex HeLa cell were pre-treated with 1 µM cytochalasin D for 30 min prior to 
incubation with the nanoparticles. After the pre-treatment, the medium was exchanged and 
the uptake of liposomes and hexosomes [30 nmol/ml (total lipid)] was monitored by live-
cell microscopy as described above. To study the role of membrane tension on the particle 
uptake, the cell membrane rigidity of Flp-Ins expressing caveolin-1-GFP was increased by a 
hypotonic treatment. The osmolarity of the culture medium was changed by gentle 
replacement with imaging media:sterile water (1:3, v/v). After an incubation of ca. 10 min, 
liposomes and hexosomes were added at 30 nmol/ml (total lipid) and the uptake monitored 
by live cell microscopy as described above. 
3.12. Image Analysis and Quantification  
After image acquisition, quantification of the particle uptake was performed using the 
software FIJI (ImageJ 1.51i). Briefly, the maximum intensity projection of each Z-stack was 
created followed by feature extraction with the Feature J Laplacian tool. Next, a threshold 
range was adjusted and the fluorescence intensity of the internalized particles was analyzed. 
3.13. Lipid Monolayer Experiments 
Lipid monolayers were formed at 37°C by spreading a total amount of 39 nmol POPC in 
chloroform on a PBS subphase in a MicroTrough XL (Kibron Inc., Helsinki, FI). After the 
solvent had been allowed to evaporate for 10 min, the monolayer was compressed at 5 
mm/min to achieve a target surface pressure of 30 mN/m. A volume of 100 µl of either 
liposomes, hexosomes [both at 15 µmol/ml (total lipid)] or the neat components [Phy, 
MaMo and P407 (all at the same concentration contained in the hexosomes)] was injected 
below the monolayer into the subphase. Due to the capacity of Quil-A® to intercalate into 
cell membranes, 206 this adjuvant was used to enable comparability with a known 
pharmaceutical relevant example. For this purpose, 0.1 mg/ml QuilA (Invivogen, San 
Diego, CA, USA) was incorporated to liposomes and hexosomes. These modified 
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formulations and QuilA in PBS (0.1 mg/ml) were injected into the subphase as described 
above. The surface pressure ( ) was recorded as a function of time using a microbalance 
equipped with a Dyneprobe (Kibron Inc.) made of a metal alloyed with a hydrophilic oxide. 
The Filmware Software version 4.0 (Kibron Inc.) was used for data acquisition and Origin 
8.1 (Origin Lab Corp.) for analysis of the adsorption curves.  
3.14. Calcein Leakage Assay  
Using the same procedure as described above, a dry lipid film was prepared from 7.8 µmol 
POPC in methanol:chloroform (3:7, v/v) and hydrated with an aqueous calcein solution in 
PBS (500 µl, 46 mM) to from calcein-containing liposomes. The vesicles were probe-type 
ultrasonicated in three cycles of 1 min with 4 s pulse and 2 s pause at an amplitude of 20% 
(Bandelin Sonopuls HD3200 with sonotrode MS72). The nontrapped dye molecules were 
removed by gel filtration using Sephadex G-50 (Sigma-Aldrich) with PBS buffer. The 
fractions containing POPC vesicles were identified by DLS and pooled. For the leakage 
assay, calcein loaded vesicles were incubated with either liposomes, hexosomes [both at 15 
µmol/ml (total lipid)] or the neat components [Phy, MaMo and P407 (all at the same 
concentration contained in the hexosomes)] with a ratio of 5:1 (calcein vesicles:formulations) 
for 1 h at rt. After incubation, a three-fold dilution with PBS was performed to reduce 
turbidity and the fluorescence intensities were measured at λex/λem 490/570 nm. Calcein 
vesicles incubated with PBS were used as a negative control and represented the absence of 
leakage. Its fluorescence intensity was used to normalize the data collected for the other 
samples.  
3.15. Giant Unilamellar Vesicles (GUV) Preparation and Imaging  
GUVs were prepared by electroformation using a Vesicle Prep Pro chamber (Nanion 
Technologies, Munich, DE) following the manufacturer´s protocol. A lipid mixture 
containing POPC (0.2 µmol) and 0.1 mol% Marina Blue DHPE in chloroform was applied to 
an indium tin oxide (ITO) coated slide and the solvent was evaporated at rt. Subsequently, 
an o-ring lubricated with silicone grease was placed around the dried lipid film and aqueous 
sucrose solution (150 mM, volume of 250 µl) was applied on the lipid film. A second ITO 
coated slide was placed on top of the o-ring and the slides were mounted in the Vesicle Prep 
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Pro chamber. Next, an alternating current electric field (3 V, 5 Hz) was applied for 5 h at 
36°C. To study the interactions of GUVs with the different lipid-based carriers, R18-labeled 
hexosomes and liposomes were diluted in 150 mM aqueous glucose solution to a final 
concentration of 60 nmol/ml of total lipid. These samples were then mixed with an equal 
volume of GUVs dispersion. After 4 h of incubation at rt, images were acquired using Zeiss 
Cell Observer Spinning Disk Confocal controlled by ZEN interface with an Axio 
Observer.Z1 inverted microscope with a 63X lens, equipped with a CSU-X1A 5000 Spinning 
Disk Unit and an EMCCD camera iXon Ultra from ANDOR. The Marina Blue DHPE and 
R18-labeled nanoparticles were excited with 405 and 561 nm lasers, respectively. 
3.16. Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Vitrified specimens of selected dispersions at approximately 5 % (w/w) of total lipid were 
prepared using a Vitrobot (FEI, Eindhoven, NL) at 22.0°C and 90% humidity. A volume of 
3.5 µl of the particle dispersion was applied on 400-mesh C-Flat CF-2/1-4C cupper grids 
(Protochips, Morrisville, NC, USA) negatively glow discharged with a Plasma Cleaner 
(EMS, Hatfield, PA, USA) at 45 mA for 45 s. After 45 s equilibration, the excess of liquid was 
removed by blotting (4 s, “blot force” –1), and the grids were automatically vitrified in liquid 
ethane below –172°C. The samples were imaged using a Tecnai Spirit microscope (FEI) 
equipped with a Tietz TemCam-F416 charge-couple device (CCD) camera and a Cryo-
Transfer Holder (Gatan, Inc., Pleasanton, CA, USA). The system was operated at an 
acceleration voltage of 120 kV under low-dose conditions (SerialEM Tecnai v3.5.6 acquisition 
software) with 26.000-, 30.000-, 42.000- and 52.000-fold magnification.  
3.17. Statistical Analysis 
All experiments were repeated at least twice with duplicates or triplicates. Statistics were 
performed by one-way ANOVA using Tukey´s post hoc test for multicomparison between 
the groups or by Student t-test for comparison with the control group. All calculations were 
carried out using OriginPro 2017 (Northampton, MA, USA). 
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4 RESULTS AND DISCUSSION 
To investigate the cell entry mechanism of hexosomes and to study the role of non-lamellar 
phases in the interaction with cells, a series of functional studies in HeLa cells was 
performed. These studies were carried out in parallel with liposomes to allow comparison. 
To get insight into their cellular uptake, we specifically inhibited major pathways using 
siRNA silencing. We further interfered with the actin cytoskeleton and membrane rigidity to 
assess their role in endocytosis. To clarify observations in cells, we employed simplified 
models of the cell membrane for biophysical studies. 
4.1. Development and physico-chemical characterization of fluorescently 
labeled nanoparticles 
To enable comparison between a non-lamellar and a lamellar particulate system, the 
experiments of this work were performed with Phy/MaMo hexosomes  88 and a common 
DOPC/DOPE (1:1 molar ratio) liposomal formulation. For uptake quantification using 
confocal microscopy, the particles were fluorescently tagged with octadecyl rhodamine B 
chloride (R18, 0.05 mol%). Due to its lipophilic character, and headgroup-tail structure, this 
fluorescent molecule is largely employed in labeling of lipid-based nanoparticles. 207, 208 We 
performed SAXS measurements to ascertain that the inverse hexagonal (HII) structure of 
hexosomes and the lamellar (Lα) structure of liposomes were not affected by the inclusion of 
R18.  
Labeled Phy/MaMo particles featured a pattern of a typical hexagonal phase, which is 
characterized by Bragg reflections at the relative positions 1,    , and   , at all temperatures 
measured (Figure 21A). 152 As seen in earlier studies, 88 the reflections shifted slightly to 
higher q-values upon a temperature increase from 25°C to 42°C, indicating a negligible 
contraction of the repeating cell unit in the HII phase. At 42°C, a broadening of the first peak 
(q = 1.583 ± 0.002 nm-1) was observed. This together with the reduction of the intensities of 
the second (q = 2.736 ± 0.002 nm-1) and the third (q = 3.181 ± 0.003 nm-1) peaks suggested the 
beginning of a phase transition. The q-values of the SAXS reflection peaks measured for 
DOPC/DOPE liposomes (1.036 ± 0.001 nm-1, 2.067 ± 0.001 nm-1 and 3.111 ± 0.007 nm-1) align 
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with the expected relative peak positions for the Lα phase 1, 2, and 3 (Figure 21B). 152 The 
internal structure was neither affected by the presence of R18 nor a change in temperature.  
 
Figure 21: SAXS curves for R18-labeled Phy/MaMo hexosomes (A) and DOPC/DOPE liposomes (B) 
recorded at indicated temperatures. The curves are shifted vertically for clarity. 
Hydrodynamic diameters (z-average) of the particles were in a similar range; however, 
liposomes showed a more heterogeneous size distribution compared to hexosomes (Table 
4). Phy/MaMo hexosomes are dispersed from the bulk phase with the help of a steric 
stabilizer (poloxamer 407), which facilitates homogenization and yields particles of more 
uniform size. While both systems posses negative surface net charges, DOPC/DOPE 
liposomes showed a higher absolute zeta-potential in comparison to Phy/MaMo hexosomes 
(Table 4). 
Table 4: z-average, PDI, and zeta-potential of R18-labeled Phy/MaMo hexosomes and 
DOPC/DOPE liposomes dispersed in PBS (mean values ± SD, n = 3) 
Nanoparticle z-Average (d.nm) PDI Zeta-potential (mV) 
Phy/MaMo hexosomes 210 ± 5 0.18 ± 0.01 -5.3 ± 0.8 
DOPC/DOPE liposomes 153 ± 3 0.34 ± 0.05 -20.3 ± 0.6 
4.2. Phy/MaMo hexosomes have a higher uptake rate in cells than 
DOPC/DOPE liposomes 
To study the impact of the physico-chemical characteristics of hexosomes and liposomes on 
their internalization kinetics, the overall uptake was quantified over time regardless of the 
type of internalization. 
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The MTT cell proliferation assay was used to identify the effect of nanoparticle 
concentration on cell viability (Figure 22). HeLa cells were exposed to a range of 
concentrations for 24 h. A dose-dependent reduction in cell survival was observed for 
Phy/MaMo hexosomes. Concentrations above 60 nmol/ml (total lipid concentration) 
drastically decreased the cell viability in comparison to liposomes, which showed minor 
cytotoxic effects at higher concentrations (Figure 22). Based on the viability results, all 
subsequent experiments were performed at 30 nmol/ml (total lipid concentration), a 
concentration at which none of the nanoparticles negatively affected cell viability.  
  
Figure 22: MTT cell proliferation assay of HeLa cells treated for 24 h with various concentrations 
of R18-labeled Phy/MaMo hexosomes and DOPC/DOPE liposomes. Each data point represents the 
mean ± SD (n = 2). 
The high-throughput quantification of particle uptake revealed a considerably higher 
internalization of Phy/MaMo hexosomes over time at 37°C in comparison to DOPC/DOPE 
liposomes (Figure 23). This may explain the striking differences observed in the toxicity 
profile of theses formulations (Figure 22). As a control, this uptake experiment was also 
performed at 4°C (Figure 23, open symbols) to enable differentiation between internalized 
and adsorbed particles. At 4°C, energy-dependent pathways are inhibited, and passive 
diffusion cannot generally take place due to the increased membrane rigidity. 209 Neither 
cells incubated with hexosomes, nor cells incubated with liposomes displayed sensible 
fluorescence signal at 4°C (Figure 23). This validated that the fluorescence measured after 
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incubation at 37°C was due to an internalization of particles. The different uptake kinetics, 
as indicated by the slopes, suggested that liposomes and hexosomes might have distinct cell 
entry pathways (Figure 23). This is in agreement with the expected impact on cell-particle 
interactions due to the specific physico-chemical properties of each system. 210 
 
Figure 23: Uptake kinetics of R18-labeled Phy/MaMo hexosomes (blue circles) compared to 
DOPC/DOPE liposomes (red triangles) by HeLa cells over a period of 4 h measured by 
fluorescence using the microplate reader. Cells were incubated with nanoparticles at 30 nmol/ml 
(total lipid), at either 4°C or 37°C. The fluorescence of R18 was normalized by the fluorescence 
intensity of DAPI (nuclear stain), which corresponds to the cell number. Data points show mean 
values ± SEM (n = 2). 
Cellular uptake of the nanoparticles was further characterized by confocal microscopy to 
confirm their intracellular localization after 1 hour and 4 hours (Figure 24A and B, 
respectively). In comparison to liposomes, Phy/MaMo hexosomes are extensively present 
intracellularly as shown in the orthogonal slices (Figure 24). This is in agreement with the 
data shown in Figure 23. 
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Figure 24: Representative confocal images of R18-labeled Phy/MaMo hexosomes and DOPC/DOPE 
liposomes incubated for 1 h (A) and 4 h (B) with HeLa cells (NP, nanoparticles shown in magenta). 
Cells were grown on coverslips, treated and fixed in PFA 4%. The plasma membrane (PM) was 
visualized by immunofluorescence using anti-CD44 antibody (shown in white). Orthogonal views 
of a single optical plane (xy, xz, yz) showing the intersection planes at the position of the white 
cross-hair. Scale bars, 10 μm. 
In general, upon interaction with cells, the fluorescent label of fusogenic particles diffuses 
along the membranes. 211 Interestingly, none of the formulations in this work showed this 
phenomenon (Figure 24) and R18 was not detected in the cell membrane. Therefore, we did 
not find visual evidences that support the hypothesis that Phy/MaMo hexosomes have 
fusogenic properties. 
4.3. Phy/MaMo hexosomes are not internalized via any of the major 
endocytic pathways 
The differences in uptake kinetics between hexosomes and liposomes raise the question of 
which endocytic mechanisms are responsible for the internalization of each type. To address 
this we downregulated specific target proteins of major endocytic pathways using siRNA 
(Figure 25). 
Clathrin-mediated endocytosis (CME) is the most characterized uptake route and depends 
on clathrin heavy chain (HC), which forms the main assembly unit of the “coated pits”. 125 
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Caveolae are flask-shaped invaginations of the cell membrane and endocytosis via this 
pathway (caveolae-mediated endocytosis, CvME) requires caveolin-1 (Cav1). 125 The 
regulation of the clathrin-independent carriers (CLICs) pathway, a less well known route, is 
mainly dependent on Cdc42 and GTPase regulator associated with focal adhesion kinase-1 
(GRAF1) (Figure 25). 133 Dynamin has been reported to be involved in CME, CvME and 
some clathrin- and caveolae-independent internalization routes. 125, 212  
 
Figure 25: Schematic illustration of different endocytic pathways and their key regulators. 
Silencing of clathrin HC, Cav1, dynamin, Cdc42, and GRAF1 did not reduce the 
internalization of hexosomes after 4 h of incubation (Figure 26A, see Figure 26B for protein 
levels). Surprisingly, knockdown of GRAF1 seemed to provoke an increase of the uptake 
(Figure 26A). Similarly, GRAF1 downregulation has already been reported to induce an 
increase in the internalization of Helicobacter pylori vesicles by human gastric 
adenocarcinoma cell line AGS (ATCC 1739). 213 This was attributed to distortions of the 
membrane promoted by GRAF1 depletion, which is supported by the crucial role of CLICs, 
in fluid internalization, homeostasis and membrane tension regulation. 134, 135 Overall, these 
results suggested a non-endocytic internalization mechanism for Phy/MaMo hexosomes. In 
contrast, inhibition of any of the proteins reduced the uptake of DOPC/DOPE liposomes to 
a similar degree after 4 h of incubation (Figure 26A). This indicated that DOPC/DOPE 
liposomes are unspecifically internalized. 
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Figure 26: Cellular uptake of R18-labeled Phy/MaMo hexosomes and DOPC/DOPE liposomes 
following siRNA-mediated depletion of target proteins. HeLa cells were incubated with 
nanoparticles at 30 nmol/ml (total lipid) for 4 h at 37°C. Uptake was quantified by fluorescence 
measurements using the microplate reader and the signal was corrected by DAPI fluorescence 
intensity. The uptake measured for untreated HeLas was set as 100%. Values are presented as 
mean + SEM (n = 3). *, p ≤ 0.05 compared to untreated (A). Representative Western blot analysis of 
HeLa cells untreated (HeLa), treated with control siRNA (Ctrl) or siRNA against target proteins 
(Cav1, Cdc42, Graf1) (B). 
It is known that blocking an endocytic route may upregulate other processes. 214 To verify 
that the unchanged overall uptake of hexosomes was not due to activation of other 
pathways, we silenced two pathways simultaneously. The uptake was monitored in live cell 
using spinning disk microscopy, which enhanced the sensitivity and accuracy of uptake 
detection at early time points of incubation. 
Simultaneous depletion of two major proteins significantly increased the cellular uptake of 
Phy/MaMo hexosomes in comparison to untreated and control siRNA treated cells after 20 
min and 60 min incubation (Figure 27A and B, respectively). These results may be in 
correlation to the increased uptake observed for single knockdown of GRAF1 (Figure 26A). 
Abundant membrane invaginations (caveolae) 215 and tubovesicular formations (CLICs) 135 
are natural membrane reserves able to protect cells against mechanical stresses. Depletion of 
proteins associated with such structures may cause a disturbance of the cell membrane and 
increase its permeability. 213 It is likely that the silencing of GRAF1 and Cav1 influenced 
membrane tension and may explain the significantly higher uptake. A very contrasting 
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scenario was observed for DOPC/DOPE liposomes. We found that the double knockdowns 
investigated had a significant additive effect and reduced the uptake by approximately 70% 
and 88% after 20 min (Figure 27A) and 60 min (Figure 27B) incubation, respectively. Overall 
these results seem to indicate the contribution of more than one endocytic pathway for the 
internalization of liposomes and an unusual mechanism of interaction between hexosomes 
and the cell membrane. 
 
Figure 27: Quantification of nanoparticle uptake by HeLa cells after silencing of regulatory 
proteins in various combinations using siRNA treatment. HeLa cells were incubated with 
nanoparticles at 30 nmol/ml (total lipid) at 37°C. The uptake was monitored using live-cell confocal 
microscopy after 20 min (A) and 60 min (B). Per condition z-stacks of at least ten different cells 
were analyzed (mean + SEM, n = 2). *, p ≤ 0.05; ***, p ≤ 0.001 compared to untreated. 
4.4. Internalization of Phy/MaMo hexosomes is not affected by cytochalasin 
D, but is drastically lowered after hypotonic cell swelling 
To better understand the intriguing internalization dynamics of the Phy/MaMo hexosomes, 
the cells were further challenged with uptake inhibition strategies of broader effect. The aim 
was to identify factors able to block or significantly reduce the uptake of Phy/MaMo 
hexosomes. 
Considering that internalization of particles is blocked at 4°C (Figure 23), and that the lower 
temperature diminishes energy-dependent processes and increases cell membrane 
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tension 209 it was coherent to analyze one of these effects separately. Since the 
downregulation of specific proteins involved in endocytosis might have impacted 
membrane tension, we decided to further investigate this aspect.  
One way to alter the tension of the plasma membrane is to expose the cells to medium with 
reduced osmolarity and so induce cell swelling. To visualize the acute cell volume changes, 
we used induced Cav1-GFP Flp-In TRex HeLa cells and recorded z-stacks to monitor the 
volume increase after 10 min incubation with a hypotonic solution (Figure 28A, side views). 
The internalization of R18-labeled nanoparticles was then measured by live cell confocal 
microscopy after 20 min. Increasing the membrane tension led to 91% and 69% reduction in 
uptake of Phy/MaMo hexosomes and DOPC/DOPE liposomes, respectively (Figure 28B). 
 
Figure 28: Representative confocal images of hypotonic swelling of induced Cav1-GFP Flp-In TRex 
HeLa cells (white). To investigate the role of membrane tension on the particle uptake, cells were 
either untreated or a hypotonic solution was added for 10 min before R18-labeled Phy/MaMo 
hexosomes (magenta) were added and the uptake measured by live cell confocal microscopy after 
20 min. Orthogonal views of a single optical plane (xy, xz, yz) showing the intersection planes at 
the position of the white cross-hair (A). The bar plot shows a quantification of internalized 
nanoparticles after 20 min (B). Per condition z-stacks of at least ten different cells were analyzed at 
the indicated time-points (mean + SEM, n = 2). Data are shown as mean values + SEM (n = 2). ***, p 
≤ 0.001 compared to control. Scale bars, 10 μm. 
It is known that increases in membrane tension reduce endocytic processes. 216 Therefore, the 
uptake inhibition observed for liposomes after the hypotonic treatment is consistent with 
our findings from the knockdown experiments. The fact that the increase in membrane 
tension nearly blocked the internalization of hexosomes is remarkable. This, together with 
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the fact that Phy/MaMo hexosomes are not internalized via any major endocytosis routes, 
suggested a direct interaction of these particles with the cell membrane. Considering that an 
increase in membrane tension was able to reduce the uptake, it could be expected that a 
decrease in membrane tension may facilitate the uptake of hexosomes. Several studies 
propose a “tension buffer” function for the invaginations of the cell membrane. 135, 215 
Therefore, the double knockdowns, through the disruption of such invaginations, might 
have promoted a decrease of membrane tension. This ultimately culminated with an 
increase of the internalization of hexosomes. Analogously, the single depletion of GRAF-1 
also appeared to facilitate the uptake of hexosomes. GRAF1 is a protein involved in CLICs 
pathways, stabilizing tubulovesicular structures of several micrometers in length. 135, 136 This 
pleiomorphic tubulation is a major regulator of the cell membrane area. 135 Therefore, the 
positive effect on the uptake of hexosomes observed after the knockdown of GRAF1 might 
have been a consequence of an increase in cell membrane area, which generated a decrease 
in cell membrane tension.  
Cell tension is a combination of two parameters: membrane tension and cortical tension. 
While the former represents the tension of the lipid bilayer itself, the latter is the 
contribution of the actin cytoskeleton. 217 To investigate the role of cortical tension and to 
study actin-dependent uptake mechanisms, such as macropinocytosis, HeLa cells were 
treated with cytochalasin D. Cytochalasin D is a potent inhibitor of actin polymerization and 
may impact several endocytic pathways, even if actin is not directly involved. This actin 
depolymerization triggers a reorganization of actin filaments in the cell, which can modify 
the function of plasma membrane proteins. 218 Despite the rather broad impact expected for 
this inhibitor, cytochalasin D did not affect the cell entry of Phy/MaMo hexosomes (Figure 
29A). However, it significantly reduced the uptake of DOPC/DOPE liposomes after 60 min 
incubation (Figure 29B).  
Together, the results confirm that hexosomes and liposomes undergo different cellular 
internalization processes. While liposomes are internalized through common and well-
described endocytic pathways, hexosomes appear to enter the cell in a distinct manner that 
is independent of endocytic machineries but dependent on membrane tension. 
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Figure 29: Representative confocal images of induced Cav1-GFP Flp-In TRex HeLa cells (green) 
incubated with R18-labeled Phy/MaMo hexosomes (A) and DOPC/DOPE liposomes (B), both are 
shown in magenta). Cells were either untreated (control) or pre-treated with 1 µM cytochalasin D 
for 30 min prior to incubation with the nanoparticles (30 nmol/ml total lipid) at 37°C. The uptake 
was monitored using live-cell confocal microscopy after 20 min and 60 min. The bar plots to the 
right show a quantification of internalized R18-labeled Phy/MaMo hexosomes (A) and 
DOPC/DOPE liposomes (B). Per condition z-stacks of at least ten different cells were analyzed at 
the indicated time-points (mean + SEM, n = 2). Data are shown as mean values ± SEM (n = 2). ***, p 
≤ 0.001 compared to control. Scale bars, 10 μm. 
4.5. Phy/MaMo hexosomes directly interact with models of the plasma 
membrane 
To enhance our understanding of the way Phy/MaMo hexosomes enter cells, we explored 
how they interact with models of the cell membrane using different techniques. We 
prepared the artificial membrane models using POPC, a zwitterionic phospholipid 
abundantly found in eukaryotic cell membranes. 219, 220 
The calcein leakage assay is widely used to measure membrane perturbation and 
permeabilization. The fluorescent dye calcein is thereby entrapped in POPC vesicles at self-
quenching concentrations. To evaluate whether Phy/MaMo hexosomes, DOPC/DOPE 
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liposomes or the neat components (Phy, MaMo and P407) exert membrane activity, we 
measured their abilities to induce calcein leakage from POPC. 221, 222 
Phy/MaMo hexosomes exhibited a significantly higher leakage activity (Figure 30) 
compared to DOPC/DOPE liposomes and to the negative control (calcein loaded liposomes 
in PBS). Among the neat components, Phy+P407 showed leakage activity, while the 
MaMo+P407 and P407 did not lead to increased fluorescence (Figure 30). Phy+P407 is 
known to form cubosomes, particles internally structured with the non-lamellar inverse 
bicontinuous cubic phase. 88, 148 Thus, our findings suggested that non-lamellar phases, such 
as inverse hexagonal and inverse bicontinuous cubic phase, were able to destabilize the 
POPC bilayer resulting in membrane perturbation and calcein leakage. 
 
Figure 30: Membrane activity assayed by release of calcein dye from POPC vesicles upon 
incubation with either DOPC/DOPE liposomes, Phy/MaMo hexosomes or the neat components 
(Phy, MaMo and P407) at a ratio of 5:1 for 1 h at rt. The calcein leakage was determined by 
fluorescence intensities superior as the negative control (calcein liposomes + PBS) and is indicated 
by the dashed line. Data are presented as mean + SEM (n = 2). 
To further evaluate the interactions between particles and model membranes, the Langmuir 
monolayer approach was employed. A POPC film was created on a subphase of PBS at 37°C 
and compressed to an initial surface pressure (π0) of 30 mN/m, corresponding to lateral 
pressure in membranes. 223 To study the interactions of Phy/MaMo hexosomes, 
DOPC/DOPE liposomes or combinations of the neat components (Phy, MaMo and P407) 
with the POPC monolayer, they were injected underneath the film and the surface pressure 
was monitored over time (Figure 31). Changes in surface pressure give information on the 
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interactions with the monolayer: While a positive increase indicates penetration into the 
lipid film, a negative change suggests loss of phospholipids from the interface into the 
subphase. 224, 225  
Injection of Phy/MaMo hexosomes under the equilibrated lipid monolayer resulted in an 
immediate steep rise in surface pressure (Figure 31, Δπ ≈ 17 mN/m). This shows that the 
hexosomes adsorb to, and insert into the POPC lipid monolayer. The neat components of 
this formulation (Phy+P407, MaMo+P407, and P407) showed weaker interactions and 
caused increases of approximately 6 mN/m, 3 mN/m, and 4 mN/m, respectively. These 
particles might have interacted predominantly with the headgroups of the POPC molecules. 
In contrast, the surface pressure slowly decreased over time after the injection of 
DOPC/DOPE liposomes (Figure 31). Similarly to our findings, Jabłonowska E et al. 226 
reported that monoolein based cubosomes, featuring primitive bicontinuous cubic phase 
(Im3m), induced surface pressure increase in a 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(DPPC) monolayer. This effect was associated to the incorporation of the nanoparticles into 
the monolayer. Interestingly, this phenomenon was found to be more pronounced in 
monolayers that are initially less compressed (5 mN/m) than in highly packed monolayers 
(35 mN/m). 226  
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Figure 31: Adsorption isotherms of nanoparticles or neat components (Quil-A®, Phy, MaMo and 
P407) onto POPC monolayers (solid lines). The nanoparticles were further modified with Quil-A® 
(dashed lines). The lipid monolayer was compressed to an initial surface pressure (π) of 30 mN m-1 
and the samples injected underneath the film at time 0. 
Quil-A® is a saponin-based adjuvant that is known to intercalate into cell membranes and so 
induces cell permeabilization. 206 To enable a comparison to a well characterized and 
pharmaceutically relevant molecule, we included Quil-A® in these experiments, 
investigating its surface activity alone and when included in the nanoparticles. Upon Quil-
A® injection (Figure 31), a drastic decrease of the surface pressure was observed, achieving a 
plateau after approximately 20 min (Δπ ≈ -3.4 mN/m). Quil-A® had the ability to disturb the 
POPC monolayer and induced the migration of the phospholipids into the subphase, 
consequently reducing the surface pressure. This is consistent with the detergent effects 
typical of saponins. 227 The incorporation of Quil-A® into hexosomes resulted in an increase 
of the surface pressure, which is similar to the effect promoted by hexosomes without Quil-
A®. Analogously, liposomes containing Quil-A® induced a slight decrease of the surface 
pressure, which is comparable to the effect of liposomes without Quil-A® (Figure 31). These 
findings provided strong evidence that the properties of the carrier are able to surpass the 
properties of its isolated components, even when these are chemically active like Quil-A®.  
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Next, we used confocal fluorescence microcopy to visualize the interactions between POPC-
based giant unilamellar vesicles (GUVs, labeled with Marina Blue DHPE) and hexosomes or 
liposomes (both labeled with R18). GUVs have been extensively used to study interactions 
of molecules with model membranes in fusion experiments mainly due to their size. Their 
large dimensions of around 3-30 μm exceed the intrinsic resolution limit of light microscopy, 
and so make them easily visualized. 225, 228, 229  
 
Figure 32: Representative confocal images showing fusion experiment between POPC GUVs 
labeled with Marina Blue DHPE (green) and either Phy/MaMo hexosomes (A) or DOPC/DOPE 
liposomes (B), both labeled with R18 (magenta). The GUVs and nanoparticles were mixed and 
incubated at 37°C for 4 h before acquiring the images. Scale bars, 10 μm. 
When R18 labeled hexosomes or liposomes were mixed with POPC GUVs, we detected 
rhodamine fluorescence in the GUV membrane only for hexosomes (Figure 32). This 
reaffirmed the superior capacity of hexosomes to directly interact with lipid membranes. 
Interestingly, R-18 labeled hexosomes were not observed inside the GUVs. The vesicles 
based on POPC represent a simplification of the plasma membrane and have, due to the 
larger dimensions, a higher membrane tension. 228, 229 This may explain why the hexosomes 
were indeed able to interact with the membrane, but may not have penetrated through the 
bilayer as we saw in live cell experiments (Figure 24). 
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To better understand the interactions of hexosomes with membranes, we used smaller POPC 
vesicles (liposomes) as a model, and employed cryo-TEM to enable visualization of the 
interactions. Depending on the observation angle, hexosomes appear in cryo-TEM images as 
internally structured particles with hexagonal shape and/or as round particles displaying 
parallel lines. 230 Due to the lower rigidity of the hexagonal arrangement, it is also common 
to observe elongated structures with curved striations as seen in Figure 33 (upper panel 
Phy/MaMo). These are formed when the tube endings converge and so connect both sides 
of the structure 230 and has also been seen in earlier experiments. 88 POPC liposomes 
appeared mainly as unilamellar spherical vesicles in the size range of approximately 50-200 
d.nm (Figure 33). We found that co-incubation of Phy/MaMo hexosomes and POPC 
liposomes influences the highly ordered lamellar structure of the vesicles as indicated by the 
white arrows in Figure 33. This effect on the integrity of the liposomal lipid bilayer suggests 
an ability of hexosomes to distort membranes. It is possible that such a distortion is directly 
responsible for a higher permeability of the membrane and hence could explain the calcein 
leakage from liposomes (Figure 30). This is also in agreement with the capacity of 
hexosomes to insert into lipid monolayers as demonstrated in Figure 31.  
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Figure 33: Representative cryo-TEM images of control Phy/MaMo hexosomes and POPC 
liposomes (top panels) and their mixture (lower panels). Phy/MaMo and POPC liposomes were 
mixed at a 4:1 ratio and incubated for 1 h at rt before specimen preparation. White arrows in the 
lower panels highlight the distortion of the POPC lipid bilayer caused by hexosomes. Scale bars, 
100 nm. 
Together, our data indicated that Phy/MaMo hexosomes have a remarkable ability to 
directly interact with lipid bilayers and pass through mammalian cell membranes. Having 
an overall negative zeta potential, their interaction with negatively charged cell membranes 
is particularly striking. In contrast to DOPC/DOPE liposomes, which are non-specifically 
endocytosed, the internalization of Phy/MaMo hexosomes does not rely on any of the major 
endocytic pathways, but rather depends on direct interactions with the lipid bilayer. Our 
findings are comparable to a recently published study on monoolein based cubosomes. 231 
According to it, these cubosomes are internalized through an uncommon pathway, which 
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appears to be cholesterol-dependent and partially energy-independent. 231 In addition, the 
internalized particles seem to mostly circumvent endosomal trafficking and accumulate in 
lipid droplets. 231 The uncommon internalization of cubosomes 231 as well as hexosomes is 
most likely related to their non-lamellar structure. Our results point to the probability that 
hexosomes distort membranes allowing them to rapidly cross this barrier, without the 
occurance of fusion or the creation of permanent pores.  
5 CONCLUSION AND OUTLOOK 
This work has investigated the cellular internalization of hexosomes and elucidated which 
role their internal inverse hexagonal phase plays in this process. The evidence from this 
study implies that the internalization of hexosomes is not dependent on any of the major 
endocytic routes, but is rather mediated through a direct interaction with the cell membrane. 
We found that only increased membrane tension and rigidity limits the cellular uptake of 
hexosomes. Accordingly, an increase in membrane area and consequent decrease of 
membrane tension are thought to facilitate their cell entry. Hexosomes also showed 
impressive affinity for POPC model membranes, which was unexpected since they are 
negatively charged and steric stabilized with poloxamer 407. Cryo-TEM micrographs 
displayed strong evidence that hexosomes might promote distortions in the cell membrane, 
which is probably the key to understand their uptake dynamics and the effects associated 
with their non-lamellar structure. These distorsions are not a sort of “surfactant effect” since 
hexosomes were shown to intercalate into a lipid monolayer, without promoting its damage 
or solubilization, as demonstrated by the saponin Quil-A®.  
Our findings highlight a significant role for hexosomes as powerful drug delivery system 
and considerable progress has been made in understanding hexosome-cell interactions. We 
are confident that this research will serve as a basis to understand its full potential. With 
regards to this, additional research is required to elucidate the intracellular fate of 
hexosomes and their cargo molecules. 
  
87 
 
CHAPTER IV  
The Supramolecular Structure of  
Nano-Self-Assemblies Influences the Adjuvant 
Efficacy of a Synthetic Mycobacterial 
Monomycoloyl Glycerol Analogue 
 
A version of this chapter is submitted for publication. 
Rodrigues L., Raftopoulos N. K., Tandrup Schmidt S., Schneider F., Dietz H., Rades T., 
Franzyk H., Elm Pedersen A., Papadakis C. M., Christensen D., Foged C., Winter G., Hubert 
M. „Adjuvants based on a monomycoloyl glycerol analogue in hexosomes and liposomes 
induce different immune responses after vaccination with the Chlamydia trachomatis major 
outer membrane protein”. 
This work was conducted in collaboration with the Soft Matter Physics Group and Institute for 
Advanced Study of the Technische Universität München, the Translational Immunology Group and 
the group for Vaccine Design and Delivery of the University of Copenhagen, and the section for 
vaccine research of the Statens Serum Institut in Copenhagen. The manuscript was written by 
Rodrigues L. The SAXS measurements were performed by Rodrigues L and Raftopoulos N K under 
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the supervision of Papadakis C M. Cryo-TEM image acquisiton was conducted by Schneider F and 
supervised by Dietz H. The animal immunization and collection of biological samples were conducted 
by the veterinarians of the animal facility of the Statens Serum Institut. Rodrigues L and Tandrup 
Schmidt S perfomed together the experiments with the collected biological samples under the 
supervision of Christensen D. The in-vitro studies with PBMCs were conducted by Rodrigues L 
under the supervision of Elm Pedersen A. All data analyses and additional experimental work were 
performed by Rodrigues L and supervised by Foged C, Winter G and Hubert M.    
 
1 ABSTRACT 
The mycobacterial lipid monomycoloyl glycerol (MMG) and its synthetic analogue MMG-1 
exert promising adjuvanticity, but little is known about how immunopotentiation is 
influenced by the supramolecular structure of the delivery system used to target MMG and 
antigen to the immune system. Here, we demonstrate that the nanostructure of MMG-based 
particles remarkably influence the responses against the Chlamydia trachomatis major outer 
membrane protein (MOMP) antigen. Hexosomes are self-assemblies of amphiphilic lipid 
molecules, internally structured with inverse hexagonal phase. They have the potential to 
deliver antigens directly to the cytosol of antigen-presenting cells, and therefore represent a 
field of great interest. Differently charged MMG-1-based hexosomes were compared to 
established cationic MMG-1-based liposomes. In vitro, hexosomes did not induce maturation 
of human dendritic cells derived from peripheral blood mononuclear cells, whereas 
liposomes up-regulated CCR7. In mice, while liposomes induced predominantly cell-
mediated responses against MOMP, hexosomes elicited mainly humoral responses, with 
high IgG titers and minimal potential T-cell effector function. This immune profile appeared 
to be independent of the zeta-potential of the hexosomes. In conclusion, this study 
emphasizes profound differences in the immunopotentiating behavior of MMG-1-based 
liposomes and hexosomes, and highlights the importance of rational particle engineering to 
achieve customized and optimal immunological responses upon vaccination. 
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Figure 34: Graphical Abstract – The Supramolecular Structure of Nano-Self-Assemblies Influences 
the Adjuvant Efficacy of a Synthetic Mycobacterial Monomycoloyl Glycerol Analogue. 
2 INTRODUCTION 
Despite the fact that vaccines constitute one of the greatest medical successes, diseases that 
are potentially preventable by vaccination are still a major global health problem 2. These 
diseases include so-called difficult prophylactic vaccine targets, e.g., tuberculosis, malaria 
and HIV, and therapeutic targets like cancer, for which efficacious and safe vaccines do not 
yet exist 2, 232. It is well known that the majority of the existing vaccines mediate protection 
through stimulation of humoral immunity. However, there is an unmet medical need for 
novel safe and efficacious vaccines that also stimulate cell-mediated immune (CMI) 
responses, which appear to be critical in providing protection against intracellular 
pathogens, e.g. Mycobacterium tuberculosis, HIV and Chlamydia trachomatis. 1, 233  
Vaccine safety has been substantially improved with the introduction of subunit vaccines. 
Unlike the traditional vaccines based on live attenuated or inactivated whole pathogens, 
subunit vaccines contain only specifically defined subunits of the pathogens, which can be 
synthetic peptides, highly purified recombinant proteins, or DNA/RNA encoding the 
antigen(s). 1 The result is increased safety, yet these systems show lower immunogenicity. 
Co-administration of adjuvants is therefore required to provoke persistent and protective 
immune responses. Ideally, adjuvants improve vaccine efficacy with minimal impact on 
safety. For a specific vaccine, the immune profile of the adjuvant has to be carefully 
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designed and optimized to induce adequate protective immunity and immunological 
memory against the pathogen. 233  
Vaccine adjuvants constitute a large group of structurally heterogeneous compounds that 
generally are classified as either immunopotentiators, delivery systems or a combination of 
both. 20 Recently, it was shown that synthetic analogues of lipid components from the cell 
wall of M. tuberculosis are extraordinarily strong CMI-stimulating immunopotentiators, and 
they are therefore highly promising as subunit vaccine adjuvants. 66, 68, 234, 235 Examples are 
synthetic analogues of monomycoloyl glycerol (MMG). 24, 66, 234 The combination of the MMG 
analogue referred to as MMG-1 and a cationic liposomal delivery system [the so-called 
cationic adjuvant formulation (CAF) 04, Statens Serum Institut, DK] has shown promising 
adjuvant activity. CAF04 induced strong Th1/Th17 biased responses, polyfunctional T cells 
and specific IgG against the tuberculosis fusion antigen Ag85B-ESAT-6 68 and the C. 
trachomatis serovar D major outer membrane protein (MOMP) antigen. 69 
We recently performed a detailed analysis of the influence of MMG structure on the 
adjuvant activity of CAF04 employing an array of MMG analogues with different alkyl 
chain lengths displaying different stereochemistry in the hydrophobic moiety and in the 
polar headgroup. 24, 69 However, little is known about the influence of the structural 
characteristics of the delivery system on the adjuvanticity of MMG. The aim of the present 
study was to compare the adjuvant activity of MMG-1-based cationic liposomes (CAF04) 
and hexosomes loaded with MOMP antigen, and to investigate the effect of surface charge. 
The hypothesis was that the nanostructural characteristics of the lipid-based delivery system 
are decisive for the way the antigen is delivered to and interacts with antigen-presenting 
cells (APCs), which in turn affects the induced immune responses qualitatively and 
quantitatively. In this way, rational particle engineering may be applied to stimulate 
customized and optimal immunological responses upon vaccination.  
Hexosomes are self-assembled particles of amphiphilic lipids, internally structured with an 
inverse hexagonal (HII) structure and dispersed in an aqueous system. They consist of rod-
shaped inverse micelles organized in a hexagonal geometry with closed water channels. 100 
Due to a high amount of lipid per particle and a network of water channels, the intricate 
structure of hexosomes allows for high loading efficiencies of hydrophilic, hydrophobic and 
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amphiphilic drug cargoes. 100 This is a promising property for overcoming encapsulation 
constraints encountered with other particulate systems applied for vaccination (e.g. 
liposomes). 100 Moreover, non-lamellar assemblies, e.g. inverse hexagonal phases, have been 
reported to show fusogenic properties. 78 Thus, hexosomes have potential for delivery of 
antigens directly to the cytosol of APCs, and in this way facilitate stimulation of cytotoxic T 
lymphocyte (CTL) immune responses. 236  
We therefore compared the immunogenicity of MOMP adjuvanted with MMG-1-based 
hexosomes and liposomes, respectively. Correlates of immunogenicity were analyzed, e.g., 
activated populations of MOMP-specific T cells (CD44hi), cytokine responses, and induction 
of MOMP-specific IgG responses. Our results demonstrate for the first time striking 
differences between these self-assembled, lipid-based delivery systems in all aspects 
analyzed. This supports the importance of particle design in the rational formulation 
engineering of subunit vaccines and reveals a potential application of this knowledge as a 
tool to tailor vaccine-induced immune responses.    
3 MATERIALS AND METHODS 
3.1. Materials 
Phytantriol (Phy) from DSM Nutritional Products Europe Ltd was a gift from Nordmann, 
Rassmann GmbH (Hamburg, DE). Dimethyldioctadecylammonium (DDA) bromide and 
poloxamer 407 were purchased from Sigma-Aldrich (Taufkirchen, DE). 1,2-Dipalmitoyl-sn-
glycero-3-phosphocholine (DPPC) and 1,2-dipalmitoyl-sn-glycero-3-phosphoglycerol 
sodium salt (DPPG) were gifts from Lipoid GmbH (Ludwigshafen, DE). Chicken egg 
ovalbumin (OVA) conjugated with Alexa Fluor 488 (OVA-Alexa488) was purchased from 
Life Technologies GmbH (Darmstadt, DE). The modified C. trachomatis serovar D MOMP 
antigen referred to by Knudsen et al. as rMOMP 237 was used as antigen (Statens Serum 
Institut). All other chemicals and reagents were of analytical grade and were purchased 
from commercial suppliers. 
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3.2. Synthesis of Mycobacterial Monomycoloyl Glycerol Analogue 1 
(MMG-1) 
MMG-1 was synthesized, purified and characterized as previously described. 68 
3.3. Preparation of Liposomes 
Cationic liposomes (CAF04) were prepared as previously described with modifications. 24 
Weighed amounts of DDA (5.3 mg) and MMG-1 (2.1 mg, equivalent to 31 mol% of total 
lipid) were dissolved in CHCl3 (Table 1). The organic solvent was completely removed by 
rotary evaporation followed by incubation for 72 h in a vacuum drying chamber at 25°C and 
15 mBar. Subsequently, 1 ml of phosphate-buffered saline (PBS, pH 7.4) was added to 
rehydrate the lipid film, and probe-type ultrasonication was performed in three cycles of 2 
min with 2 s pulse, 2 s pause, and 30% amplitude (Bandelin Sonopuls HD3200 with 
sonotrode MS72, Berlin, DE).  
3.4. Preparation of Hexosomes 
Hexosomes were prepared as previously reported. 88 Briefly, appropriate amounts of each 
lipid (Table 5) were weighed and melted at 70°C using the Thermomixer comfort 
(Eppendorf, Hamburg, Germany). The samples were agitated for 30 min in a dual 
asymmetric centrifuge (SpeedMixerTM DAC 150.1 CM41) at 3500 rpm to homogenize the 
lipid melt. Subsequently, 1 ml of poloxamer 407 solution in PBS was added to each sample 
(3.25 mol% of the total lipid content). The samples were probe-type ultrasonicated in three 
cycles of 2 min with 2 s pulse and 2 s pause at an amplitude of 30% (Bandelin Sonopuls 
HD3200 with sonotrode MS72).  
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Table 5: Adjuvant compositions. 
Adjuvant Phase 
Phy 
(mg/ml) 
MMG-1 
(mg/ml) 
Charged lipid 
(mg/ml) 
Lipid adjuvantsc 
CAF04  Lα 0.0 2.1 5.30 (DDA) MMG-1 and DDA 
Phy/MMG-1a HII 18.4 6.9 --- MMG-1 
Phy/MMG-1a +DDAb HII 16.5 6.2 0.78 (DDA) MMG-1 and DDA 
Phy/MMG-1a +DPPCb HII 18.4 6.9 1.00 (DPPC) MMG-1 
Phy/MMG-1a +DPPGb HII 18.4 6.9 1.02 (DPPG) MMG-1 
aAll hexosome dispersions contain 18 mol% MMG-1 of the total lipid content (Phy+MMG-1). 
bCharged lipids (DPPC/DPPG/DDA) were added to hexosomes at 2 mol% of total lipid (Phy+MMG-1). 
cTotal concentration of lipid adjuvants was kept constant at 2.42 mmol/ml in all formulations. 
3.5. Small-Angle X-ray Scattering (SAXS) 
SAXS analyses were performed using a Ganesha 300XL instrument (SAXSLAB ApS, 
Copenhagen, DK) equipped with a GENIX 3D microfocus Cu X-ray source (XENOX, 
Sassenage, FR) and a 2D Pilatus 300K detector (Dectris, Baden-Daettwil, CH). The sample 
chamber and beam path were under vacuum. Concentrated particle dispersions (Table 5) 
were loaded into glass capillaries (1 mm light path, SAXSLAB), which were hermetically 
sealed and mounted in a temperature-controlled cell. The samples were measured after 10 
min of equilibration at 37 °C. The wavelength was λ = 1.54 Å, the sample-to-detector 
distance was 406.2 mm, and the acquisition time was 180 min. A pin diode was used to 
measure the transmission of the sample. The 2D images were azimuthally averaged, and the 
background from the glass capillaries was subtracted, taking the transmission into account.   
To identify the different liquid crystalline phases, the q-position [               is the 
momentum transfer] of each Bragg reflection was determined by fitting a Lorentz function 
(  is the scattering angle). The ratios of the relative peak positions were calculated and 
compared to patterns described in the literature. 152 The repeat distance, d, was calculated 
using Bragg´s law,        , where q1 is the position of the first peak. The mean lattice 
parameter, a, was determined according to the scattering law for the inverse hexagonal 
phase, namely        . 154 
3.6. Cryogenic Transmission Electron Microscopy (Cryo-TEM) 
Vitrified specimens of selected dispersions at approximately 5 % (w/w) of total lipid were 
prepared using a Vitrobot (FEI, Eindhoven, NL) at 22.0°C and 90% humidity. A volume of 3 
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µl of the particle dispersion was applied on 400-mesh C-Flat CF-2/1-4C cupper grids 
(Protochips, Morrisville, NC, USA) negatively glow discharged with a Plasma Cleaner 
(EMS, Hatfield, PA, USA) at 35 mA for 45 s. After 30 s equilibration, the excess of liquid was 
removed by blotting (3 s, “force” –1), and the grids were automatically vitrified in liquid 
ethane below –172°C. A subset of samples was imaged using a Tecnai Spirit microscope 
(FEI) equipped with a Tietz TemCam-F416 charge-couple device (CCD) camera and a Cryo-
Transfer Holder (Gatan, Inc., Pleasanton, CA, USA). The system was operated at an 
acceleration voltage of 120 kV under low-dose conditions (SerialEM Tecnai v3.5.6 acquisition 
software) with 26.000-, 30.000-, 40.000- and 50.000-fold magnification. The second subset of 
samples was imaged using a Titan Krios microscope (FEI), equipped with a Falcon 3EC 
direct electron detector. The system was operated at an acceleration voltage of 300 kV under 
low-dose conditions (EPU Titan v1.9 acquisition software) with 37.000- and 47.000-fold 
magnification. Image analysis was performed using the Fiji software (National Institutes of 
Health, Bethesda, MD, USA). 
3.7. Dynamic Light Scattering (DLS) 
A Malvern Zetasizer Nano ZS (Malvern Instruments, Worcestershire, UK) was used to 
measure the intensity-weighted average hydrodynamic diameter (z-average), polydispersity 
index (PDI) and zeta potential of the particles. The dispersions were diluted (1:100) and 
added into PMMA cuvettes (BRAND®) or DTS1060C capillary cells (Malvern Instruments) 
for the analysis of z-average and zeta potential, respectively. The measurements were not 
affected by the sample concentration within the range used in this study. For viscosity and 
refractive indexes, the values of PBS were used. The measurements were carried out in 
triplicate at 25°C under buffering conditions relevant for biological experiments (PBS, pH 
7.4). Zetasizer Software version 7.03 (Macromedia, Inc.) was used for acquisition and 
analysis of the data. 
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3.8. In vitro Experiments:  
3.8.1. Preparation of Primary Dendritic Cells (DCs) Derived from 
Peripheral Blood Mononuclear Cells (PBMCs) 
Leukocytes were isolated from fresh human venous blood (provided by the blood bank at 
Rigshospitalet, Copenhagen, DK) by gradient centrifugation using LymphoprepTM 
(Fresenius Kabi, Oslo, NO). The cells were washed three times with PBS and resuspended in 
RPMI1640. Using 0.2% eosin as an indicator of viability, the cells were counted and 
subsequently cultured in 6-well plates (1×107 viable cells/well) with complete medium 
(RPMI1640 supplemented with GlutamaxTM, 100 U/ml penicillin, and 100 µg/ml 
streptomycin) with 15% (v/v) human AB serum (Valley Biomedical Inc., Winchester, VA, 
USA). After 1.5 h incubation (37°C, 5% CO2), the wells were carefully washed to remove 
non-adherent cells. In order to differentiate the PBMCs into DCs, 2 ml complete medium 
containing 5% (v/v) human AB serum, 50 ng/ml granulocyte-macrophage colony-
stimulating factor (GM-CSF) and 25 ng/ml interleukin (IL)-4 (both from PeproTech Nordic, 
Stockholm, SE) were added to each well. After three days of incubation, the cytokine-
containing medium was renewed, and the cells were incubated for additional three days. 
The purity of the DC cultures was higher than 70% on day 6. This was evaluated based on 
the surface expression of CD11c (PE-labeled anti-mouse CD11c antibody, clone B-ly6, BD 
Pharmingen, San Diego, CA, USA), which was quantified by flow cytometry using a BD 
FACScalibur (BD Biosciences, San Jose, CA, USA). 
3.8.2. Viability Assay 
PBMC-derived DCs were harvested on day 6, and then the cells were seeded in 96-well 
plates (3×104 cells/well) in complete medium supplemented with 5% (v/v) human AB 
serum. Different concentrations of the particle dispersions (0-0.102 nmol of lipid 
adjuvant/ml) were added to each well, and the cells were incubated with the samples for 24 
h (37°C, 5% CO2). The medium was subsequently replaced with 100 µl of [3-(4,5-
dimethylthiazol-2-yl)-5-(carboxymethoxyphenyl)-2-(4-sulfenyl)-2H-tetrazolium]/phenazine 
methosulfate (MTS/PMS) reagent solution (140 µg/ml MTS and 2.4 µg/ml PMS in PBS) 
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according to the vendor´s recommendations (Promega, Madison, WI, USA). Following 4 h of 
incubation, the absorbance was measured at 492 nm. 
3.8.3. Uptake Experiments  
To investigate cellular uptake in vitro, 50 µg/ml of the fluorescently labeled model antigen 
OVA (OVA-Alexa488) was added to the prepared liposomal dispersion. The net negative 
charge of OVA at physiological pH [isoelectric point (pI) = 4.5 238] is suggested to contribute 
to the adsorption of the antigen to the cationic liposomes via attractive electrostatic 
interactions. 239 To prepare hexosomes for the uptake studies, 50 µg/ml of OVA-Alexa488 
were added to the lipid melt together with the poloxamer solution, followed by sonication. 
PBMC-derived DCs were harvested on day 6 of differentiation, and the cells were cultured 
in 96-well plates (1×105 cells/well) in complete medium supplemented with 5% (v/v) 
human AB serum. Selected nanoparticle dispersions, loaded with OVA-Alexa488 were 
added to the cells in triplicate at 20 pmol of lipid adjuvant/ml. The uptake experiments were 
performed at 37°C and 4°C, respectively, to distinguish particle internalization from 
interaction with the cell membrane (blockage of membrane trafficking at 4°C). 204 After 2 h 
incubation, the cells were harvested, washed three times with PBS, and the uptake was 
quantified by flow cytometry (BD FACScalibur).  
3.8.4. Stimulation of DCs and Evaluation of Surface Marker Expression  
PBMC-derived DCs were incubated on day 5 of differentiation with the dispersions at 20 
pmol of lipid adjuvant/ml for 24 and 48 h (37°C and 5% CO2). Cells stimulated with 
lipopolysaccharide (LPS, 3 µg/ml) served as positive control. After incubation, the cells were 
harvested, washed twice with PBS, and incubated for 10 min at room temperature (rt) with 
blocking buffer [PBS containing 2% (v/v) human AB serum]. Subsequently, the cell 
suspensions were centrifuged (5 min at 600 g and 4°C), and the cell pellets were 
resuspended in 50 µl antibody staining solution (single staining). The staining solutions 
were PE-labelled anti-mouse CD11c antibody (clone B-ly6, BD Pharmingen), FITC-labelled 
anti-mouse CD80 antibody (clone L307.4, BD Pharmingen), APC-labelled anti-mouse CD83 
antibody (clone HB15e, Biolegend), FITC-labelled anti-mouse CD86 antibody (clone 
2331/FUN-1, BD Pharmingen), FITC-labelled anti-mouse HLA-DR antibody (clone AB3, 
Dako), APC-labelled anti-mouse CD40 antibody (clone 5C3, Biolegend), PerCP-Cy5.5-
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labelled anti-mouse CD197 (CCR7) antibody (clone G043H7, Biolegend), and proper isotype 
controls (BD Pharmingen) diluted according to manufacturer´s recommendations in staining 
buffer [PBS containing 1% (w/v) BSA]. The cells were incubated with the staining solutions 
on ice and protected from light for 45 min. The cells were subsequently washed twice with 
cold staining buffer, and resuspended in 150 µl 4% (v/v) paraformaldehyde (PFA) and 150 
µl staining buffer. The samples were stored at 4°C and protected from light until analysis by 
flow cytometry (BD FACScalibur). 
3.9. Animal Experiments  
Five-fold dilutions of CAF04 and MMG-based hexosomes (Table 5) were loaded with 25 
µg/ml C. trachomatis serovar D MOMP antigen, and then aliquoted in dose volumes of 200 
µl. For the hexosomal formulations, MOMP was incorporated into the lipid melt together 
with the poloxamer solution. For CAF04, MOMP was surface-adsorbed to the prepared 
liposomes. To enable comparability between the different vaccine delivery systems, all 
formulations contained the same concentration of MOMP antigen (5 µg/200 µl dose) and the 
same molar concentration of total lipid adjuvant (0.484 mmol adjuvant/ml, Table 5). Female 
CB6/F1 (6-8 weeks old) were purchased from Harlan (Horst, NL). All experiments were 
carried out in accordance with the European Community Directive (86/609), and the 
experimental protocol (2014-15-2934-01065) was approved by the Danish Council for Animal 
Experiments. The mice in each group (n = 6) were immunized twice subcutaneously at the 
base of the tail, with an interval of two weeks. A group of mice immunized with the non-
adsorbed antigen in PBS (without carrier system and adjuvant) was used as negative 
control. The mice were euthanized ten days after the last immunization, and the spleen, 
inguinal lymph nodes, and plasma were harvested and analyzed.  
3.9.1. Intracellular Cytokine Staining (ICS) 
Single cell suspensions from lymph nodes and spleen were prepared by homogenization of 
the organs through a nylon mesh. The cells were washed twice with RPMI1640 (Gibco 
Invitrogen, Carlsbad, CA, USA) and seeded in 96-well plates at a density of 2×105 cells/well 
in complete medium [RPMI1640 supplemented with 1 mM L-glutamine, 10% (v/v) fetal calf 
serum, 5 µM 2-mercaptoethanol, 100 U/ml penicillin, 100 µg/ml streptomycin, 1% (v/v) 
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sodium pyruvate, and 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)]. 
Cells isolated from three mice were pooled to ensure sufficient cell numbers in samples from 
the lymph nodes, resulting in a total of two groups per treatment group. The cells were 
restimulated for 1 h (37°C, 5% CO2) with 2 µg/ml MOMP in the presence of 1 µg/ml of the 
co-stimulatory anti-mouse CD28 (clone 37.51) and CD49d (clone MFR4.B, both from BD 
Biosciences) antibodies. Cells stimulated with phorbol-12-myristate-13-acetate (PMA, 0.05 
µg/ml, Sigma Aldrich) and ionomycin (1 µg/ml, Sigma Aldrich) served as positive controls, 
and cells incubated with complete medium only served as negative control. Subsequently, 
brefeldin A (10 µg/ml, Sigma Aldrich) and Monensin/GolgiStop (0.7 µl/ml, BD Biosciences) 
were added and the cells were further incubated for 5 h (37°C). The cells were washed with 
FACS buffer [PBS containing 1% (v/w) fetal calf serum] and stained for surface markers 
with the anti-mouse antibodies CD4:eFluor780 (clone RM4-5), CD8:PerCp-Cy5.5 (clone 53-
6.7), and CD44:FITC (clone IM7, all from eBioscience, San Diego, CA, USA) (30 min at 4°C). 
Following permeabilization with the Cytofix/Cytoperm kit (BD Biosciences) according to 
the manufacturer´s recommendations, the cells were stained intracellularly with the anti-
mouse antibodies interferon-γ (IFN-γ):PE-Cy7 (clone XMG1.2), tumor necrosis factor-α 
(TNF-α):PE (clone MP6-XT22), and IL-2:APC (clone JES6-5H4, all from eBiosciences) (30 min 
at 4°C). All antibodies used for the stainings were diluted 1:200 in FACS buffer. After three 
washing steps in FACS buffer, the cells were submitted to quantification via flow cytometry 
using a FACSCanto (BD Biosciences) and analyzed by using the FlowJo 10 software (FlowJo, 
LLC, Ashland, OR, USA). 
3.9.2. Evaluation of Cytokine Release  
Cells isolated from spleen and lymph nodes were restimulated for 72 h with 2 µg/ml 
MOMP. Cells stimulated with concanavalin A (ConA, Sigma Aldrich, 5 µg/ml) and 
complete medium only were used as positive and negative controls, respectively. After 
incubation, the concentrations of IFN-γ, IL-17, and IL-5 in the supernatants were quantified 
using enzyme-linked immunosorbent assay (ELISA) kits (BD Biosciences). MaxiSorp plates 
(Nunc, Roskilde, DK) were coated with the respective capture anti-mouse antibodies (IFN-γ, 
IL-17 and IL-5) overnight at 4°C, and subsequently blocked with 2% (w/v) bovine serum 
albumin (BSA) or skim milk powder in PBS. The supernatants were added at eight-fold 
dilution in PBS and allowed to incubate for 2 h at rt. Biotin-conjugated anti-IFN-γ, anti-IL-17 
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and anti-IL-5 antibodies were added (1 h, rt) followed by addition of streptavidin-
conjugated horseradish peroxidase (HRP, 30 min, rt). Detection was performed with 
3,3´,5,5´-tetramethylbenzidine (TMB, Kem-En-Tec, Taastrup, DK), and the reaction was 
stopped with 0.2 M H2SO4. The optical density was read at 450 nm with correction at 570 
nm. 
3.9.3. Evaluation of Antibody Responses in Serum  
Ten days after the last immunization, blood was collected from the heart, and serum was 
isolated by centrifugation (10,000 g for 10 min). MaxiSorp plates (96-well) were coated with 
MOMP (1 µg/well) overnight at 4°C, and blocked with 2% (w/v) BSA in PBS. The serum 
was added in serial dilutions in PBS and incubated for 2 h at rt, followed by addition of 
HRP-conjugated anti-mouse IgG antibody. TMB was used for detection, and the reaction 
was stopped with 0.2 M H2SO4. The optical density was detected at 450 nm with correction 
at 570 nm. A cutoff based on the average background observed for the negative control 
(samples isolated from mice immunized with non-loaded antigen in PBS) added by three 
times the standard deviation was established. The reciprocal value of the highest dilution 
giving a signal higher than the cutoff was considered the antibody titer.  
3.10. Statistical analyses  
Statistics were performed by one-way ANOVA using Tukey´s comparison test to analyze 
the differences between the groups. All calculations were carried out using OriginPro 2016 
(Northampton, MA, USA). 
4 RESULTS AND DISCUSSION 
When designing nanoparticle-based antigen delivery systems, a number of parameters are 
decisive for the quality and magnitude of the immune response. In the present study, we 
compared the immunostimulatory activity of liposomes and hexosomes in vitro and in vivo. 
Although both types of self-assembled systems are based on lipids, their composition, shape 
and internal structure are highly diverse. For example, addition of stabilizer is required for 
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the self-assembly of hexosomes, and charged lipids were included to study the effect of 
surface charge. 103 These parameters may influence the biodistribution upon administration, 
cellular internalization and, most importantly, the quality and the quantity of the triggered 
immune response. 240 Here we compared the physicochemical and adjuvant properties of a 
novel MMG-1-based hexosomal adjuvant with those of MMG-1/DDA liposomes (CAF04). 68  
4.1. Systems composed of MMG-1 and phytantriol self-assemble into an 
inverse hexagonal phase.  
Hexosomes and liposomes based on MMG-1 were prepared to study the effect of particle 
structure and composition on adjuvanticity. The physical characteristics of the CAF04 
liposomal adjuvant were thoroughly investigated in previous studies. 68, 69 Strong 
immunological responses were measured for liposomes containing 31 mol% MMG-1. 68 For 
this reason, a content of MMG-1 corresponding to a molar ratio of 31% was selected for the 
liposomes tested in the present study. To design MMG-1-based hexosomes, phytantriol 
(Phy) was combined with 18 mol% MMG-1 and dispersed with poloxamer 407 in PBS. At 
this molar ratio, the respective bulk phases displayed appropriate physical stability, i.e. no 
phase separation or precipitation was observed after several weeks of storage at rt (data not 
shown). In addition, the SAXS measurements revealed three distinct peaks for Phy/MMG-1 
(18 mol%) at 1.617 ± 0.001 nm-1, 2.805 ± 0.004 nm-1 and 3.247 ± 0.009 nm-1 (Figure 35). These 
peaks correspond to the 1,     and    reflections, which are characteristic for the inverse 
hexagonal (HII) structures of hexosomes. 152  
For a number of adjuvant systems, DDA has been shown to play an important role for 
induction of immune responses. 68, 69, 241 This activity has been largely attributed to the 
positive headgroup charge, but the adjuvant mechanisms of DDA are not fully clarified 
yet. 242, 243 To investigate the impact of DDA on the biological performance of hexosomes, 
DDA was included in one of the formulations. Likewise, formulations containing 
zwitterionic DPPC or anionic DPPG were included to study the effect of surface charge 
(Table 6).  
DDA, DPPC, and DPPG were added at 2 mol%, resulting in the self-assembly of hexosomes 
(Figure 35) with highly diverse zeta potentials (Table 6). Reflections characteristic for HII 
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structures were measured for all dispersions (Figure 35), indicating that the internal 
arrangement of the self-assembled nanoparticles is similar to that measured for Phy/MMG-
1 hexosomes. Interestingly, the addition of charged lipids induced an enlargement of the 
lattice parameter from 4.48 ± 0.01 nm for Phy/MMG-1 to 4.56 ± 0.01 nm, 4.62 ± 0.01 nm, and 
4.80 ± 0.01 nm for dispersions containing DDA, DPPC, and DPPG, respectively. Preservation 
of the HII structure and an increase of the lattice parameter upon incorporation of charged 
lipids have also been observed for hexosomes based on Phy and mannide monooleate in 
previous studies. 88 In the present work, DPPG had the most pronounced impact on the 
hexagonal arrangement, inducing an increase in the lattice parameter of approximately 0.32 
nm. This can be explained by the negative charge and the larger headgroup volume of 
DPPG as compared to DDA or DPPC. 169 Taking into account that the Phy/MMG-1 
dispersion has a net negative zeta potential (Table 6), the inclusion of a more bulky group 
with the same net charge may induce repulsion in the headgroup region of the hexagonal 
arrangement, eventually resulting in an increased lattice parameter. Similarly, DPPC also 
has a bulky headgroup. However, due to the zwitterionic character, the overall charge of 
DPPC is neutral. As a result, both the repulsion and its impact on the lattice parameter were 
weaker for DPPC, as compared to DPPG. The HII structure appears to have a high 
accommodation capacity for DDA, which promotes minimal increase of the lattice 
parameter due to its relatively small and positively charged headgroup.  
Measurements of the z-average hydrodynamic radius suggested that the hexosomes are 
smaller than the CAF04 liposomes and show a more heterogeneous size distribution (Table 
6). However, these results should be interpreted with caution because the measurements of 
the hydrodynamic diameter are based on the assumption that the nanoparticles are 
spherical. 244 While liposomes are known to adopt a spherical shape, hexosomes can be 
elongated. 245 In addition, hexosomes are coated with a layer of steric stabilizer (poloxamer 
407), which may influence the diffusion rate of the particles, and thus may alter their 
hydrodynamic size. For this reason, the dispersions were also characterized by cryo-TEM, 
which enables a detailed morphological evaluation of the particles in the frozen-hydrated 
state. 96 Electron micrographs revealed that CAF04 liposomes are unilamellar vesicles 
displaying a faceted morphology (Figure 36A). 69 The faceted appearance of liposomes 
containing DDA has been previously reported, and it may be attributed to the 
fluidity/rigidity of the bilayer and the phase transition temperature of the lipid mixture. 68 
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The electron micrographs of the hexosomes (Figure 36B-E) corroborated the SAXS data, as 
they showed internally-structured particles featuring curved striations and/or a hexagonal 
shape, which is characteristic for hexosomes. 97 In addition, the images of the hexosomes 
(Figure 36B-E) confirm the size heterogeneity also suggested by the DLS measurements 
(Table 6). 
 
Figure 35: SAXS curves recorded at 37°C for hexosomes dispersed in PBS (pH = 7.4) composed of 
either Phy/MMG-1 (▬) or Phy/MMG-1 + 2 mol% of either DDA (▬), DPPC (▬) or DPPG (▬), 
stabilized with 3.25 mol% poloxamer 407. The curves are shifted vertically for clarity. The dashed 
line indicates a shift of the Bragg reflections to lower q-values for samples containing charged 
lipids. 
 
Table 6: z-average, PDI, and zeta-potential of MMG-1-based liposomes and hexosomes dispersed 
in PBS (mean values ± SD, n = 3) 
Adjuvant z-Average (d.nm) PDI Zeta-potential (mV) 
CAF04 186 ± 1 0.17 ± 0.01 50.7 ± 2.5 
Phy/MMG-1 151 ± 2 0.34 ± 0.04 -8.1 ± 0.4 
Phy/MMG-1 +DDA 107 ± 1 0.29 ± 0.03 18.6 ± 0.8 
Phy/MMG-1 +DPPC 140 ± 3 0.46 ± 0.05 -8.9 ± 0.8 
Phy/MMG-1
 
+DPPG 143 ± 2 0.42 ± 0.01 -30.2 ± 0.7 
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Figure 36:  Representative cryo-TEM images of CAF04 liposomes (A) and hexosomes composed of 
Phy/MMG-1 (B), Phy/MMG-1 + 2 mol% of either DDA (C), DPPC (D) or DPPG (E), all stabilized 
with 3.25 mol% poloxamer 407. 
4.2. MMG-1-based hexosomes do not induce DC maturation, whereas 
CAF04 liposomes stimulate up-regulation of CCR7. 
Initially, the immunostimulatory potential of the adjuvants was evaluated in vitro in cultures 
of human PBMC-derived DCs by examining their effects on the expression level of selected, 
relevant maturation markers using flow cytometry (Figure 37). The nanoparticle dispersions 
were administered to the cells at a well-tolerated adjuvant concentration of 20 pmol/ml, 
which was pre-determined using the MTS/PMS viability assay (data not shown). Incubation 
of PBMC-derived DCs with MMG-1-based hexosomes did not affect the expression level of 
any of the examined maturation markers (Figure 37). In contrast, CAF04 liposomes induced 
an increase in the expression of CC-chemokine receptor 7 (CCR7). The homing receptor 
CCR7 is expressed only at very low levels by immature DCs. In response to up-regulation of 
CCR7, DCs migrate to the draining lymph nodes. 246 These results suggest that CAF04 
liposomes may have the capacity to induce lymph node homing of human PBMC-derived 
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DCs. To exclude that the absence of DC stimulation upon incubation with hexosomes was 
not due to lack of internalization, uptake experiments were performed and analyzed via 
flow cytometry, which clearly showed internalization of hexosomes to the same extent as 
found for liposomes in an energy-dependent manner (Figure 38). 
 
Figure 37: Histograms showing the expression of the surface activation markers CD80, CD83, 
CD86, HLA-DR, CD40 and CCR7 by PBMC-derived DCs after 48 h of stimulation with liposomes 
(CAF04) and hexosomes (Phy/MMG-1; Phy/MMG-1+DDA; Phy/MMG-1+DPPC; Phy/MMG-
1+DPPG). Yellow: isotype control; Red: unstimulated cells; Blue: stimulated cells. Representative 
plots of three analyses are shown. Acquisition gates were introduced in the granulocyte cell 
population in the forward scatter (FSC) versus side scatter (SSC) plot (not shown). 
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Figure 38: Histograms showing the uptake of formulations by DC-PBMCs in vitro. DC-PBMCs 
were incubated with CAF04 liposomes (A), Phy/MMG-1 hexosomes (B) and Phy/MMG-1 + DDA 
hexosomes (C) at 4°C and 37°C for 2 h. Particle internalization was quantified by flow cytometry. 
Gray: cells incubated with unlabeled formulations. Blue: cells incubated with formulations 
containing Alexa488-labeled OVA. Representative plots of three analyses are shown. 
4.3. MMG-1-based hexosomes and CAF04 liposomes induce antigen-
specific CD4
+
 T-cell responses characterized by different cytokine profiles.  
The adjuvanticity of cationic liposomes and hexosomes in vivo was compared using the 
MOMP antigen from C. trachomatis. In the present work, mice were immunized twice 
subcutaneously with MOMP antigen alone or with MOMP adjuvanted with the particle 
dispersions. Activation of MOMP-specific CD4+ and CD8+ T cells in the spleen and lymph 
nodes was measured as CD44 upregulation. The expression level of CD44 was used to 
distinguish naïve T cells (CD44low) from activated antigen-specific T cells (CD44hi). 247 Using 
ICS and flow cytometry, CD8+CD44hi and CD4+CD44hi T cells were subsequently analyzed 
for their secretion of IL-2, IFN-γ, and TNF-α. 
Analyses of the antigen-specific CD4+CD44hi and CD8+CD44hi T-cell populations revealed 
significantly larger populations of activated cells only for splenocytes from mice immunized 
with hexosomes containing either DDA, DPPC or DPPG, compared to those from mice 
immunized with unadjuvanted MOMP (Figure 39). Significant differences were not 
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observed between the effects of these three differently charged hexosomes. It has already 
been reported that unadjuvanted MOMP induces immune responses (self-adjuvant 
effect). 237 This could explain the similarity between the activated antigen-specific T-cell 
populations encountered in lymph nodes for all formulations (Figure 40) and in the spleens 
of mice vaccinated with MOMP adjuvanted with either CAF04 or Phy/MMG-1 compared to 
unadjuvanted MOMP (Figure 39).  
In the lymph nodes of mice vaccinated with MMG-1-based particles, there was no 
measurable statistically significant advantage regarding the expansion of antigen-specific 
CD4+ and CD8+ T-cell (CD44hi) populations in comparison to unadjuvanted MOMP (Figure 
40). 
 
Figure 39: MOMP-specific, activated (CD44hi) CD4+ (A) and CD8+ (B) T cells from spleen. Ten days 
after the second immunization, splenocytes were isolated and restimulated with MOMP ex vivo. 
The frequencies of MOMP-specific CD4+CD44hi and CD8+CD44hi lymphocytes were measured by 
flow cytometry. Columns represent average values ± SEM (n = 6). *, p < 0.01 (comparison between 
control mice immunized with unadjuvanted MOMP in PBS and mice immunized with MOMP 
adjuvanted with hexosomes containing DDA, DPPC or DPPG). 
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Figure 40: MOMP-specific, activated (CD44hi) CD4+ (A) and CD8+ (B) T cells from inguinal lymph 
nodes. Ten days after the second immunization, cells were isolated from the lymph nodes and 
restimulated with MOMP ex vivo. Frequencies (cell numbers)  of MOMP-specific CD4+CD44hi and 
CD8+CD44hi lymphocytes were analyzed by flow cytometry. Columns represent average values ± 
SEM (n = 6). 
Measurement of the MOMP-specific intracellular cytokine levels in CD4+CD44hi splenocytes 
revealed significantly higher numbers of IL-2-producing cells in mice immunized with 
hexosomes containing either DDA, DPPC or DPPG than in mice immunized with CAF04-
adjuvanted MOMP or unadjuvanted MOMP (Figure 41A). Interestingly, these three 
different hexosome-based adjuvants also induced the largest populations of CD4+CD44hi 
and CD8+CD44hi T cells (Figure 39). These findings may be explained by the growth-
promoting function of IL-2, which induces survival and proliferation of antigen-specific T 
cells. 248 In contrast, significantly larger populations of CD4+CD44hi splenocytes producing 
intracellular IFN-γ and TNF-α were measured following immunization with CAF04 
liposomes compared to unadjuvanted MOMP and MOMP adjuvanted with hexosomes. 
These findings suggest that hexosomes and liposomes induce qualitatively different 
immunological responses. While IL-2 promotes differentiation and expansion of T-cell 
populations, IFN-γ and TNF-α have effector functions, and are essential for processes 
related to the direct killing of infected cells and the elimination of intracellular pathogens. 249, 
250 The levels of all three intracellular cytokines in mice vaccinated with hexosomes 
containing either DDA, DPPC or DPPG were comparable. 
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In contrast to the intracellular cytokine levels in spleen cells (Figure 41A), the frequency of 
cytokine-producing cells from the inguinal lymph nodes (Figure 41B) was significantly 
increased only for TNF-α in mice vaccinated with MOMP adjuvanted with CAF04 liposomes 
in comparison with MOMP antigen alone. There were no statistical differences in the IL-2 
and IFN-γ levels in cells from the lymph nodes of mice vaccinated with the different 
formulations. 
 
Figure 41: MOMP-specific CD4+ T-cell responses of cells from spleen (A) and inguinal lymph 
nodes (B) restimulated with MOMP, measured by intracellular cytokine staining. Ten days after 
the second immunization, the spleens and lymph nodes were collected, and the numbers of 
MOMP-specific CD44hiCD4+ T cells producing either IL-2, IFN-γ, or TNF-α were analyzed by flow 
cytometry. Columns represent mean values ± SEM (n = 6). *, p ≤ 0.05; **, p ≤ 0.01; ***, p ≤ 0.001 
compared to the highlighted groups. 
4.4. MOMP adjuvanted with CAF04 liposomes induces higher CMI 
responses than MOMP adjuvanted with MMG-1-based hexosomes.  
In addition to the magnitude of the T-cell response, several recent studies suggest that the 
quality of the T-cell response is an additional crucial factor for vaccine-induced protection. 7 
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Polyfunctional T cells produce different cytokines simultaneously and exert multiple 
effector functions. 251 A number of studies have linked the induction of polyfunctional T-cell 
responses with improved protective efficacy, as compared to the efficacy of monofunctional 
T-cell responses. 7, 252, 253 The T cells within the CD4+CD44hi population were divided in seven 
groups, based on their secretion of IL-2, IFN-γ or TNF-α alone, or in any combination to 
further investigate the relative frequencies of multifunctional cells. Unadjuvanted MOMP 
induced predominantly single-positive cells and minor populations of multifunctional cells 
(Figure 42A). MOMP adjuvanted with CAF04 liposomes induced single-positive but also 
multifunctional cell subsets expressing IL-2 and TNF-α, as well as triple-positive cells 
(Figure 42B). The IL-2 single positive cells dominated the T-cell response after vaccination 
with hexosomes, representing 75-90% of the subpopulation (Figure 42C-F). IL-2 plays an 
important role for T-cell proliferation, survival and the longevity of the response. 248 Several 
studies suggest that IL-2-single positive cells are potential central memory T cells (TCM), 
which remain after the infection has been reduced or the antigen has been eliminated. 7, 254 
TCM cells are crucial for long-term immunity by mediating rapid antigen recall responses, 
which are characterized by high expression of IL-2 and induction of killing mechanisms. 7 
In contrast, the subpopulation profile observed in mice vaccinated with MOMP adjuvanted 
with CAF04 liposomes was more diverse, including potential TCM cells and potential 
effector/effector memory T cells (TE/EM) characterized by IFN-γ production. 255 This suggests 
improved T-cell response induced by MOMP adjuvanted with CAF04 liposomes in 
comparison with the responses elicited by unadjuvanted MOMP and MOMP adjuvanted 
with hexosomes. Through the simultaneous secretion of IFN-γ and TNF-α, functions related 
to direct killing of parasites may be activated. The combined secretion with IL-2 supports 
survival and expansion of this cell population. 7  
Since other studies imply that the quality and frequency of subsets of cytokine-secreting T 
cells may depend on the strength and duration of the antigen signal, 249 we suggest that the 
observed differences may be explained by different clearance kinetics of hexosomes and 
liposomes. For instance, it is well known that the adjuvant mechanism of cationic liposomes 
involves the formation of a depot at the injection site, which causes binding and retention of 
the antigen. 68, 256 This results in a delayed clearance of the antigen and prolonged vaccine 
exposure compared to vaccination with unadjuvanted antigen. 68, 256 Thus, this adjuvant 
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enhances antigen presentation, and the consequence is induction of stronger CMI 
responses. 257 In contrast, hexosomes are sterically stabilized with poloxamer 407, and depot 
formation at the site of injection is therefore less likely. However, further studies of the 
biodistribution profile of hexosomes are needed to confirm this hypothesis. Induction of IL-
2-only secreting cells may be an indication of insufficient T-cell stimulation, or suggestive of 
the termination of T-cell effector responses and differentiation into TCM cells. 254, 255 
 
Figure 42: Polyfunctionality analysis by Boolean gating of cytokine-producing MOMP-specific 
CD4+CD44hi splenocytes. Cells isolated from mice immunized with unadjuvanted MOMP (A), 
MOMP surface-adsorbed to CAF04 liposomes (B), and MOMP loaded in MMG-1-based hexosomes 
(C-F). Only groups with data ≥1% are shown. 
The polyfunctionality profiles of CD4+CD44hi T cells isolated from lymph nodes were again 
very different between the groups of mice vaccinated with unadjuvanted MOMP, MOMP 
surface-adsorbed to CAF04 liposomes, and MOMP loaded in MMG-1-based hexosomes 
(Figure 43). However, a general observation was an increase in the frequency of multi-
functional cell populations for all groups compared to the distribution found in spleens. In 
addition, the number of TNF-α positive cells (alone or in combination with IL-2) was 
increased remarkably in all groups. This was most pronounced for the hexosome-
adjuvanted vaccines, which also induced higher frequencies of IFN-γ positive cells in the 
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lymph nodes (Figure 43C-F) than in the spleens. This suggests a stronger effector character 
of the activated cells and potential differentiation into both TCM and TE/EM cells. 255 Therefore, 
vaccination with MOMP adjuvanted with CAF04 liposomes displayed again a T-cell 
stimulation profile of improved quality in comparison with unadjuvanted and hexosome-
adjuvanted MOMP vaccines. CAF04 liposomes showed the largest subsets of double- and 
triple-positive cells, which could be an indication of induction of durable protection. 7 
However, further studies are needed to prove this hypothesis. 
Unexpectedly, hexosomes displaying different zeta-potentials showed similar profiles with 
respect to the polyfunctionality of T cells in both spleen and lymph nodes. 
 
Figure 43: Polyfunctionality analysis by Boolean gating of cytokine-producing CD4+CD44hi cells 
from inguinal lymph nodes. Cells were isolated from mice immunized with unadjuvanted MOMP 
(A), MOMP surface-adsorbed to CAF04 liposomes (B), and MOMP loaded in MMG-1-based 
hexosomes (C-F). Only groups with data ≥1% are shown. 
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4.5. MMG-1-based hexosomes and CAF04 liposomes induce different 
immunostimulation  
Next, we investigated the capability of antigen-specific CD4+ T cells from lymph nodes and 
spleen to produce cytokines following in vitro restimulation with MOMP (Figure 44). The 
overall cytokine secretion profile provides useful information on the quality of the cellular 
immune responses. 258, 259 The release of IFN-γ, IL-17, and IL-5 was evaluated as an 
indication of potential Th1-, Th17-, and Th2-biased responses, respectively.  
Cells isolated from spleen and lymph nodes of mice vaccinated with MOMP adjuvanted 
with CAF04 liposomes showed a significant increase in IFN-γ and IL-17 titers compared to 
the titers for mice vaccinated with unadjuvanted MOMP or MOMP adjuvanted with 
hexosomes (Figure 43, p ≤ 0.001). Together with the low levels of IL-5 (Figure 43), this 
demonstrates that CAF04 liposomes stimulates immune responses via the Th1/Th17 
pathway as previously reported. 69, 260 MOMP adjuvanted with MMG-1-based hexosomes 
induced low levels of all three cytokines under investigation, similar to levels measured for 
unadjuvanted MOMP. Compared to the cytokine secretion pattern measured for mice 
vaccinated with CAF04-adjuvanted MOMP, these results suggest a different mechanism of 
immunostimulation for the hexosomes. 
C H A P T E R   I V    The Supramolecular Structure of Nano-Self-Assemblies Influences the Adjuvant Efficacy 
of a Synthetic Mycobacterial Monomycoloyl Glycerol Analogue 
DEVELOPMENT OF NOVEL VACCINE CARRIERS                                                                                                                           113 
 
 
Figure 44: Release of IFN-γ, IL-17, and IL-5 determined by ELISA in the supernatant of cell 
cultures obtained from the spleen (A) and the inguinal lymph nodes (B). In A, each data point 
represents samples obtained from one mouse (n = 6). In B, each data point represents three mice 
pooled (average of triplicates ± SD). *, p ≤ 0.05 and ***, p ≤ 0.001 compared to the group vaccinated 
with unadjuvanted MOMP and mice immunized with hexosome-adjuvanted MOMP, unless 
otherwise indicated in the graphics. 
4.6. MMG-1-based hexosomes induce stronger humoral responses than 
CAF04 liposomes.  
The MOMP-specific serum IgG titers were quantified by ELISA. Data suggest that MMG-1-
based hexosomes were more efficient in inducing MOMP-specific IgG responses than 
MOMP surface-adsorbed to CAF04 liposomes or unadjuvanted MOMP (Figure 45). No 
significant differences were observed for the IgG titers between the differently charged 
hexosomes. The narrow data distribution within each hexosome group may indicate a more 
concerted and faster drainage to the lymph nodes. 261 This may be due to the steric 
stabilization of hexosomes by poloxamer 407. The higher IgG titers indicate that at least a 
fraction of the hexosomes are retained in the lymph nodes, which enables uptake by tissue-
resident DCs, B cell activation and improved antibody responses. 261, 262 Zhuang et al. 
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suggested that a similar mechanism is involved in the overall improvement of the immune 
responses elicited by PEGylated dioleoyl-trimethylammoniumpropane (DOTAP) liposomes 
loaded with OVA, as compared to those elicited by non-PEGylated liposomes. 261 However, 
in contrast to the findings of the present work, the PEGylated DOTAP liposomes studied by 
Zhuang et al. induced higher levels of IgG, but also levels of IFN-γ comparable to the non-
PEGylated formulation.  261 These findings support the hypothesis that steric stabilization 
and reduction of depot formation are crucial for the induction of diverse immunological 
pathways and for the enhancement of humoral responses. However, other factors, e.g., 
particle composition and structure, may also contribute to the induction of these highly 
diverse immune responses mediated by hexosomes and liposomes. Complementary studies 
are necessary to fully understand the mechanisms of action of these systems, and to 
determine the basis of each response. We speculate that combining the attributes of 
hexosomes and liposomes into one single vaccine formulation may offer a promising 
strategy to design new adjuvant systems capable of potentiating concomitant humoral and 
CMI responses. For instance, T-cell activation combined with lymphatic targeting would be 
optimal properties of a Chlamydia vaccine. Further, rational combination of the two different 
carriers may be used to modify immunological outcomes, and thereby induce optimal 
responses needed for protective immunity against a given pathogen. The present work 
demonstrates that the type of vaccine formulation used to deliver the antigen has a strong 
impact on the elicited immune responses. 
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Figure 45: MOMP-specific serum IgG titers measured by ELISA. Each data point represents 
samples obtained from one mouse (n = 6). ***, p ≤ 0.001 compared with the group of control mice 
immunized with unadjuvanted MOMP in PBS. 
5 CONCLUSIONS AND OUTLOOK 
This study highlights differences between the immunostimulatory behavior of MMG-1-
based hexosomes and liposomes as vaccine delivery systems. While MMG-1-based 
liposomes induced predominantly cellular-mediated responses against the MOMP antigen, 
hexosomes elicited mainly humoral responses with high IgG titers, but with minimal 
effector T-cell stimulation. Differently charged hexosomal formulations induced comparable 
immune responses. The diverse immunological behavior of cationic hexosomes and CAF04 
liposomes, both containing DDA and MMG-1, suggests that the nanostructure of the 
particles, rather than the surface charge or the adjuvant composition, dictates the immune 
response. This highlights a significant role of the structural features of the nanoassemblies in 
terms of antigen presentation to B cells, activation of DCs and overall kinetics of the immune 
responses. To understand further the biological performance of the novel MMG-1-based 
hexosomes and explain their immune profile, comprehensive biodistribution studies 
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monitoring kinetics, characterization of memory T cells, and tracking of antigen-positive 
cells will be essential.  
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CHAPTER V  
General Conclusions and Outlook 
The principal objective of this work was the development and characterization of new 
vaccine carriers with adjuvant properties, based on lyotropic liquid crystalline structures. 
Due to the great potential of these systems and the uncountable open questions surrounding 
them, our attention was focused on one of the less studied assemblies, the hexosomes. In the 
literature only very few reports describe the development of this kind of formulation 
combined with an evaluation of its applicability in the biological context. The present work 
greatly advanced the state of knowledge in this field and gives a comprehensive description 
of the formulation development and biological performance of hexosomes.  
In Chapter II, we showed the development of stable hexosomes based on Phy and MaMo. 
SAXS, cryo-TEM, and polarization microscopy were used throughout this process to 
characterize the self-assembled structure. Additionally, we demonstrated a great versatility 
of these particles by modifying size, surface charge, and internal structure in a controlled 
manner. We were also able to show that these systems can be stabilized by a range of 
different surfactants including poloxamer 407, Myrj 59, and Pluronic F108. These findings 
argued against the common knowledge that particles internally structured with lyotropic 
liquid crystals are difficult to customize due to their highly sensitive internal structures. 100 
When compared to the development of liposomal formulations, where measurements of size 
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and zeta potential usually drive the initial establishment of the systems, the formulation 
development of non-lamellar structured particles is much slower and challenging. In this 
case, the formulation development is initially guided exclusively by the resulting internal 
structure of the particles and the size optimization is performed in a posterior stage. Thus, at 
the beginning, the development work is driven by laborsome methods and techniques that 
are not easily accessible (e.g. SAXS, cryo-TEM). This highlights the need to establish other 
approaches that enable the acquisition of structural information. In this work, we chose a 
less costly approach by using polarization microscopy to create a phase diagram to screen 
compositions before employing SAXS measurements. This strategy clearly facilitated the 
formulation development and allowed for drastic reduction of the number of samples 
measured with SAXS. However, it is only applicable for bulk phases. This is an important 
limitation, because the particle preparation requires the addition of steric stabilizer and this 
might impact the internal structure of the particles. Other approaches based on sample 
turbidity and viscosity could also be developed to investigate bulk phases. 100 However, 
their application in particle dispersions is also difficult due the fundamental role played by 
sample concentration in the determination of turbidity and viscosity. Differential scanning 
calorimetry (DSC) of high sensitivity has been used to determine the phase transition 
temperatures of lipid-based particles. 263-265 This may assist the strategic planning of SAXS 
measurements and allow for a reduction of the number of temperature points measured per 
sample. If SAXS lab sources are used, acquisition times can be very long (up to hours) and a 
previous scanning of phase transitions with DSC may optimize the overall experiment 
duration.  
In this study, we also investigated the particle loading of two different model antigens, OVA 
and LYS. Our data indicated a geometric mismatch between the dimensions of the repeating 
unit (lattice parameter) and the cargo proteins. This suggested that the loaded proteins could 
not be entrapped in the water channels of the hexosomes without considerably impacting 
the HII structure. Based on these findings we proposed a loading mechanism based on 
interactions with the lipidic network. However, this hypothesis has not been confirmed yet 
and the localization of the entrapped macromolecule has yet to be clarified. This is an 
interesting matter, but also very challenging to solve. We believe that small angle neutron 
scattering (SANS) combined with computer simulation and modeling might be the most 
suitable approach to investigate this issue. SANS enables the differentiation between 
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different molecules, based on the scattering length density and contrast-match in D2O. 266 
Approaches based on fluorescent labeling of components, such as Förster resonance energy 
transfer (FRET), are not suitable for this investigation, because the staining might change the 
properties of the molecule and change the manner in which the protein interacts with the 
lipid molecules. Thus, as generally observed in the field of lyotropic liquid crystalline 
dispersion for biomedical uses, the interdisciplinary work is essential for the obtention of 
fast progress. Considering a potential application of hexosomes as vaccine carriers, it will be 
crucial to elucidate the loading mechanism of different antigens (e.g. surface adsorption, 
encapsulation) as this is known to play an important role in the induction of immune 
responses. 267 Although we were unable to clarify how exactly proteins are entrapped into 
hexosomes, we demonstrated a reproducible approach to produce stable and versatile 
hexosomes loaded with model antigens, which have a potential as vaccine delivery systems.  
Following the development of Phy/MaMo hexosomes, Chapter III focuses more in detail on 
the interaction of these systems with HeLa cells and model membranes. It has been 
hypothesized that one of the most advantageous properties of non-lamellar structured 
particles is their potential fusogenic character, which would enable delivery of sensitive 
biomolecules directly to the cytoplasm. 103, 104  In the context of vaccination, this may play a 
major role in antigen presentation via MHC class I and a consequent induction of CTL. 143 
Contrary to the expectations, the hexosomes used in our study did not appear to have the 
ability to fuse with membranes. We found that the uptake of Phy/MaMo hexosomes was 
not mediated by any of the major endocytic mechanisms but instead induced through 
distortions of the cell membrane that allowed their rapid passage through this barrier. This 
was only reduced or inhibited by high membrane tension and rigidity, which further 
supports the hypothesis of a cell entry mechanism based on a direct interaction of the 
particles with the membrane. In comparison to DOPC/DOPE-based liposomes, the 
internalization efficiency of hexosomes was particularly superior. However, this rapid 
uptake kinetics appeared to correlate with higher toxicity. It is important to highlight that all 
experiments were performed with the formulations at concentrations considered safe 
according to the viability assay (MTT test). Comprehensive analysis using POPC model 
membranes (calcein leakage assay, Langmuir monolayer and giant vesicles) indicated a 
surprisingly high affinity of hexosomes for the lipid membranes when compared to their 
neat components and to liposomes. These results suggest that hexosomes could be 
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promising delivery systems for therapeutic molecules whose target is localized 
intracellularly or molecules that normally do not have the ability to get through the cell 
membrane. To the best of our knowledge, this study reports for the first time how 
hexosomes are internalized by cells. Despite of the encouraging findings, further efforts are 
necessary to evaluate the reproducibility of our results with other cell types. In addition to 
this, considering a potential application of hexosomes as cytoplasmatic delivery systems for 
sensitive biomolecules, it is of utmost importance to elucidate the intracellular fate of their 
cargo molecules. In this regard, the analysis of uptake and fate of hexosomes loaded with 
different molecules may provide clear insights about their capacity to circumvent the 
endosomal/lysosomal system. To this end, we believe that transmission electron microscopy 
is the method of choice. Despite being laborious and time consuming, this method could 
enable direct visualization of the integrity and fate of hexosomes after cell entry. Other 
techniques, such as confocal microscopy, require fluorescent labeling and enable solely an 
indirect analysis. Considering that our findings suggested a direct interaction of the 
hexosomes with the cell membrane, it is of fundamental importance to evaluate how the 
surface properties of these particles (e.g. charge, different densities and lengths of steric 
stabilizers) affect the cellular uptake. For this purpose, the customization strategies 
described in Chapter II could be applied. Overall, the findings reported in Chapter III 
provide a good starting point to understand the performance of hexosomes in the biological 
environment. Moreover, these data open new horizons with respect to potential applications 
for hexosomes in the biomedical context. However, it is evident that much remains to be 
done in order to establish these particles as vaccine/drug delivery vehicles.      
In Chapter IV, the adjuvancity of hexosomes based on Phy and MMG-1 was studied in vitro 
and in vivo. MMG-1 is a synthetic analogue of the mycobacterial lipid monomycoloyl 
glycerol found to have promising adjuvancity especially when combined to cationic 
liposomes. 68, 69 In our studies, to enable comparability to established and well known 
delivery systems with immunostimulatory character, the positive control used consisted of 
cationic liposomes based on MMG-1 and DDA (CAF04). A limiting factor in the formulation 
development of Phy/MMG-1 hexosomes was the challenging preparation of synthetic 
MMG-1. By applying the knowledge that we gained from the studies shown in Chapter II, 
we were able to significantly shorten and to simplify this process. Hence, a range of 
differently charged hexosomes was created and compared to CAF04. 
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Interestingly, all aspects evaluated (e.g. expression of surface markers by DCs derived from 
PBMCs, T-cell activation, cytokine expression and release, polyfunctionality, specific serum 
IgG) revealed highly contrasting results for liposomes and hexosomes. Overall, the 
immunogenicity of liposomes was determined mainly by cellular-mediated responses, and 
the responses induced by hexosomes were predominantly humoral. Furthermore the 
different hexosomal formulations showed similar activity, indicating that the charges played 
only a minor role (if any) in the adjuvancity of these particles. It is extremely challenging to 
explain the differences between the performances of hexosomes and liposomes and to track 
the origin of each outcome. This is because, besides structural aspects, the two types of 
nanoparticles comprise different amounts of lipid per particle, vary in their physicochemical 
properties and interact differently with the entrapped antigen. Considering that all these 
aspects may influence the type and kinetics of the immune responses elicited, an 
unequivocal and straightforward interpretation of the experimental outcomes is difficult in 
this stage. Additionally, it is important to consider that the punctual analysis of the 
correlates of immunogenicity does not reveal the whole immunological outcome. Therefore, 
additional experiments to monitor the kinetics of the responses and determine their profile 
as a whole seem to be critical. Moreover, to explain the type and magnitude of the responses 
elicited, the investigation of biodistribution of the carriers and tracking of antigen-positive 
cells are fundamental.  
In these experiments we studied the responses against the Chlamydia antigen MOMP. The 
protection against MOMP is typically induced via the CD4 signaling pathway. 268 For this 
reason, another important open research question is whether hexosomes are able to delivery 
antigen directly to the cytosol, which may help to induce CTL responses. In Chapter III, we 
reported interesting evidences suggesting that hexosomes are internalized through an 
uncommon uptake mechanism based on the direct interaction of these particles with the cell 
membrane. Based on this, it could be speculated that hexosomes are potential cytoplasmatic 
delivery systems. This kind of antigen delivery could mimic the antigen presentation of 
intracellular pathogens and facilitate CTL responses. 143 To investigate this hypothesis it 
would be necessary to perform in vivo immunization studies with an antigen characterized 
by both signaling pathways (i.e. CD4 and CD8), such as OVA. 73, 269    
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The present work presents new insights in the fields of vaccine delivery and lyotropic liquid 
crystalline dispersions. Great progress was made regarding the development and 
application of hexosomes. Further efforts are needed to continue increasing the 
understanding about these remarkable particulate systems and to ultimately establish them 
as vaccine/drug carriers. Overall, this thesis provides an essential contribution to provoke 
new discussions and guide future works in the field of vaccine delivery and lyotropic liquid 
crystalline dispersions. 
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SUMMARY 
n this work, combined interdisciplinary research in the fields of Pharmaceutical 
Technology, (Bio)Materials Science, and Biology is presented to understand and promote 
lyotropic liquid crystalline dispersions as novel vaccine carriers. 
The work was initiated with a detailed development of lyotropic mesophases based on 
phytantriol. The aim was to gain knowledge on the phase behavior of the system and also 
on the structural impact of additives. Therefore, formulations with increasing degree of 
complexity were sequentially characterized. The study started establishing a phase diagram, 
in which bulk phases of phytantriol in excess of highly purified water were characterized, 
upon temperature increase, applying polarization microscopy and small angle X-ray 
scattering (SAXS). Subsequently, pursuing the development of a system with 
immunostimulatory properties, the impact of mannide monooleate on phytantriol-based 
mesophases was investigated. Mannide monooleate is an emulsifier widely used in adjuvant 
formulations and found to promote immune responses in emulsion form. Thus, 
progressively higher amounts of mannide monooleate were incorporated into the system 
and the structural modifications were monitored upon temperature increase. The phase 
diagram allowed for a deep understanding of the mesophase behavior and enabled the 
selection of a feasible phytantriol/mannide monooleate ratio for the subsequent 
investigations. In this way, a stable formulation, featuring inverse hexagonal structure was 
identified. Next, to enable dispersion of the characterized bulk and to produce a 
nanoparticulate system, different steric stabilizers were evaluated. Here, the selection 
criteria were based on the dispersion efficiency at low concentrations and on the impact on 
the internal structure of the particles. The last part of the formulation development was 
concerning the application and customization of the formed hexosomes. Thus, the particle 
loading with the model antigens ovalbumin and lysozyme was studied, as well as strategies 
to introduce new features to the particulate system in a controlled way, preserving the 
inverse hexagonal structure. Here, negatively and positively charged hexosomes could be 
prepared through the incorporation of charged phospholipids into the formulation. 
Additionally, a formulation based on phytantriol and mannide monooleate, which typically 
formed an inverse hexagonal structure was shown to self-assemble with bicontinuous cubic 
double diamond structure upon addition of octyl-β-D-glucopyranoside.  
I 
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The aim of the second part of this work was the verification of one of the most important 
hypothesis with respect to the biological performance of non-lamellar lyotropic liquid 
crystalline dispersions. More specifically, it is known that non-lamellar structures are 
involved in fusogenic processes of the cell membrane. For this reason, it was speculated that 
particles internally structured with non-lamellar phases, such as hexosomes, could have 
fusogenic properties. Thus, to verify this hypothesis and elucidate the cellular uptake 
mechanism of hexosomes, we investigated the interactions of these particles with cells and 
with models of the cell membrane. For this purpose, the established hexosomes, based on 
phytantriol/mannide monooleate, were fluorescently labeled and their toxicity in cultures of 
HeLa cells was determined. Series of uptake experiments were carried out after suppression 
of the major endocytic pathways using highly specific approaches (e.g. single and double 
knockdown of regulatory proteins), and also inhibition strategies of broader effect (e.g. 
temperature reduction to 4°C, hypotonic treatment, cytochalasin D treatment). Additionally, 
experiments using models of the cell membrane (e.g. phospholipid monolayers and bilayers) 
were performed. All the analyses were carried out with hexosomes and liposomes in parallel 
to enable the comparison between particles featuring non-lamellar and lamellar structures, 
respectively. The results revealed a steeper toxicity curve and faster internalization kinetics 
for hexosomes in comparison to liposomes. Interestingly, against the expectations, 
indications of fusogenic properties were not observed. However, strong evidences that 
hexosomes have an alternative cell entry pathway that bypasses standard endocytosis were 
identified. In contrast, liposomes appeared to enter the cells through well-known endocytic 
pathways, such as caveolae-mediated and clathrin- mediated endocytosis. 
The final part of this work consisted of the evaluation of the biological performance of 
hexosomes within the vaccination context. The experiments were performed in vitro and in 
vivo, in parallel with the already established and promising cationic liposomal formulation 
CAF04, which is based on dimethyldioctadecylammonium (DDA) and on a synthetic 
analogue of monomycoloyl glycerol (MMG-1). Since MMG-1 and the positive charge of 
DDA are considered the core of the success of this formulation, differently charged 
hexosomes containing MMG-1 were developed and included in the study. The development 
process was driven by the lessons learned in the first phase of the project with 
phytantriol/mannide monooleate systems. In this way, to create particles internally 
structured with inverse hexagonal phase, MMG-1 was combined to phytantriol. After the 
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establishment of the formulations, the immunogenicity of plain particles (without antigen) 
was investigated in vitro in cultures of dendritic cells derived from human peripheral blood 
mononuclear cells. Through the evaluation of the expression of several surface markers, it 
was found that, while CAF04 liposomes induced the upregulation of the homing receptor 
CCR7, all hexosomal formulations tested did not provoke any sign of adjuvanticity. 
Considering that the cultures of dendritic cells represent a dramatic simplification of the 
immune system, further experiments were performed in vivo. Thus, mice were immunized 
with the formulations loaded with Chlamydia trachomatis major outer membrane protein 
(MOMP) antigen. The immunological output was analyzed through several parameters (e.g. 
T-cell activation, cytokine expression and release, polyfunctionality, specific serum IgG) and 
all of them revealed dramatic differences between the immunizations performed with the 
unadjuvanted antigen and antigen adjuvanted with either liposomes or hexosomes. In 
comparison to the unadjuvanted systems, liposomes and hexosomes were both able to 
increase the magnitude of the immune responses. However, the immune responses elicited 
by CAF04 liposomes and by hexosomes were very distinct, the first eliciting mainly cellular 
mediated responses and the second humoral responses.  
Throughout this work, it was shown that stable and robust lipid-based lyotropic liquid 
formulations, that allow customization without impairment of the internal structure, can be 
rationally designed. In addition, keeping track of the structural modifications induced by 
each additive (separately) was shown to be a key strategy to enable further optimization in 
advanced stages of the formulation development. Regarding the performance of hexosomes 
in the biological environment, we have obtained accurate results demonstrating, in vitro and 
in vivo, drastic differences in comparison to liposomes. This intriguing outcome was 
observed for different formulations and in completely independent experiments. Overall, 
the insights presented in this thesis show hexosomes as promising delivery systems with 
uncommon properties and an applicability potential that goes beyond the vaccination 
context.  
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